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Abstract
This thesis has two inter-related aims: to investigate the effects of a series of lipid 
lowering regimens on the metabolism of the apoB containing lipoproteins and to 
provide new information on the pathophysiology of human lipoprotein metabolism.
By studying the effects of simvastatin, the resins colestipol and cholestyramine, 
acipimox and the fibric acid derivatives ciprofibrate and fenofibrate, alone and in 
selected combinations, it was possible to offer new mechanisms of action for these 
lipid lowering drugs in patients with primary moderate hypercholesterolaemia. The 
studies involved the measurement of lipids, lipoproteins and an assessment of either 
apoB or apo-LDL metabolism at baseline and during the drug therapies. The data 
obtained from the kinetic studies were analysed using a multicompartmental 
mathematical modelling strategy. This allowed the computation of rate constants 
and sub-compartmental masses for each of the apoB containing lipoproteins, which 
served as a mathematical approximation of apoB or apo-LDL metabolism. 
Additionally, in the case of simvastatin and fenofibrate, an assessment of the in 
vivo effects of these drugs on cholesterol biosynthesis was made using assays for 
the cholesterol precursors, mevalonic acid and lathosterol.
The main findings from these studies were a new appreciation for the metabolic 
heterogeneity that underlies primary moderate hypercholesterolaemia, an increased 
recognition of the role of the apoB/E receptor in the clearance of LDL precursors as 
seen in studies with simvastatin and colestipol, formulation o f a proposed 
mechanism for the hypertriglyceridaemia often noted with sequestrant resin therapy 
and support for the significance of hepatic lipase in IDL-LDL conversion as 
demonstrated in the study with acipimox. Confirmation of the efficacy of combined 
lipid lowering therapy is offered, as is a novel mechanism for the enhanced LDL 
clearance observed with fibrate therapy. The latter involves drug induced changes 
in the ligand rather than the receptor. Further investigation of the effects of 
fenofibrate suggested that, unlike simvastatin, this fibrate had no consistent effect 
on cholesterol biosynthesis. The latter is an important new in vivo observation 
which supports a growing body of in vitro work.
This thesis concludes with a discussion of unanswered questions which are of 
interest both in terms of lipoprotein metabolism and the development o f 
atherosclerosis. New approaches to the study of lipoprotein kinetics are suggested 
involving the application of stable isotope technology , and an hypothesis, based on 
kinetic and structural observations, that the direct synthesis of LDL apoB is linked 
more closely with the larger, lighter LDL subfractions, is stated.
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1Chapter 1 Introduction
These are the springs of man’s existence: from them spread throughout his body 
those rivers with which his mortal habitation is irrigated, those rivers which bring 
life to man as well, for if ever they dry up, then man dies.
Hippocrates, De Corde c 260 BC.
1.1 Clinical Significance o f Lipoprotein Research
Even in antiquity, the importance of cardiovascular function and integrity were well 
recognised. Today the words of Hippocrates have greater relevance than ever 
before, for coronary heart disease (CHD) is the leading cause of death in the UK 
and the developed world. In 1989 CHD accounted for 26% of the annual all-cause 
mortality in England and Wales (Office of Population Censuses and Surveys 1990) 
and the annual cost of this disease to the health service has been estimated at 
approximately £500 million (Office of Health Economics 1990).
The aetiology of coronary heart disease has been the subject of intense study over 
the last few decades and many contributory or risk factors have been identified, and 
these are well summarised by Isles & Hole (1991). Much attention has focussed on 
the three principal and modifiable risk factors viz. smoking, hypertension and 
hypercholesterolaemia. These risk factors have been identified repeatedly 
throughout the literature (Kannel etal 1971, Shaper et al 1981, Multiple Risk Factor 
Intervention Trial Research Group 1982) and are now well accepted. Their 
modification on a population basis, particularly by dietary means, is advocated by 
several agencies including the British Government (Committee on Medical Aspects 
of Food Policy 1984 & 1991) and the World Health Organization (1990). That 
changes can be made at all, and in a relatively short time, is clear when we examine 
the worldwide trends in age-adjusted death rates for CHD in men between the years 
1970 and 1985 (Uemura & Pisa 1988). The US leads this field, having achieved 
an almost 50% reduction in deaths from CHD in this period while countries such as 
Romania and Poland have shown marked increases of more than 70%. Scotland,
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in the same 15 year period, has shown a fall of approximately 10% but remains at 
or near the top of the international league table of male CHD mortality (Marmot 
1988). Scotland does not, however, have the highest mean total cholesterol levels 
in the world. Of the 20 countries surveyed in the on-going WHO MONICA project 
(1988) Scotland has the joint third highest (6.2 mmol. L_1 in males aged 35-64 
yrs), but revealingly led the world in the prevalence of multiple CHD risk factors. 
This point re-iterates the fact that CHD is a multifactorial disease.
As this thesis takes as its basic premises, firstly, that hypercholesterolaemia is a 
major risk factor for CHD and secondly that modification of the plasma cholesterol 
level is worthy of pharmacological intervention when dietary management fails, we 
must further examine the evidence for these.
The putative role of hyperlipidaemia in the development of atherosclerosis goes 
back almost 150 years to the work of Vogel (1845) in Leipzig. It was he who first 
noted the presence of cholesterol in atheromatous tissue. The term atherosclerosis 
itself was coined by Marchand in c l860 (quoted by Aschoff 1924) but it was not 
until the early years of the twentieth century that the association between dietary 
cholesterol and atherosclerotic lesions was confirmed experimentally. Anitschkow 
(1913) in St. Petersburg fed egg yolk to rabbits and observed the development of 
lesions in their aortae, identical to the atherosclerotic lesions in man. As this work 
progressed, Anitschkow (1915) became convinced only two years later that, ‘there 
can be no atheroma without cholesterol’.
From such beginnings an impressive edifice of epidemiological research has been 
built, culminating in incontrovertible evidence for the recognition of 
hyperlipidaemia as an important causative factor in the development of 
atherosclerosis. Because hyperlipidaemia may be readily corrected, in most cases, 
by dietary and pharmacological means, it has been the focus of much clinical 
attention.
The Lipid Research Clinics Coronary Primary Prevention Trial (Lipid Reseaerch 
Clinics Program 1984a & 1984b) and Helsinki Heart Study (Frick et al 1987), 
clearly showed that the lowering of plasma cholesterol levels brings benefit in terms 
of reduction of coronary morbidity. Such findings coupled with advances in 
therapeutics and biotechnology have detonated an explosion of interest and activity 
within the scientific and medical communities in the last five years.
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Our ability to modulate the cholesterol and lipoprotein levels in the plaisma, and in 
turn the coronary heart disease risk of an individual, is a reflection o f the efforts 
devoted to this subject over the past twenty years, and depends largely on our 
understanding of lipoprotein metabolism. With the control of lipoprotein 
metabolism comes the control, at least in part, of the development o f  atheroma. 
There follows a description of the structure and function of the plasma lipoproteins, 
an overview of normal and deranged lipoprotein metabolism, a discussion of the 
methods employed to study lipoprotein synthesis, interconversions and catabolism, 
and a review of the different forms of hypolipidaemic therapies now in clinical use.
1.2 Lipids,Lipoproteins, and their Metabolism.
Lipids are important sources of energy, of synthetic precursors, and cellular 
components. Because of this a complex system has evolved to solve the problem 
of transporting lipids around the body in the aqueous environment of the plasma. 
This system depends on the packaging of neutral lipids (cholesteryl esters and 
triglyceride) with specific proteins and amphipathic lipids (phospholipids and 
cholesterol) to create multimolecular particles called lipoproteins that are readily 
miscible with water (figure 1). The major organs involved in lipid metabolism are 
the intestine and the liver. Together these organs are responsible for the majority of 
lipoprotein synthesis and catabolism. Regulation of lipid transport is exerted by 
several means: apolipoproteins with specific signalling and cofactor functions, 
specific cell-surface lipoprotein receptors, intravascular lipolytic enzymes and 
transfer proteins that act in concert to maintain cholesterol and triglyceride 
homeostasis. Malfunction of these regulatory factors may cause or contribute to the 
development of dyslipidaemia and in turn atherosclerosis. A simple overview of 
lipoprotein metabolism illustrating the roles that each plays in lipid transport is 
illustrated in figure 2.
1.2.1 Classification and Nomenclature of Plasma Lipoproteins
The resolution of the plasma lipoproteins was made possible largely due to the use 
of the ultracentrifuge in the 1950s (Gofman etal 1950a, Turner etal 1951). The 
most widely used system of nomenclature defines five main classes of lipoprotein 
based on their hydrated density (g. mL_1) (Mills, Lane & Weech 1984). 
Lipoproteins have also been defined by their electrophoretic mobility, particle size, 
apolipoprotein composition and flotation rate (Mills et al 1984). The latter is 
commonly quoted and merits further explanation. In this system the lipoproteins
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Figure 1. Impression of Lipoprotein Structure.
Lipoprotein particles are multi-molecular complexes of roughly spherical shape. 
The example illustrated above shows the main elements of all lipoprotein classes. 
Each has a surface monolayer of phospholipid, cholesterol and the hydrophilic 
domains of tie constituent apolipoproteins. In this diagram, the exploded section 
reveals the tydrophobic core of the particle, which contains triglyceride and 
cholesteryl *sters. The hydrophobic domains of the apolipoproteins and the 
phospholipid tails are thought to abut on this lipid cargo. The size and composition 
of a lipoproiein particle vary from one class to another. Although the precise 
apolipoproteii configuration illustrated here is imaginary, the molecular scale of this 
diagram woi(d suggest a particle diameter of 50nm, approximating its structure 
most closely o that of VLDL i.
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Figure 2. Overview of Lipoprotein Metabolism
Following its absorption, dietary fat is packaged into large, triglyceride-rich 
chylomicron particles within the enterocyte and secreted into the circulation. There, 
lipolysis reduces the particle’s triglyceride core and makes redundant part of its 
surface coat, vhich is shed to high density lipoprotein (HDL). The remnants 
produced in th? process are rapidly assimilated by a receptor-mediated mechanism 
in the liver, h  the fasting state, very low density lipoprotein (VLDL) replace 
chylomicrons as the major triglyceride transporters and the liver dominates 
lipoprotein mttabolism. Cholesterol and triglyceride elaborated in this organ, are 
released into tie plasma where they are subject to tissue lipolysis. This degrades 
them to low deisity lipoprotein (LDL) via an intermediate species (IDL). The LDL 
is removed by eceptors present on the liver and peripheral tissues. When these are 
saturated, altenative scavenger receptor pathways become dominant.
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are defined by their rate of flotation through a salt solution of fixed density in the 
analytical ultracentrifuge. For lipoproteins of density less than 1.063 g. mL_1 the 
salt solution used is NaCl d. 1.063 g. mL_1, while the high density lipoproteins are 
defined using a density solution of 1.210 g. mL’1. All densities are defined at 
26°C and the units used are Svedberg units (Sf) where one Sf unit=10'13 cm. s_1. 
dyne-1, g-1 at 26°C. Both systems are very flexible; while five main lipoprotein 
classes are traditionally defined, any lipoprotein preparation that does not fit these 
established windows may be characterized by its limiting densities or flotation rate 
interval. The physical properties of the plasma lipoproteins are summarised in table 
1, and their chemical compositions are shown in table 2. Each lipoprotein class 
exhibits a unique structure, function, and metabolism as described below in 
sections 1.2.2-1.2.11.
1.2.2 Structure and function o f Lipoprotein classes and subgroups.
The structure of the different lipoprotein classes, their lipid composition and their 
apolipoprotein components are inextricably linked to their function and to their 
metabolism in the body. As such it is artificial to separate the two and structure and 
function will be discussed together in the subsequent sections.
1.2.3 Intestinal Lipid Metabolism
Daily we ingest about 0.5g of cholesterol (as free and esterified sterol) and lOOg of 
triglyceride. Digestive enzymes in the intestinal lumen hydrolyze the lipid esters, 
releasing free cholesterol, fatty acids and mono- and diglycerides. These 
amphipathic molecules form water-soluble micelles that carry the lipid to absorptive 
sites in the duodenum (Danielson & Sjovall 1975). Under normal circumstances, 
triglyceride absorption is virtually complete. However, only about 50% of the 
cholesterol is taken up, the remainder being lost in the faeces (Norum etal 1983). 
Within the enterocyte, absorbed cholesterol is rapidly re-esterified by the action of 
the membrane bound cytoplasmic enzyme acyl Coenzyme A: cholesterol 
acyltransferase (ACAT) (Norum et al 1983) and packaged with reconstituted 
triglyceride into large, lipid-rich chylomicron particles containing about 1% protein. 
These appear in abundance in the intestinal mucosal cells following a meal and are 
secreted into lacteals within the wall of the small bowel. The availability of a 
specific structural apolipoprotein known as apolipoprotein B (apoB) is a 
prerequisite for the production of such particles. Subjects with the inherited 
disorder known as abetalipoproteinaemia (Kane & Havel 1989) fail to secrete the
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Table 1. The Physical Properties of the Plasma Lipoprotein Classes
Lipoprotein Density 
Range 
g. mL-1
Sf 
at 26°C & 
1.063 g. mL-1
Diameter
nm
Corresponding
Electrophoretic
Mobility
Chylomicron <0.94 >400 75-1200 Origin
VLDL i/2 0.94-1.006 60-400 30-80 Pre-B
20-60
DDL 1.006-1.019 12-20 25-35 Slow pre-B
LDL 1.019-1.063 0-12 18-25 B
h d l 2 1.063-1.125 - 10-15 a
h d l 3 1.125-1.210 - 5-10 a
Physical data taken from Mills, Lane & Weech (1984)
Table 2. The Chemical Composition of the Plasma Lipoprotein Classes.
Lipoprotein Percentage of Lipoprotein Mass
20 40 60 80
Apolipoprotein
Content
Chylomicron
/  /
/  &  /  /
/  y  /  /
/  /  &  /
/  /  ^  // /  ^  /
/  /  /  ^
/  /  < ?
1 /1_______iL_____ i______ 1______
B-48, Al, AIV, C, E
VLDL 1/2 B-100, C, E
IDL B-100, C, E
LDL B-100
h d l 2 Al, AH, C, E
h d l 3 Al, All, C, D
Compositional data taken from Mills, Lane & Weech (1984) and from own data.
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chylomicrons from their enterocytes following a fatty meal. The condition results 
in failure to thrive in infancy and is associated with specific retinal and erythrocyte 
defects that are progressive and derive ultimately from defective absorption of fat 
soluble vitamins.
ApoB found in chylomicrons is a modified, lower molecular weight form of that 
synthesised by the liver and secreted with VLDL. The former is termed apoB-48 
and the latter apoB-100 in the nomenclature of Kane, Hardman & Pauls (1980). It 
has recently been noted (Levy et al 1990) that the gut also produces apoB-100 
although this does not appear in chylomicrons. Other proteins are also present on 
the chylomicron surface. Some (apo Al, AH, AIV and possibly C) are elaborated 
by the gut and secreted with the chylomicron (Green & Glickman 1981) while 
additional peptides are acquired from high density lipoprotein (HDL) in interstitial 
fluid. The latter include apoC and apoE, both of which participate in subsequent 
processing of the particle (Green & Glickman 1981; Imaizumi, Fainaru & Havel 
1978; Green etal 1979).
Several rapid changes take place in the chylomicron when it enters the plasma. 
Within the capillary beds of skeletal muscle and adipose tissue it is exposed to the 
lipolytic action of endothelium-bound lipoprotein lipase. This enzyme hydrolyzes 
its triglyceride core, releasing free fatty acids and mono- and diglycerides for 
energy production or storage (Nilsson-Ehle, Garfunkel & Schotz 1980). Further 
delipidation results in the generation of so-called ‘chylomicron remnants*. These 
particles are structurally distinct from the parent chylomicron (Mjos etal 1975), not 
only because they are the products of the degradation process outlined above but 
also because they acquire lipid, particularly cholesteryl ester, from denser 
lipoproteins like LDL and HDL, facilitated by cholesteryl ester transfer protein 
(CETP). Zilversmit (1984) demonstrated that this cholesteryl ester is exchanged for 
triglyceride transferred in the opposite direction, i.e., into LDL and HDL. 
Deficiency of CETP activity as described by Eto etal (1990) results in markedly 
elevated plasma levels of HDL. The extent of this process, which effectively 
enriches chylomicron remnants in cholesteryl esters, is governed by the residence 
time of the chylomicron in the circulation. Rapid chylomicron clearance resulting 
from highly efficient lipolysis, gives the particle little opportunity to acquire 
cholesteryl ester. Besides these alterations in its hydrophobic core, the surface coat 
of the remnant shows substantial differences from that of its parent. All the apoB 
initially present in the particle is retained, but the relative amounts of the other 
proteins are altered. ApoAI and apoAH are transferred into the HDL density range
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(Schaefer, Jenkins & Brewer 1978; Tall etal 1979) while apoAIV, upon release 
from the chylomicron, seems to exist free in the plasma since its affinity for other 
lipoproteins is low (Tall etal 1979). As noted above the C protein content initially 
rises as a result of transfer from HDL (Havel, Kane & Kashyap 1973). This is of 
particular significance with regard to apoCH since this is an obligatory cofactor for 
lipoprotein lipase, increasing the particle’s affinity for the enzyme. The role of 
apoCIH, the major C peptide on the chylomicron surface, is less clear although it 
may be responsible for regulating the lipolysis of the particle (Ginsberg etal 1986) 
or delaying its hepatic clearance (Windier, Chao & Havel 1980). As the 
chylomicron progresses down the lipolytic cascade the C proteins are transferred 
gradually back into the reservoir within HDL. ApoE, which is acquired by the 
particle simultaneously with apoC, is not involved in lipolysis (Blum 1982), but 
thereafter plays a role in triggering hepatic uptake of the remnant particle (Mahley & 
Innerarity 1983).
The liver is responsible for the efficient and rapid clearance of cholesteryl ester rich 
chylomicron remnants from the circulation. Hepatic parenchymal cells contain, on 
their surfaces, receptors that recognise and bind to particular charged domains of 
the remnant’s apoE (Brown & Goldstein 1987). This interaction results in the 
delivery of the particle to lysosomal degradation within the hepatocyte. The key 
role played by apoE in this process is evident from studies performed on 
individuals who express a mutant form of the E protein (apoE2) in which the 
conformation of the receptor-binding region is altered. They exhibit delayed 
clearance of the remnants from the bloodstream (Gregg et al 1981). The 
metabolism of chylomicrons may be regarded as a bi-functional process, involving 
the delivery of dietary triglyceride to skeletal muscle and adipose tissue, and of 
cholesterol to the liver. The activity of lipoprotein lipase in a tissue is constantly 
changing and is under hormonal control. Thus the enzyme has some of the 
properties of a membrane receptor in determining the direction of triglyceride flow.
1.2.4 Hepatic Lipid Metabolism
Although the liver has the capacity the make all the cholesterol and triglyceride that 
it needs, preformed components that are available either from the diet or from 
adipose tissue via fatty acid/albumin transport are preferred. Mobilization of depot 
fat in adipose tissue is under humoral control by agents such as adrenaline (Krebs 
& Beavo 1979). The fatty acids released from the adipocyte into the circulation are 
rapidly extracted by many tissues including the liver, which is able to use them for
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energy and as substrates for the synthesis of phospholipids and triglyceride. When 
the availability of these substrates is limited, the liver can generate fatty acid from 
small molecular weight precursors (Barter & Kevin 1972). Similarly a cholesterol 
deficit can be met by endogenous synthesis, following activation of the rate limiting 
enzyme 3-hydroxy 3-methylglutaryl Coenzyme A reductase (HMG CoA reductase) 
(Goldstein & Brown 1984).
Lipids synthesized in the liver have several fates (Noram etal 1983; Packard & 
Shepherd 1986). First, a significant proportion of the cholesterol and triglyceride is 
secreted in VLDL, the major vehicle for endogenous triglyceride transport. 
Secondly, lipid surplus to requirements may be stored, temporarily, as cytoplasmic 
oil droplets within the hepatocyte. And, thirdly, the liver cell has the unique ability 
(Dietschy & Wilson 1970) to eliminate cholesterol into the bile, either unchanged or 
following oxidation to bile acids. Large (gram) quantities of lipid flux through 
these pathways each day and so it is imperative for the hepatocellular economy that 
the mechanisms involved are precisely interregulated. This is achieved by the 
coordinated control of certain key enzymes whose activities appear in turn to be 
modulated by bile acids. These compounds, produced by the liver and secreted into 
the gut to aid digestion, are reabsorbed in the terminal ileum and extracted from the 
portal blood by the liver. Their return to their site of origin in this ‘enterohepatic 
circulation’ produces several important effects (Angelin, Bjorkhem & Einarsson 
1986), viz:
a. Cholesterol 7a hydroxylase, the rate limiting enzyme in bile acid synthesis, is
downregulated.
b. HMG CoA reductase, the enzyme that governs cholesterol production, is also
suppressed, although whether this is a direct or indirect effect of bile acids is a 
matter of controversy.
c. Phosphatidic acid phosphatase, which stands at the fork between the pathways of
triglyceride and phospholipid synthesis, is inhibited, favouring production of 
the latter.
The net result of these regulatory events is to ensure that, as bile acids flow back to 
the liver, they suppress their de novo synthesis while stimulating adequate secretion 
of the co-emulsifier, lecithin into the bile. The enterohepatic flow of bile acids 
follows the cycle of dietary intake, and so strong diurnal rhythms are induced in 
these control mechanisms as evident from detailed studies of rats kept under 
conditions of controlled lighting and feeding (Danielson & Sjovall 1975; Dietschy
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& Wilson 1970; Myant & Mitropoulos 1977). When food is administered during 
the dark period it triggers a release of bile acids from the hepatobiliary tree. This 
produces a peak in the synthesis of hepatic triglyceride, cholesterol and bile acids, 
and secretion of VLDL into the blood stream also reaches a peak (Goh & Heimberg 
1979) The above phenomena are reversed in the middle of the light period when 
the liver is replete with recycled bile acids. However, although this scheme 
provides a plausible explanation for the laboratory observations, it is incomplete 
since even continuously fasted animals show periodicity in hepatic synthesis 
(Myant & Mitropoulos 1977); and in man such diurnal rhythms are less well 
documented, although there is some good evidence to indicate that they occur 
(Parker etal 1982).
It is clear from the above argument that medical or surgical interruption of the 
enterohepatic circulation of bile acids will have profound effects on hepatic lipid 
metabolism. Such therapeutic manoeuvres can therefore be used to advantage in the 
management of hypercholesterolaemia.
1.2.5 Metabolism o f ApoB Containing Lipoproteins
In the post absorptive state, VLDL replaces the chylomicron as the main vehicle of 
triglyceride transport in the plasma. ApoB is integral to the particle and essential for 
its normal secretion. Apo B in VLDL is, as noted above, the larger molecular 
weight apoB-100, but shares a number of antigenic sites with the gut-derived apoB-
48. The B-100 protein has now been sequenced using recombinant DNA 
technology (Knott etal 1985; Carlsson etal 1985; Chan eta l 1985). It is a huge 
protein of 4336 amino acid residues that has many repeat sequences. Following 
synthesis in the rough endoplasmic reticulum, the protein associates with a 
triglyceride/phospholipid droplet in its passage to the Golgi apparatus where it 
becomes glycosylated before being secreted (Hamilton 1983). Examination of 
VLDL particles isolated from purified Golgi membranes has shown that they are 
heterogeneous, encompassing a size range from 40-70nm. They therefore do not 
have a stoichiometrically definable structure (Hamilton 1983). This information 
accords with complementary metabolic evidence that the liver has the capacity to 
elaborate a range of VLDL particles whose size and lipid composition may vary in 
response to changes in nutritional status. Besides apoB-100, nascent VLDL 
particles contain a few molecules of apoC and apoE that are augmented by transfer 
from HDL when the lipoprotein meets the interstitial fluid.
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Triglyceride-rich VLDL enter a metabolic cascade similar to that described for 
chylomicrons, and indeed both compete for the same lipolytic sites in skeletal 
muscle and adipose tissue capillary beds. Studies designed to examine the 
metabolism of VLDL have focussed largely on its B protein moiety. Early work 
with radioiodinated VLDL of density less than 1.006 g. mL-1 (Berman etal 1978) 
indicated that apoB was transferred through an intermediate lipoprotein fraction, 
IDL to LDL. In the process the particle’s core is hydrolyzed by lipoprotein lipase 
(Nilsson-Ehle etal 1980), a reaction that requires the participation of apoCII on the 
particle. Again, in parallel with chylomicron metabolism, cholesteryl esters 
(Eisenberg 1985) are acquired from other lipoproteins (principally HDL) by 
exchange, while surface coat apoC is transferred in the opposite direction (Berman 
etal 1978). LDL therefore represents a ‘remnant* of VLDL catabolism in which the 
triglyceride core is virtually eliminated and apoB is the sole protein component. In 
most subjects, whether normolipaemic or not, the rate of synthesis of apoB into 
VLDL (Janus etal 1980) exceeds that into LDL. Not all VLDL particles are 
therefore destined to complete their journey down the delipidation cascade to LDL. 
This phenomenon has been examined in detail (Shepherd etal 1984b, Packard etal 
1984) using procedures that permit fractionation of the VLDL spectrum in order to 
follow the fates of particles of a narrower compositional range. The evidence that 
emerged indicated that lipolysis of large VLDL (Sf 60-400) generated remnants of 
Sf 12-60 (i.e., within the small VLDL/EDL flotation interval), most of which were 
removed directly from the plasma without appearing in LDL. The latter seemed to 
come from rapid and quantitative transformation of small VLDL particles that had 
been secreted directly by the liver.
Both of the major plasma lipolytic enzymes, lipoprotein lipase and hepatic lipase 
have been implicated in the metabolism of apoB-100 containing particles (Nicoll & 
Lewis 1980). It is known that the affinity of lipoprotein lipase is greater for large, 
triglyceride-rich particles than for smaller remnants, whereas hepatic lipase, which 
expresses both triglyceride lipase and phospholipase activities, seems to favour 
smaller VLDL and IDL particles. The complementary roles of these lipases are 
perhaps best exemplified in studies of patients who, for genetic reasons (Carlson, 
Holmqvist & Nilsson-Ehle 1986; Demant et al 1988), lack the enzymes, or in 
animal studies where enzyme activity has been inhibited using antibodies (Behr etal 
1981; Goldberg etal 1982). Under such conditions, absence of lipoprotein lipase 
results in accumulation of particles of flotation rate greater than Sf 100 that contain 
both apoB-100 and apoB-48 (i.e., of gut and liver origin, respectively). Smaller, 
denser apoB containing lipoproteins virtually disappear from the plasma.
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Conversely, antibody induced inhibition of hepatic lipase in cynomolgus monkeys 
(Goldberg etal 1982) causes the accumulation of smaller VLDL and IDL; and LDL 
becomes relatively enriched in triglyceride. Similarly, individuals with hepatic 
lipase deficiency express high plasma concentrations of small VLDL and IDL that 
are accompanied by reduced circulating levels of LDL (Demant etal 1988).
The product of the lipolytic cascade, LDL, has been recognised for some years as 
structurally heterogeneous in patients with hypertriglyceridaemia (Hammond et al 
1977; Fisher 1983), and more recently has been found to exist in the plasma of all 
individuals as a group of discrete but overlapping particle populations or 
subfractions (Shen et al 1981; Krauss & Burke 1982). These subfractions have 
traditionally been separated on the basis of hydrated density and particle size, using 
density gradient ultracentrifugation and gradient gel electrophoresis respectively, 
and are defined as LDL-I to LDL-IV (Krauss 1987a). Gofman and his coworkers 
were the first to demonstrate that LDL is heterogeneous in the analytical 
ultracentrifuge and to suggest that certain subfractions may be more closely 
associated with CHD than others (Gofman etal 1950b). These early observations 
have now been substantiated in a series of cross-sectional studies that have revealed 
a constellation of abnormalities in LDL structure and concentration that lead to 
increased risk of CHD (Crouse et al 1985; Musliner & Krauss 1988). A 
predominance of small, dense LDL in combination with a raised triglyceride and 
low levels of HDL has been associated with a three-fold increase in risk of 
myocardial infarction (Austin etal 1988). These changes have been collectively 
described as an atherogenic lipoprotein phenotype or ALP (Austin et al 1990b). 
There is strong evidence to suggest that ALP, and more specifically the distribution 
of LDL subfractions, is influenced by a major gene (Austin & Krauss 1986; Austin 
etal 1990a). However, the profile is also subject to the environmental effects of 
diet and drugs (Griffin etal 1992).
1.2.6 Metabolism o f ApoA Containing Lipoproteins
The plasma lipoprotein spectrum also encompasses particles whose main protein 
component is apoA. They lie in the density interval 1.063-1.210 g. mL_1 and are 
the smallest of the lipoproteins, having a molecular weight not much different from 
plasma protein components such as <X2-macroglobulin. A typical HDL particle is 
about 7nm in diameter and almost 3000 times smaller than the average VLDL 
particle in terms of volume. HDL is, therefore, the smallest of the lipoproteins yet
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the most numerous, being a heterogeneous mixture of particles endowed with a 
diversity of metabolic properties.
HDL represents an amalgam of diverse components that come together following:
a. direct secretion by the liver and intestine;
b . transfer from other lipoproteins;
c. transfer from peripheral tissues.
The major HDL proteins, apoAI and apoAII are elaborated in precursor form in the 
liver and intestine. Estimates of the contribution from each of these organs, at least 
in rats, suggest equal sharing of synthesis (Wu & Windmueller 1979). Certainly, 
intestinal apoA production is prodigious as evidenced from its copious appearance 
in the urine of chyluric patients (Green etal 1979). Some o f the protein is secreted 
with chylomicrons and appears in the HDL density interval following lipolysis of 
these particles (Green & Glickman 1981). Consequently after a fatty meal the 
levels of apoAI and apoAH in the plasma rise. In addition, the intestine is capable 
of elaborating and secreting small apoA containing particles directly into the HDL 
density interval (Green, Tall & Glickman 1978), a process that is continuous even 
in the fasting state. Studies using perfused intestine preparations have shown that 
under conditions where lecithin: cholesterol acyltransferase (LCAT) activity is 
blocked, a discoidal particle is produced, rich in free cholesterol and phospholipid 
and with apoA arranged around its circumference. Particles with a similar structure 
are also isolable from lymph (Dory et al 1985), a body fluid that is naturally low in 
LCAT activity. Exposure of such particles to the enzymatic and transfer activities of 
plasma transforms them into mature spherical HDL (Dory etal 1983). The apoA 
proteins lost from the surface of chylomicrons during lipolysis are thought also to 
appear initially in bilayer discs that undergo rapid conversion in the plasma to 
mature HDL spheres (Tall & Small 1978). Electron micrographic studies have 
shown that lipolysis, by reducing the core volume of the chylomicron renders some 
of its surface coat redundant. The surface monolayer responds by folding upon 
itself to form a frond-like bilayer that, shed into the plasma, comes under the 
influence of LCAT and is converted to mature HDL. The central role of LCAT in 
the maturation of HDL is evident from studies of those rare patients (Norum 1984) 
who present with an inherited deficiency of the enzyme. Their HDL circulates as 
bilayer discs that readily undergo transformation in vitro to normal HDL with the 
addition of LCAT.
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As noted above, the liver and the intestine share equally in the synthesis of HDL. 
Perfusion studies in rats have shown that the primary hepatic secretion product is 
again discoidal (Hamilton et al 1976) and rich in both apoAI and apoE. Exposure 
to LCAT induces its rapid conversion to HDL. In this process, apoAI is retained 
while E is lost to lipoproteins of lower density (Norum 1984).
The action of LCAT on discoidal HDL triggers a change in the disposition of 
cholesterol within the particle. The enzyme catalyzes the transfer of a fatty acid 
from lecithin to the hydroxyl residue on cholesterol, leading to the generation of 
lysolecithin and cholesteryl ester (Norum 1984). The polarities of these products 
are fundamentally different from those of their precursors. Lysolecithin is more 
hydrophilic and dissociates readily from the lipoprotein into the aqueous 
environment. On the other hand, esterification of the sterol increases its 
hydrophobicity and causes it to partition into the nonpolar interior of the particle. 
The surface site vacated by the sterol is then available to accept additional 
cholesterol molecules either from other lipoproteins or from cell surfaces. Thus, 
LCAT has a dual action: it facilitates the sequestration of cholesterol within the 
hydrophobic core of HDL, generating in the process a chemical potential gradient 
that leads to continued uptake of the sterol. Even mature HDL particles have a free 
cholesterol/phospholipid ratio that is less than that of VLDL or LDL. Therefore it is 
not surprising that HDL is a good acceptor of tissue cholesterol while VLDL and 
LDL are not. Acquisition of cholesterol by HDL proceeds until the nascent disc is 
fully transformed into a pseudomicellar spherical structure. Obviously, this process 
would be constrained by the size of the HDL particles were it not possible for the 
sterol ester to undergo transfer to less dense lipoproteins facilitated by a neutral lipid 
transfer protein. This protein exchanges the cholesteryl ester in the core of HDL for 
triglyceride acquired from VLDL or chylomicrons. The triglyceride enriched HDL 
then becomes more susceptible to intravascular lipolysis, which renders it smaller 
and denser (Deckelbaum, Olivecrona & Eisenberg 1984). Thus the size o f 
circulating HDL depends on the balance between the opposing forces of cholesterol 
esterification, which increases particle size, and lipolytic digestion, which reduces 
it. A recent report by Cheung etal (1991) has suggested that the size of HDL 
particles may be clinically important. These workers found that smaller particle size 
was associated with CHD and that particle size was a much stronger predictor of 
disease than HDL cholesterol.
The dominant components of mature plasma HDL are its proteins, which constitute 
about 50% of its mass and cover approximately 90% of its surface. They are
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responsible for its interaction with enzymes (apoAI is a cofactor for LCAT) and 
may govern its recognition by receptors on cell membranes. Added to the structural 
heterogeneity within HDL is the diversity that characterizes its proteins. O f 
particular interest are the isoforms of apoAI and apoE, which comprise 6 and 3 
major variants respectively. The apoAI polymorphism arises largely from post- 
translational proteolytic cleavage of the protein (Brewer et al 1983). The nascent 
protein first appears within the cell in a pre-pro-form (Law, Gray & Brewer 1983) 
with a 24 amino acid extension to its amino terminus. A peptide of 18 amino acids 
is cleaved within the cell to release a pro-protein that is secreted into the circulation. 
There it undergoes slower proteolytic transformation to the mature protein, with 
release o f the 6 amino acid propeptide. On average, this final step takes about 6 
hours. Pro-apoAI is more basic than its mature product and is distinguishable by 
isoelectric focussing, even although it normally only represents 1-2% of the total 
apoAI mass. In patients who express the HDL defect known as Tangier Disease, 
pro-apoAI constitutes a much larger proportion of total apoAI, a finding that 
initially led to the proposal (Zannis et al 1982) that the disease results from defective 
pro-apoAI maturation. However, kinetic studies have shown (Bojanovski, Gregg 
& Brewer 1984) that the rates of production and clearance of the pro-protein are 
normal in this condition. Hypercatabolism of the mature form appears to be 
responsible for the relative increment in the mass of pro-apoAI in the circulation. 
ApoAII, the other main HDL protein, is also synthesised in pre-pro-form. 
However, both pre- and pro-peptides are cleaved intracellularly, and only the 
mature form is found in the plasma (Gordon etal 1983). It is not yet known if  
there is any link between apoA maturation and the formation of nascent or mature 
HDL.
Although apoE represents only a minor component of HDL, its presence on some 
of these particles may have a profound influence on their metabolic behaviour. 
Particles that contain the protein can be separated from the bulk of HDL by affinity 
chromatography (Weisgraber & Mahley 1980). They are larger than average and 
bind with high affinity both to the apoB/E receptor and to the putative apoE receptor 
on hepatocytes. Thus, the presence of apoE on HDL particles opens up the 
possibility that they may selectively feed into catabolic pathways controlled by the 
activities of these two receptors. It has already been noted that apoE exists in 
several isoforms, the major representatives being E2 , E3 and E*. These apo E 
phenotypes influence the amount of apoE associated with HDL, in that individuals 
with the E2 phenotype transport more of the protein in that density interval than do 
those with E4. One of two processes may contribute to this phenomenon: either the
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E2 containing particles may bind less efficiently to the receptor and therefore 
accumulate in the plasma (Rail et al 1983), or the E2 itself may form covalent 
disulphide bonds with apoAII, trapping the protein in HDL in a form that is a poor 
ligand for the receptor (Innerarity etal 1978). Indeed, the E-AII complex has been 
identified by Innerarity and his colleagues (1978) as a physiological mechanism for 
delaying the catabolism of apoE containing particles.
Early analytical ultracentrifugation studies made it clear that HDL was not 
monodisperse (DeLalla, Elliott & Gofman 1954) but rather, existed as two or more 
populations that were originally designated HDLi, HDL2 and HDL3. It transpired 
that ‘HDLi’ actually represented a mixture, the main component of which was a 
variant of LDL viz. Lp(a). O f the other two, HDL3 (d. 1.125-1.210 g. mL-1) was 
major and HDL2 (d. 1.063-1.125 g. mL-1) minor in mass terms, but not in clinical 
significance. Further work in the Donner Laboratory in Berkley, California, 
resolved HDL into a number of subspecies (HDL2a> HDL2b, HDL3a, HDL3b, and 
HDL3c) using gradient gel electrophoresis (Blanche etal 1981). The importance of 
each fraction has been the subject of intensive investigation. The polydispersity that 
exists in HDL is good evidence for the existence, within the size constraints of this 
fraction, of a limited number of thermodynamically stable, distinct entities. 
Moreover, we are now beginning to relate changes in metabolism to alterations in 
HDL size. In hypertriglyceridaemic individuals, for example, HDL is a small, 
dense particle that is relatively depleted in cholesteryl ester (Deckelbaum etal 1984). 
As noted above, it seems to be generated by transfer of a proportion of its core 
cholesteryl ester into the large mass of circulating VLDL in exchange for 
triglyceride. The action of hepatic lipase on this particle then causes it to shrink as 
triglyceride and phospholipid are hydrolysed from its core and coat respectively. At 
the opposite end of the spectrum, patients, who suffer from abetalipoproteinaemia, 
have extremely low plasma triglyceride levels, and large circulating HDL, which is 
cholesteryl ester and apoE enriched (Deckelbaum etal 1982).
Normal individuals do not remotely approach either o f the above extremes, 
although throughout the day they do exhibit cyclical variations in plasma 
triglyceride that impact on the distribution of HDL and, indirectly, on coronary 
heart disease risk. Patsch and his colleagues (1984) have found that individuals 
who possess an efficient chylomicron clearing mechanism show only minor 
increments in the flotation rates and negligible changes in the masses of their plasma 
HDL subfractions following a fatty meal. In such patients, HDL2 and HDL3 
become enriched in phospholipid, which is gradually lost, probably through the
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action of hepatic lipase, as the post-prandial lipaemia resolves. HDL probably acts 
in this situation as a single acceptor of chylomicron coat phospholipid, shed during 
hydrolysis of the triglyceride-rich particle. At the other end of the normal spectrum 
exist individuals whose ability to clear chylomicrons is low. They show marked 
and prolonged lipaemia following a fatty meal. The increased residence time of 
triglyceride in their plasma facilitates its transfer into HDL in exchange for 
cholesteryl ester. Phospholipid is also transferred from the chylomicron to HDL 
during the lipolytic process (Schaefer etal 1982) so that these denser particles 
acquire both coat and core components. This results in an increase in their 
susceptibility to hydrolysis by hepatic lipase that leads to a shrinkage of the particles 
and an increase in their density. The magnitude of this change is so great that 
particles, which initially appeared in the HDL2 density interval, now isolate as 
HDL3 (Patsch etal 1984). Such individuals therefore present, even in the fasting 
state, with a lower HDL2/H D L 3 ratio than is found in those whose lipolytic 
processes are efficient. Reduced HDL levels, and in particular low HDIVHDL3 
ratios have been equated with increased risk of coronary heart disease (Gofman, 
Young & Tandy 1966). It is possible that this finding is not of primary importance 
but is merely a reflection of the status of triglyceride-rich particle metabolism. 
Certainly, Simpson and his colleagues (1990) have found that individuals with 
angiographically proven coronary heart disease not only have lower HDL/HDL3 
ratios in their plasma but also suffer from a defect in their ability to clear 
chylomicrons from their bloodstream.
1.2.7 Lipoprotein (a)
Lipoprotein (a) [Lp(a)] was first described by Berg (1963), and its structure has 
since been defined by several groups. Lp(a) is very similar to LDL in its lipid 
composition and like LDL contains a single copy of apoB-100. In addition it 
possesses a large glycoprotein called apo(a), which is thought to be linked to the 
apoB-100 moiety by a single disulphide bridge (figure 3). Apo(a) has been shown 
to have striking structural homology with plasminogen (MacLean etal 1987) (figure 
4) and varies in size from approximately 400 kD to more than 800 kD (Utermann et 
al 1987) (figure 4). Human apo(a), like plasminogen, consists of a protease-like 
sequence, linked to multiple repeat domains held together by three internal 
disulphide bridges and called kringles. Unlike plasminogen, apo(a) is extensively 
glycosylated and a single copy of kringle 5 is linked to a variable number of kringle 
4 repeats (Gavish, Azrolan & Breslow 1989).
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There is much less known about the metabolism of Lp(a) than the other lipoproteins 
but a summary of present knowledge is provided by MBewu & Durrington (1990). 
Lp(a) is probably secreted directly into the circulation and is not a product of 
intravascular delipidation like LDL. Apo(a) is thought to be primarily of hepatic 
origin but its metabolic fate is unknown.
In an attempt to reveal the determinants of plasma Lp(a) levels, which vary widely 
between subjects, the genetic basis of the apo(a) size heterogeneity has been 
uncovered. Genotyping of apo(a) performed by pulsed field gel electrophoresis 
(Lackner etal 1991) has shown that the size of the apo(a) gene correlates directly 
with the size of the apo(a) protein and inversely with the Lp(a) plasma 
concentration. Segregation analysis of the apo(a) gene also revealed that in normals 
the Lp(a) plasma level was largely determined by alleles at the apo(a) gene locus.
A number of studies have demonstrated that Lp(a) is an independent risk factor for 
coronary heart disease. Most recently, Rosengren et al (1990) found, in a 
prospective study of Swedish middle aged men, that plasma Lp(a) level is an 
important determinant of risk of myocardial infarction. Wiklund etal (1990) have 
also reported that apo (a) may be useful in the identification of those FH 
heterozygotes who are particularly at risk of coronary heart disease. But, how does 
Lp(a) contribute to such risk? Because its structure links it with both lipoprotein 
and thrombotic risk factors two main lines of research have been pursued in an 
attempt to answer this question. There is autopsy (Rath et al 1989) and biopsy 
(Cushing etal 1989) evidence for the presence of Lp(a) in the intima of the artery 
wall. Within the intima, Lp(a) is thought to be immobilized by binding 
extracellularly to glycosaminoglycans (Bihari-Varga et al 1988). There is 
immunological evidence for the presence of Lp(a) in foam cells (Niendorf et al
1990), which would suggest that these lipoproteins can be taken up by 
macrophages and contribute to foam cell conversion. Oxidative modification of 
Lp(a), which has recently been described by Sattler and coworkers (1991), may 
render the lipoprotein a suitable substrate for macrophage scavenger receptor- 
mediated uptake. These workers have also discovered that Lp(a) is much more 
resistant to in vitro oxidation than LDL, perhaps because of its higher N- 
acetylneuraminic acid content. This relative protection from oxidation may be 
overcome in part by the prolonged residence of Lp(a) in the intima where it remains 
bound and trapped, but may also account for the apparently low intracellular levels 
of Lp(a).
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Thrombosis is an important prodromal event in myocardial infarction. Evidence to 
support this statement comes not only from post mortem evidence of occlusive 
thrombi in coronary arteries already narrowed by atheroma, but also from the 
beneficial effect of post-infarction thrombolytic therapy seen in the Second 
International Study of Infarct Survival (ISIS-2 1988). The other main explanation 
offered for the atherogenicity of Lp(a) centres on the possible link between this 
lipoprotein and fibrinolysis and thrombosis. Apo(a) has a high degree of structural 
homology with plasminogen and has been hailed as the missing link between 
atherosclerosis and thrombosis. The evidence to date, while supportive of this 
hypothesis, in no way confirms it. The subject is reviewed by Miles & Plow 
(1990) who present evidence to suggest that Lp(a) inhibits fibrinolysis by 
competing for plasminogen binding sites, which in turn leads to an increased 
likelihood of thrombosis. Fibrinolysis may also be influenced by the effect of 
Lp(a) on plasminogen activator inhibitor-1 (PAI-1). Etingin et al (1991) 
demonstrated in cultured endothelial cells that Lp(a) regulated the expression of 
PAI-1, and Edelberg, Reilly & Pizzo (1991) suggest that Lp(a) may regulate 
fibrinolysis by competing with PAI-1 and plasminogen for fibrinogen or heparin- 
bound tissue-type plasminogen. The effects of Lp(a) on fibronectin have also been 
investigated. Ehnholm, Jauhiainen & Metso (1990) have shown that this protein is 
subject to proteolytic cleavage by apo(a). The importance of each of these findings 
in vivo is as yet unknown but this grey area between the fields of lipoproteins and 
thrombosis continues to attract extensive research.
Lp(a) is an intriguing particle that has given up few of its secrets despite three 
decades of research. One of the most fundamental questions, which remains 
unanswered, is its physiological role. A number of hypotheses have been put 
forward but one of the most unusual comes from Rath & Pauling (1990) who 
suggest, based on evolutionary data, that Lp(a) is a surrogate for ascorbic acid.
1.2.8 The ApoB/E Receptor and ApoB Metabolism
The discovery and characterization of the apoB/E receptor has become the paradigm 
of lipoprotein research and was the result of the efforts of Brown & Goldstein
(1987). This molecule is a single transmembrane glycoprotein with its 839 amino 
acids arranged into five functional domains (figure 5). The ligand binding domain 
is found in the 300 amino acid N-terminal segment, which consists of seven 40 
amino acid repeat units, each of which is enriched in aspartate and glutamate 
residues arranged in a configuration that facilitates electrostatic interaction with
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complementary arginine and lysine residues found on two apolipoproteins, apoB 
and apoE (Mahley & Innerarity 1983). The receptor therefore recognises and 
interacts with particles containing these proteins, but with different affinities since 
the E protein binds ten times more effectively than the B. In theory then, the whole 
spectrum within the VLDL-LDL interval, which contains these proteins is substrate 
for the apoB/E receptor. Early metabolic studies (Bilheimer, Stone & Grundy
1979) focused on LDL since it was the lipoprotein recognised to be markedly 
increased in familial hypercholesterolaemia (FH). However, as knowledge 
develops it is becoming clearer that the impact of receptor deficiency is felt along the 
length of the VLDL delipidation cascade, suggesting that the ‘LDL’ receptor has a 
wider role in apoB metabolism than its name suggests.
Tracer kinetic analysis following administration of [i25I]-labelled LDL to humans 
has shown that approximately 30-40% of the entire LDL mass in the plasma is 
catabolised each day. Chemical modification of the tracer with agents such as 1,2 
cyclohexanedione (Shepherd eta l  1979a), glucose (Kesaniemi, Witztum & 
Steinbrecher 1983), or 2-hydroxylacetaldehyde (Slater etal 1984), which interact
NH'
1
NH'
□
C O O H
C O O H
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with arginine or lysine residues on its apoprotein moiety, reduces its clearance by 
50-70%. Since this treatment blocks binding of the lipoprotein to the receptor, 
clearly receptor activity must make a major contribution to LDL turnover. The role 
of the receptor falls by half in those subjects with heterozygous FH and is abolished 
in homozygous individuals (Shepherd etal 1979a). In consequence, more LDL is 
directed into alternative catabolic mechanisms that are mediated via the macrophage 
scavenger receptors (Matsumoto etal 1990).
We know from extensive experiments on cultured cells that the activity of apoB/E 
receptors is regulated by variation in the intracellular sterol pool. When the 
requirement for cholesterol is increased, receptor synthesis is stimulated and LDL 
uptake promoted. Conversely, in times of surfeit, receptor expression is 
diminished and LDL assimilation suppressed. Extrapolation of these concepts to 
man has enlightened our understanding of the regulation of LDL metabolism and 
provided an explanation for the actions of a number of cholesterol lowering drugs. 
This is discussed further in section 1.6 below.
As indicated earlier, theoretical considerations suggest that we ought to expect the 
apoB/E receptor to be implicated in the metabolism of VLDL and IDL. In 1982, 
Soutar, Myant & Thompson discovered that IDL clearance is retarded in FH. This 
problem was further examined in detail using cumulative flotation 
ultracentrifugation to follow the flux of apoB from VLDL through IDL to LDL 
(James et al 1989). FH homozygotes accumulate cholesterol-rich remnants within 
their VLDL density interval because they lack the capacity to clear them normally. 
IDL catabolism is also perturbed to such an extent that its pool size increases as 
much as that of LDL, the level of which rises 3.5 fold in the plasma. Absence of 
the apoB/E receptor, therefore, has a profound impact on apoB metabolism in its 
entirety. But, what of its role in normolipaemic subjects? This question may be 
addressed by following the approach outlined earlier that relies on modification of 
the ligand to affect its receptor binding. Treatment of large, triglyceride-rich VLDL 
(Packard etal 1985) has no effect on its direct clearance from the plasma or its 
conversion to IDL. However, subsequent catabolism of apoB containing particles 
is significantly retarded. Additional evidence supporting the view that apoB/E 
receptors participate in VLDL remnant and IDL clearance comes from clinical 
observation of patients with dysbetalipoproteinaemia. This condition is 
accompanied by high circulating levels of both these lipoprotein fractions due to 
their inability to bind efficiently to hepatic lipoprotein receptors. Up-regulation of 
the apoB/E receptor with an HMG CoA reductase inhibitor lowers the concentration
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of VLDL remnants and IDL in the plasma of these patients (Vega, East & Grundy
1988).
Familial hypercholesterolaemia (FH), the autosomal codominant trait that occurs in 
its heterozygous form in 1 in 500 of the population is associated with high levels of 
LDL cholesterol in the plasma and premature coronary heart disease and is known 
to arise because of a defect in the apoB/E receptor. Since its discovery more than 
150 different mutations of the apoB/E receptor have been described (Hobbs etal 
1990) that are responsible for FH. The many deletions, insertions and base pair 
substitutions within the apoB/E receptor gene can have profound effects on LDL 
catabolism. Recent observations suggest that similar and equally deleterious effects 
may result from defects in its primary ligand, apoB-100. This is most commonly 
seen in a condition called familial defective apoB-100, which is due to a mutation at 
a CG dinucleotide in residue 3500 of the apoB gene and is present again at a level 
of approximately 1 in 500 of the population (Innerarity etal 1990). Such changes 
in apoB sequence appear to be of real clinical significance and further mutations are 
currently being sought.
1.2.9 The HDL Receptor and Reverse Cholesterol Transport
From the discovery that plasma HDL levels are associated with protection from 
coronary heart disease (reviewed by Gordon etal 1989) came the concept that this 
lipoprotein acts as a vehicle to transport sterol from peripheral tissues to the liver. 
The necessity for such a mechanism is unquestionable since the 
perhydrocyclopentanophenanthrene nucleus of cholesterol cannot be catabolized to 
any significant extent in animals and must therefore be excreted intact via its major 
organ of elimination, the liver. HDL has the capacity to acquire cholesterol from 
cells in vitro as an initial step in the ‘reverse cholesterol transport pathway* 
advocated by Glomset (1968).
The precise mechanism responsible for uptake is, however, currently disputed. It 
is generally accepted that the free sterol, rather than its ester, participates in the 
transfer process. Whether this occurs during cell-lipoprotein collisions, as a result 
of passive diffusion, or through capture and release of HDL by cells, is not clear. 
The binding process would require the specificity inherent in a receptor protein, and 
there have been several publications claiming the detection of proteins that appear 
to meet this requirement. If such a mechanism exists, the binding site should be 
saturable and subject to regulation, on the basis, for example, of cell cholesterol
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content. Biesbroecke and his colleagues (1983) have evidence to suggest that the 
interaction of HDL with fibroblasts displays these characteristics and promotes 
cholesterol release from cells. Binding can be inhibited by alteration of the tyrosyl 
residues of the HDL protein with tetranitromethane (Tabas & Tall 1984; Chacko 
1985) but is unaffected by arginine and lysine modification. The binding process 
seems specific for HDL proteins. LDL fails to compete, while liposomes 
containing apoAI, the major protein in HDL, bind with high affinity. Recently, 
Tozuka & Fidge (1989) have confirmed the presence of cell surface proteins that 
bind both HDL proteins, Al and AH. Furthermore, these workers report that HDL3 
is the principal ligand for these receptors and that LDL was unable to compete. The 
removal o f cholesterol from peripheral cells may also occur via an elegant 
internalization process involving the whole HDL particle. Postulated by Alam etal
(1989), this process results in the intracellular remodelling of HDL, increasing its 
size and apoE content, after which the particle emerges from the cell by a process of 
‘retroendocytosis’. Against the receptor concept, however, is the evidence that 
limited proteolysis of either the lipoprotein or the cell membrane surface fails to 
inhibit binding. Nevertheless, data from two sources suggest that the binding 
process is regulated by the free cholesterol content of the cell and may be modulated 
by mitogens such as platelet derived growth factor (Oppenheimer, Oram & Bierman 
1987), which was shown to decrease both HDL binding and cholesterol efflux.
A fascinating development in this field is offered by Milda, Fielding & Fielding
(1990) who give supportive evidence for an hypothesis that the functional 
heterogeneity of HDL encompasses the ability of this lipoprotein to process 
cholesterol from peripheral cells and other plasma lipoproteins independently. This 
further refinement in our understanding of HDL metabolism only serves to remind 
us of how much we have still to learn.
1.2.10 The ApoE Receptor and Chylomicron Metabolism
As noted above, dietary lipids are packaged within the enterocytes o f the small 
intestine into large triglyceride-rich chylomicron particles that contain approximately 
1-2% protein. The latter consists primarily of apoAI, apoAII, apoAIV and apoB- 
48. This shortened B protein lacks the apoB/E receptor binding site, and the 
chylomicron must acquire an alternative receptor-binding ligand before it can be 
taken up by the liver (Chen etal 1987). This occurs soon after the particle enters 
the circulation as a result of transfer of apoE, principally from HDL. Lipolysis of 
the triglyceride core of the chylomicron in the capillary beds of skeletal muscle and
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adipose tissue generates a relatively cholesterol enriched remnant, which is 
purported to be atherogenic since it is able to produce cholesteryl ester deposition in 
macrophages. Ideologically, there is biological benefit in clearing these remnants 
as quickly as possible from the bloodstream. This function is performed by the 
liver, which has a highly efficient uptake mechanism capable of clearing the blood 
of these remnants in a single pass. The apoB/E receptor could in theory participate 
in this process but is unlikely to do so since chylomicron remnant metabolism is not 
compromised in homozygous FH subjects (Rubinsztein etal 1990). The most 
promising putative chylomicron remnant receptor (also called the apoE receptor) is 
the LDL receptor-related protein (LRP) (Heiz etal 1988). LRP is a cell surface 
protein that is much larger than the apoB/E receptor but is structurally homologous, 
comprising the elements of four apoB/E receptors (figure 5). LRP has been shown 
to be an apoE binding protein (Beisiegel et al 1989) and to mediate the uptake of 
cholesteryl esters derived from apoE enriched lipoproteins in vitro (Kowal et al 
1989). One of the most intriguing aspects of this newly defined protein is the 
observation that it acts as a receptor for the plasma protein <X2-macroglobulin 
(Strickland et al 1990). I f  LRP does have two apparently unrelated ligands, apoE 
and (X2-macroglobulin we are faced with some difficult problems. What will the 
primary function of this protein be in vivo, how may its expression be manipulated, 
and how could such a double receptor protein evolve? Some attempt to shed light 
on these important questions is made by Brown etal(1991) but they conclude that 
much more work has to be done before we will be in a position to accept the LRP 
as the definitive chylomicron remnant receptor that has been sought for so long.
1.2.11 Modified Lipoproteins and the Scavenger Receptors
Detailed electron microscopic studies have shown that in cholesterol fed non-human 
primates the earliest prodromal sign of a developing atherosclerotic plaque is focal 
infiltration of the subendothelial space of the arterial wall by cells of the 
monocyte/macrophage series (Fagiotto, Ross & Harker 1984). When examined in 
culture, these cells are able to assimilate and deposit cholesteryl esters in 
intracellular lipid inclusions (Brown & Goldstein 1983). The source of this sterol 
has been the topic of a large body of research. Plasma LDL, the most abundant 
sterol transporter, does not generate these deposits. However, modified LDL 
particles extracted from the aorta (Hoff & Morton 1987) have this ability. They 
differ from the normal lipoprotein by being more electronegative, like the artificially 
produced acetyl LDL, which is avidly assimilated and deposited in macrophages 
(Goldstein etal 1979). Indeed, these cells exhibit on their membranes proteins that
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facilitate the rapid unregulated uptake of acetyl LDL to the extent of generating foam 
cells reminiscent of those found in the atherosclerotic lesion. Because a wide 
variety of negatively charged compounds can compete with acetyl-LDL for these 
receptors they have become known as scavenger receptors (Brown eta] 1980). 
Clearly, the physiological ligand for these receptors is not acetyl LDL, nor are they 
present to facilitate the production of foam cells. Steinberg etal( 1989) have found 
that charge modified lipoproteins, in the form of oxidized LDL, compete with 
acetyl-LDL and cause foam cell conversion. They concluded that modified 
lipoproteins may be the in vivo ligand for these scavenger receptors. A number of 
observations support the hypothesis that oxidized LDL is important in the 
development of atheromatous plaques. Firstly, there is immunological evidence for 
the presence of oxidized LDL in atheromatous lesions and even human fatty streaks 
(Haberland, Fong & Cheng 1988; Yla-Herttuala etal 1989, 1991). Secondly, LDL 
isolated from atherosclerotic plaques (Goldstein etal 1981; Yla-Herttuala etal 1989) 
is electronegative and produces foam cell transformation in vitro. And, thirdly, 
Carew, Schwenke & Steinberg (1987) have attributed the protective action of the 
drug probucol to its ability to scavenge free radicals and limit the rate of LDL 
oxidation, rather than to its lipid lowering properties. When the drug was 
administered to Watanabe rabbits, LDL uptake into atherosclerotic lesions fell by 
65%, while a comparative group given alternative lipid lowering drugs showed no 
improvement.
The mechanism for the modification of LDL in vivo is speculative. Evidence from 
tissue culture work (Steinbrecher et al 1984; Henricksen, Mahoney & Steinberg 
1987) suggests that endothelial cells or even macrophages themselves, through their 
ability to generate superoxide radicals, may initiate oxidative damage to the 
lipoprotein’s lipid and protein moieties. This could obviously occur exclusively 
within the artery wall, accounting for the inability to detect the damaged or modified 
lipoproteins in the plasma (Frei etal 1988).
There is evidence to suggest that multiple scavenger receptors must exist on the 
macrophage membrane (Sparrow, Parthasarathy & Steinberg 1987) and it is now 
known that these cells express at least two types of scavenger receptor protein that 
have been isolated and cloned (Kodama et al 1990, Rohrer et al 1990). Both 
human type I and type II scavenger receptors have been localized on foam cells in 
atheromatous plaques (Matsumoto etal 1990). The presence of macrophage 
scavenger receptor mRNA in atherosclerotic lesions with little associated apoB/E 
receptor mRNA (Yla-Herttuala etal 1991) further points to a key role for these
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scavenger receptors in the uptake of cholesterol and conversion of macrophages to 
foam cells.
The effect of oxidized lipoproteins on vascular tone is another important area 
(reviewed by Henry & Bucay 1991) where lipoproteins have been shown to have 
effects on the cardiovascular system in addition to their long-recognized role in 
atherogenesis. Oxidized LDL has been found to impair arterial relaxation in vitro in 
response to agents that act by stimulating the release of endothelium-dependent 
relaxing factor (EDRF) from endothelial cells. Clinical reports (Vita et al 1990; 
Zeiher et al 1991) have further raised interest in this area by indicating that 
hypercholesterolaemia may be associated with a decreased responsiveness to 
endothelium dependent vasodilators (e.g. acetylcholine). This defect, it is 
suggested, may seriously limit vasodilatory reserve and contribute in part to 
myocardial ischaemia in such patients. Such a vasomotor syndrome resulting from 
hypercholesterolaemia resembles the in vitro observations that have been explained 
by the presence of oxidized LDL. This work is still at an early stage but clearly if 
confirmed will have profound implications for clinical management.
Oxidative modification of LDL has also been postulated as one of the very first 
steps in the development of the fatty streak. Mild oxidation of LDL particles, 
resulting in so-called, minimally-modified LDL (MM-LDL), gives rise to a 
lipoprotein that is not chemotactic in itself but that stimulates the release of 
monocyte chemotactic protein-1 (Berliner eta l 1990; Cushing et al 1990). 
Moreover, MM-LDL has also been shown to promote endothelial-monocyte 
binding, an important step in early atherosclerotic plaque formation A further 
putative link between lipoproteins and the thrombotic system has been put forward 
by Drake et al (1991) who showed that MM-LDL when cultured with human 
endothelial cells induces the expression of tissue factor (tissue thromboplastin), 
which may be involved in platelet adhesion.
1.3 Methods for Studying Lipoprotein Metabolism
While in vivo experiments in man are the studies of choice to provide the most 
biologically relevant data on human lipoprotein metabolism, a number of practical 
and ethical constraints have necessitated the use of in vitro systems such as cell 
culture and isolated perfused organs. Although the studies of apolipoprotein B 
metabolism described in this thesis have involved human in vivo techniques 
exclusively it is pertinent in this general discussion to include a short section on in 
vitro methodology.
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As outlined in section 1.2 normal lipoprotein metabolism depends on the 
coordinated actions of a number of enzymes, lipid transfer proteins and specific cell 
surface receptors. In vivo experiments can provide information on the integrated 
processes of lipoprotein interconversions, but in order to study individual 
components of this system, tightly controlled experimental models must be 
designed. However, if the in vitro system under study is to have any physiological 
relevance a number of basic rules, as set forth by Eisenberg (1986) should be 
followed:
a) Undamaged lipoproteins should be used in preference to adulterated 
preparations, lipid emulsions, or artificial lipid:protein complexes.
b) Lipoproteins under study should be exposed to multiple reactants, as they are in
vivo.
c) Continuous metabolic cycling must be permitted in the in vitro system or the
interruption of such cycles should be recognised.
These rules are attempts to recreate the physiological state in the test tube, and serve 
as reminders that while we may simplify a system in order to make it accessible to 
study, we may, in so doing, render it fundamentally different from the original and 
therefore biologically irrelevant.
It is important, however, to realise that in vivo and in vitro studies are 
complementary; many aspects of lipoprotein metabolism having only been 
elucidated by the application of both approaches. Greater confidence is naturally 
placed in the results if  several entirely independent techniques have arrived at 
consistent answers.
1.3.1 Cell Studies.
Studies involving cultured human skin fibroblasts have contributed a great deal to 
our understanding of lipoprotein metabolism. The discovery and characterization of 
the apoB/E receptor by Goldstein and Brown was by means of a series of 
experiments that used fibroblasts from patients with homozygous and heterozygous 
FH (Brown, Faust & Goldstein 1975). Cell culture studies using in addition to 
fibroblasts, hepatoma cell lines, e.g. Hep G2 cells, cultured macrophages and 
hepatocytes, are the most widely used methods in the study of lipoprotein 
metabolism. They have undoubtedly allowed many of the cellular and intracellular 
events of lipoprotein synthesis and catabolism to be elaborated, but the results
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obtained from such studies should always be subject to validation by in vivo  
experiments either in animals or, preferably, man.
1.3.2 Perfused Organ Studies.
The study of hepatic lipoprotein metabolism has been made possible by measuring 
the output of isolated, perfused livers (Marsh 1986). Livers of animals as large as 
pigs have been successfully perfused in studies of lipoprotein metabolism (Nakaya 
et al 1977) but the most convenient and therefore most widely used animal liver is 
that of the rat. Perfusion experiments may be carried out in situ (Hamilton et al 
1974) or in an extracorporeal apparatus (Felker etal 1977). Re-circulation of the 
perfusate provides an isolated organ system that is close to the physiological state, 
but does not allow for measurement of hepatic lipoprotein synthesis due to hepatic 
catabolism of secreted products. Alternatively, single pass perfusion may be used 
in isolated organs. This technique has the advantage that it prevents lipoproteins or 
enzymes released by the liver from being continuously exposed to hepatic 
degradation, but also has the disadvantage that huge volumes of perfusate are 
generated. Other perfused organs have included the rat heart (Chajek & Eisenberg 
1978) to examine the effects of endothelial bound lipase on triglyceride rich 
lipoproteins, and the intestine (Windmueller, Herbert & Levy 1973) to investigate 
intestinal apolipoprotein synthesis.
1.3 .3  In V ivo Study o f  Lipoprotein M etabolism  U sing  
Radioisotopes.
Early studies of plasma cholesterol and triglyceride kinetics were based on the use 
of labelled precursors ([^Jglycerol, Farquhar etal 1965, [14C]fatty acids, Baker & 
Schotz 1964) that were incorporated into the plasma lipid fractions. Measurement 
of their clearance from the bloodstream gave preliminary crude information on 
whole body turnover rates. However, the limitations of this approach became 
apparent when it was realised that plasma lipids were associated with specific 
proteins that are capable of exchange between the different lipoprotein species. 
Consequently, most of the recent metabolic studies have used an exogenous 
labelling procedure in which the lipoprotein or apolipoprotein under study is 
isolated and trace-labelled, usually by iodination. The tracer is then introduced back 
into the subject and frequent timed blood samples are drawn to follow its 
catabolism. The plasma disappearance rate of radioactivity from the protein 
associated with a specific lipoprotein fraction is used as an estimate of the fractional 
catabolic rate (FCR) of the protein; this is expressed in ‘pools catabolized per day\
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Determination of the plasma pool itself (in mg) permits the calculation of the 
absolute catabolic rate (ACR) of the protein (in mg per day), which is usually 
expressed per kilogram body weight. In ‘steady state’, this is numerically equal to 
the apolipoprotein synthetic rate. Building on early work on the metabolism of free 
fatty acids and triglyceride turnover, this method was first applied to lipoproteins in 
the early investigations of Gitlin et a /(1958), but most o f the present day work in 
lipoprotein kinetics is derived from the studies of Langer, Strober & Levy (1972). 
They were the first to isolate a defined lipoprotein class (LDL) and determine the 
synthetic and catabolic rates of its protein component (apoB).
The validity of exogenous labelling techniques is dependent on the following 
assumptions:
a) The labelling process does not alter the structure or function of the lipoprotein
under study, i.e., tracer and tracee are metabolically equivalent.
b) The tracer is structurally and metabolically homogeneous.
c) Catabolism occurs in or close to the plasma compartment or in a pool that is in
rapid equilibrium with the plasma.
d) The concentration (pool) of the tracee plasma lipoprotein does not change during
the period of study, i.e., there is no long term trend or periodic rhythm.
The first assumption is very important and the attempts to validate this must be 
reviewed. The problem of tracei/tracee equivalence was first examined by Langer 
and his colleagues who showed that iodinated lipoproteins had the same 
electrophoretic, immunological, and flotation characteristics of unlabelled 
autologous particles (Langer e ta l 1972). Similarly, several other groups 
(Eisenberg e ta l 1973; Nestel efa/1983; Sigurdsson, Nicoll & Lewis 1975; 
Kissebah etal 1982) have examined this very important issue and concluded that 
iodination of a lipoprotein does not affect its properties on cellulose acetate 
electrophoresis, immunoelectrophoresis, gel chromatography or heparin affinity 
chromatography.
Isolation and radioiodination of a lipoprotein may not render it significantly 
different from other isolated lipoproteins but this does not mean that it is 
metabolically indistinguishable from circulating lipoproteins that have never been 
exposed to ex vivo processes. Some experimental data (Berman etal 1978) suggest 
that a portion of such radioiodinated lipoproteins is frequently cleared by a rapid 
catabolic pathway, after reinjection, assumed to be a consequence of tracer damage.
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Comparisons, however, between VLDL apoB and LDL apoB kinetic parameters in 
hypertriglyceridaemic individuals derived from exogenous radiolabelling (Kissebah 
et al 1976; Sigurdsson, Nicoll & Lewis 1976), and endogenous labelling with 
labelled amino acids (Fisher etal 1980) are very similar.
The methods used to analyse the protein radioactivity data may significantly affect 
the final interpretation of the results. A number of mathematical procedures have 
been used (Berman, Grundy & Howard 1982), including curve peeling, 
deconvolution analysis, interactive simulation, and multicompartmental modelling. 
The last, originally applied to lipoprotein systems by Berman and his colleagues 
(1978), is the most versatile and can be used as a tool to test quantitative hypotheses 
about the system under study. The use of amino acid precursors to follow 
apolipoprotein kinetics has not been a widely applied technique because of 
reluctance to give the large doses of [14C] needed to obtain meaningful results. 
Fisher and coworkers (1980) have provided some data on the incorporation of 
[14C]leucine into apoB containing lipoproteins while Eaton & Kipnis (1972) used 
[75Se]selenomethionine. Synthetic rates can be measured directly with labelled 
precursors if a good estimate of the immediate (usually hepatic) precursor amino 
acid pool can be obtained. Recycling of the tracer species usually limits the 
application of these methods to rapidly turning over species like VLDL. Complex 
computer modelling, which accounts for re-utilisation of labelled amino acids is 
required if  species with prolonged half-lives, e.g. LDL and HDL, are studied.
1.3.4 In V ivo Study o f  Lipoprotein M etabolism Using Stable 
Isotopes.
The potential of endogenous labelling has been further investigated more recently 
using stable isotope labelled precursors. The use of stable isotopes in biological 
research is hardly new since the first isotopic tracer studies used the stable isotope 
of hydrogen to study fat metabolism in mice (Schoenheimer & Rittenberg 1935). 
Their application to lipoprotein kinetic research is, however, more recent and has 
been facilitated by recent advances in mass spectrometry technology. The kinetic 
work performed thus far has produced comparable results with exogenous 
radiolabelling studies (Cryer et al 1986). The general problems inherent in 
endogenous labelling are also applicable to stable isotope technology (Wolf 1984), 
but an important advantage in using stable isotopes is that of increased patient safety 
and acceptability. The analysis of stable isotope data cannot, however, be viewed 
as directly analogous to that of radioisotope data (Cobelli et al 1987). Stable
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isotope precursors used have been [15N]-glycine (Cryer etal 1986, Schauder etal
1989), D3-leucine (Cohn etal 1988) and [13C]-phenylalanine (Shaefer etal 1988). 
Early results with this technology are encouraging and provide data that closely 
mirror those obtained with radio-iodinated tracers. Such studies are of course still 
hampered by the problem of re-cycling that is seen with radioactive endogenous 
precursors. I f  further validated the use of such stable isotope protocols may be 
extended for the first time to the study of lipoprotein kinetics in children and in 
pregnancy, as well as multiple studies in the same patient. In spite of these 
advantages, it is difficult to envisage how this technology would ever completely 
replace the use of exogenously labelled tracers, and the information it provides 
should be considered complementary to radioisotope studies.
1.4 Methods o f Analysis
All kinetic experiments in complex systems such as the human body present two 
problems. The first is how to collect the data, and the second is how to interpret it. 
The latter is often no less daunting than the former. Section 1.3 described methods 
for gathering information on lipoprotein interconversion and catabolic rates; the 
discussion that follows outlines various mathematical analyses that may be applied 
to the raw data to extract physiologically meaningful parameters. It should be 
remembered that all such analyses are approximations to reality, and all involve 
assumptions that are often little more than intelligent guesses as to what is 
happening in the body.
1.4.1 Urinary Excretion as a Measure o f Catabolism
If the site of irreversible loss of trace-labelled material is restricted to the plasma or a 
compartment in rapid equilibrium with it then the ratio of urinary radioactivity to 
that in plasma is a measure of the fractional catabolic rate (FCR) of the lipoprotein. 
This urine/plasma ratio (U/P ratio) is valid if it can be demonstrated that:
a) urine is the only site of loss
b) the level of small-molecular weight degradation products in plasma is negligible
c) the tracer is homogeneous
d) urine collections are complete over each 24 h period
Early studies by Berson & Yalow (1957) established the use of these urinary 
radioactivity measurements as a means of assessing the catabolism of iodinated 
proteins, and the lipoproteins, LDL and HDL, can usually be analysed by this
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method. Normally the total urine radioactivity in a 24 h period is measured and 
related to the mean plasma radioactivity during the same period. With 
radioiodinated tyrosine there is normally a 0.5 day delay between its appearance in 
the plasma and its excretion in the urine. Thus a better measure of the mean plasma 
c.p.m. may be taken as the radioactivity at the start of the 24 h period. It is usual to 
collect urine continuously over the 14 d of an LDL or HDL turnover and examine 
the daily U/P ratio (figure 6). Deviation from a steady value may be due to tracer 
damage (especially high peak values in the first two days) or more likely tracer 
heterogeneity. The latter is readily seen in most LDL turnovers in normal subjects 
but not in those with hypercholesterolaemia (Packard etal 1976). The U/P ratio is a 
valuable parameter and can be viewed as a daily survey of the catabolic potential of 
the tracer. A mean of all 14 U/P values may be used as a measure of the FCR of 
LDL and it bears a close resemblance to the value obtained by analysis of plasma 
data. However, the suggestion (Turner etal 1984) that a single U/P ratio estimate 
at day 7 of an LDL turnover may be sufficient to determine the LDL-FCR precisely 
is not valid (Vega & Grundy 1989a).
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Figure 6. Urine/plasma radioactivity ratios determined throughout the 14 day 
period following injection of [125I] apo-LDL into a control subject and one with 
heterozygous FH. The inconstancy of the ratio in the control subject probably 
reflects metabolic heterogeneity within the LDL spectrum. This phenomenon is less 
apparent in the FH heterozygote.
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Urine data are a valuable source of information in LDL and HDL turnovers 
particularly if a multicomparmental approach is used in analysis as described below. 
It is an important marker of catabolism and should be included, where possible in 
all protocols.
1.4.2 Determination o f Fractional Catabolic Rate from Plasma Data
When daily plasma radioactivities are plotted on semi-logarithmic graph paper, most 
lipoproteins and apolipoproteins display bi-exponential kinetics, i.e., the decay 
curve can be described by equation 1, where Ci and C2 are the intercepts on the Y- 
axis, and bi and b2 are the slopes of the two exponentials (figure 7).
Equation 1__________Y*Cie~^-+ Ciem^2t________________________________
If the tracer is homogeneous and catabolized solely from the plasma compartment 
then a number of kinetic parameters may be determined by the mathematical 
approach of Matthews (1957), viz. the fractional catabolic rate (equation 2), the 
percentage of intravascular tracer (equation 3), and the capillary transfer rate 
(equation 4)
Equation 2 FCR=  1__
__________________________(Ci/bi+C2/b2)
Equation 3 % intravascular3 iC l/bl+C 2/b2)2
[Ci/(bi)2+CV(b2)2]
Equation 4 CTR= CiC2(b2-bi)2
_________________________(Cib2+C2bi)
Practically, the plasma data are plotted to determine the start of the second, slow 
exponential. Simple regression can then be used to provide a line of best fit to this 
exponential, yielding bi and Q . The first exponential is then extrapolated to the Y- 
axis and these projected values are subtracted from the plasma curve at suitable 
intervals (e.g. 0.5, 1.0, 2.0, 2.5, 3.0, 3.5, 4.0 days in an LDL turnover) to 
calculate the second exponential. Linear regression is used again to derive t>2 and 
C2. If  the second exponential is curvilinear then further ‘curve-stripping’ is needed 
and extra terms must be added to the kinetic equations but usually two exponentials 
are sufficient for analysis of LDL and HDL decay curves.
Chapter 1 Introduction 36
* o
■8
c
0
1
I
10
8
6
4
Slope b,
2 Slope b
10 30 50 70 90 110 130 150
Time (Hours)
Figure 7. Analysis of biexponential plasma radioactivity curve by resolving into 
two monoexponentials defined by the parameters bi and b2 (slopes) and Ci and C2 
(intercepts).
Determination of the plasma FCR by either the Matthews approach or the U/P ratio 
permits an absolute catabolic rate (ACR) to be calculated i.e., FCR x mass of 
apolipoprotein in the circulation. If  it can be demonstrated that the subject is in 
steady state then the ACR is equal to the synthetic rate of the apolipoprotein. 
Pragmatically we accept steady state if:
a) the subject’s weight has not altered over the study period,
b) there is no trend (i.e., gradient of > 10%) in the plasma concentration of the 
lipoprotein under study,
c) the coefficient of variation of serial estimations is less than 10%
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1.4.3 Analysis of Prccursor-Product Specific Activity Curves
Studies of lipoprotein interconversions such as the VLDL to LDL delipidation 
cascade have been analysed using a variety of techniques. A popular approach has 
been to calculate the specific activities (c.p.m. per mg apoB) of the precursor 
lipoproteins (VLDL) and the products (LDL or IDL and LDL). The relationship 
between these curves reveals something of the metabolic links between the 
lipoprotein species.
Zilversmit (1960) has shown that if a labelled precursor, A, is the sole source of the 
product, B, then the decay curve for the specific activity of A will cut the product 
curve at the maximum (peak) of B. I f  the specific activity of B is less than the 
specific activity of A at the time of the peak then other ‘cold* input is contributing to 
the mass of pool B. This simple analysis was used in early studies to establish the 
link between apoB in VLDL and LDL. Furthermore, the areas under the precursor 
and product curves may be used to derive quantitative measures of the VLDL-LDL 
conversion rate (Soutar etal 1982).
A more sophisticated technique for mathematical analysis of specific activity data 
has been used by Sigurdsson (1982). Deconvolution or impulse analysis 
represents an extension of indicator dilution theory. It relies on:
a) obtaining disappearance curves for [125I]VLDL apoB and [l31I]LDL apoB,
b) measuring an appearance curve for [ 125I] apoB in LDL, and
c) unequivocal extrapolation of the precursor curves to infinity (i.e., to ‘zero’).
The above techniques, which depend on the relationships between curves have been 
termed ‘model independent’ and to a certain extent this is valid since they make few 
assumptions about the system under investigation. The term, however, is 
misleading in that fundamental preconceptions such as precursor and product 
homogeneity are inherent in the functions used for analysis. The approach is also 
limited in the amount of information it can derive from a given data set.
1.4.4 Multicompartmental Modelling
Of the various methodologies associated with its study, it is the use of 
compartmental modelling that has resulted in the formation of a uniform theory of 
lipoprotein metabolism (Zech, Boston & Foster 1986). Data fitting using
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compartmental or mechanistic models is a powerful, general approach to the study 
of lipoprotein kinetics. It has been used successfully in the analysis of both lipid 
and apolipoprotein turnovers and has been of great importance to the elucidation of 
the metabolism ofapoB. Building on the original lipoprotein turnovers performed 
by Gitlin and coworkers (1958) who observed the transfer of tracer from the Sf 10- 
100 interval to the S f 3-9 (i.e., from VLDL to LDL), an apo B ‘delipidation chain’ 
was first included in a multicompartmental model by Phair and his colleagues in 
1975. This work was extended at the NLH and a new mechanistic model of apoB 
metabolism was proposed in 1978 that incorporated a slowly turning over VLDL 
compartment (Berman etal 1978). Since that time several groups have proposed 
alterations of the multicompartmental model that is used as an hypothesis of apo B 
metabolism. This evolution of a model, based on new experimental observations, 
is an essential part of its character, however, as models become increasingly 
complex in order to explain metabolic reality they become increasingly abstract and 
inaccessible to the user. One of the main disadvantages in using 
multicompartmental analysis is that these detailed, structured models have to be 
specified based on the physiological processes under investigation, but often they 
contain features necessary for the solution that cannot be attributed to a known 
metabolic step. In any modelling process it is vital to remember that the model in 
use is simply a model, i.e., a mathematical representation of reality. The solutions 
we obtain are mathematical approximations to the metabolic reality based on the 
constraints of the model.
The most powerful tool that has been used in this area of lipoprotein metabolism is 
the Simulation, Analysis And Modeling (SAAM) computer program generated by 
Berman & Weiss (1974). This is a package originally devised to operate in a batch 
mode but is now available in an interactive version, CONS AM (Boston, Greif & 
Berman 1982). This form of the program has, as its acronym suggests, a 
conversational potential for interrogation, display, modification of the model and 
the solutions, and for setting up and executing various modelling tasks. These 
modelling programs, given an observed data set and initial estimates, will alter the 
parameters in an iterative manner until they reach a minimum sum of squares for the 
residual differences between observed and calculated data.
Multicompartmental modelling can be used for parameter estimation in complex 
metabolic pathways and is limited mainly by the quality and quantity of information 
contained in the data set. It also allows quantitative hypotheses to be generated and 
tested.
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1.5 Concepts o f Hypolipidaemic Therapy.
With the decision to measure an individual’s lipoprotein profile must go the 
willingness to offer rational management if a dyslipidaemia is detected. The form 
of that management may range from simple verbal advice to lifelong multiple drug 
therapy or even surgery. Clearly, such decisions must not be taken lightly and 
must be based on the best knowledge available. In addition, the treatment of 
dyslipidaemia must not be separated from the management of the other main 
correctable risk factors, smoking and hypertension. In recognition of this fact some 
hospital lipid or lipoprotein clinics have changed their names in recent years to Risk 
Factor Clinics (Evans, Taylor & Taylor 1990).
1.5.1 Criteria for Therapy
The decision of who should receive management of dyslipidaemia has been clarified 
to some extent by a series of major reports. The guidelines issued by the British 
Hyperlipidaemia Association (Shepherd etal 1987), the Study Group, European 
Atherosclerosis Society (1988), and the National Cholesterol Education Program
(1988) provide a consensus on the management of patients with elevated cholesterol 
levels. It is clear from an inspection of these reports that a number of issues have 
not been addressed, viz. how age and sex influences the criteria for management. 
There is still, therefore, some controversy over these issues and they will only be 
resolved by further clinical research involving large primary and secondary CHD 
prevention studies.
1.5.2 Therapeutic Options. Non-pharmacological.
Once hyperlipidaemia has been confirmed by repeated testing and the main 
secondary forms have been excluded by clinical and biochemical monitoring of 
endocrine and renal function a number of therapeutic options exist. Published 
guidelines for the management of patients with hyperlipidaemia concur that diet is 
of prime importance and they advocate the first line use of a general lipid lowering 
diet or ‘step-one diet* (Consensus Conference 1985; Shepherd etal 1987; National 
Cholesterol Education Program 1988; Study Group, European Atherosclerosis 
Society 1988). This step-one diet involves: reducing calorie intake to achieve and 
maintain desirable body weight; reducing total fat intake to less than 30% of total 
calorie intake; increasing the ratio of polyunsaturated to saturated fat intake to 1:1 
and taking 10-15% of total calories as monounsaturated fat; and reducing dietary 
cholesterol intake to less than 300 mg. d-1. This advice, and variations on it, form 
the cornerstone of the initial management of hyperlipidaemia. While the response to
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this step one diet has been criticised by Ramsay, Yeo & Jackson (1991) in their 
meta-analysis of dietary studies as ‘too small to have any value’ other groups have 
used it with reductions in total cholesterol of up 22% (Evans, Turner & Ghosh 
1972; Jones et al 1982; National Cholesterol Education Program 1988).
The WHO (1990) has further advocated more recently the adoption of diets 
relatively rich in monounsaturated fats and with increased intakes of fruits and 
vegetables to help reduce the incidence of CHD. These diets approximate to those 
of the Mediterranean countries and the obvious attraction o f such a diet is that its 
long term safety and indeed clinical efficacy have been tested, albeit in an 
uncontrolled fashion, in a natural experiment lasting more than 4000 years.
A detailed discussion of other non-pharmacological means of controlling 
dyslipidaemia is beyond the scope of this introduction, but they include exercise, 
which has been shown to increase HDL cholesterol levels (Hardman etal 1989), 
LDL apheresis, which has been used in a variety of forms to lower LDL-cholesterol 
levels radically (Tait etal 1991), and the surgical procedures of partial ileal bypass 
(Buchwald et al 1990), portacaval shunt (Starzl etal 1983), and, in extreme 
circumstances, liver transplantation (Starzl etal 1984). A future possibilty for the 
management of the genetic dyslipidaemias may be manipulation of the human 
genome by so-called ‘gene therapy’. The ethics of such procedures were resolved 
for British workers in a report published early in 1992 (Committee on the Ethics of 
Gene Therapy 1992), and after the successful transduction of hepatocytes in vitro 
from WHHL rabbits (Wilson et al 1988), work is now progressing to facilitate 
retro-virus gene transfer of the apoB/E receptor gene into the hepatocytes of 
individuals with FH.
1.6 Therapeutic Options Hypolipidaemic Drugs
A range of lipid lowering and lipid regulating drugs is now available to the 
physician. Each class of drug has a unique mechanism of action although there is 
considerable overlap in the specific indications for their clinical use. The six main 
classes of drug currently used in the UK are discussed in the following sections
1.6.1 Bile Acid Sequestrant Resins
The bile acid sequestrant resin, cholestyramine, was used as a lipid lowering drug 
as early as 1959 (Bergen et al 1959). This drug, like its sister compound, 
colestipol can lower total cholesterol levels in the plasma by 15-30% but in practice
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their efficacy is often severely limited by poor patient compliance (Lipid Research 
Clinics Program 1984b). The resins are marketed as insoluble powders that must 
be mixed with fluids such as fruit juice, or sprinkled directly on food before being 
swallowed. As such, many patients find them unpalatable and they are often 
associated with gastro-intestinal side effects such as constipation and dyspepsia.
Both resins have complex structures (figure 8 ) and have the same mode of action, 
acting as non-absorbed anion-exchange resins that bind bile acids irreversibly in the 
intestinal lumen preventing their reabsorption in the terminal ileum. Resin-induced 
interruption of the enterohepatic circulation has profound effects on a number of 
processes regulating lipid metabolism in the liver. Normally, bile acids in the portal 
blood limit hepatic cholesterol oxidation by inhibiting 7a-hydroxlase. De­
repression of this enzyme exerts a drain on regulatory liver sterol pools, which are 
replenished by cholesterol derived from circulating LDL particles via the apoB/E 
receptor. The resultant fall in LDL-cholesterol is, however, limited by an increase 
in hepatic cholesterol synthesis secondary to activation of the enzyme HMG CoA- 
reductase. Sequestrant resins also affect triglyceride metabolism in the liver, 
possibly by releasing bile acid induced inhibition of the pacemaker enzyme of 
triglyceride synthesis, phosphatidic acid phosphatase (Angelin, Bjorkhem & 
Einarsson 1986). As a result, secretion of triglyceride-rich VLDL increases. Most 
individuals can compensate by regulating VLDL metabolism accordingly, but for 
some this response is inadequate, and hypertriglyceridaemia persists.
The clinical efficacy of the sequestrant resins in treating hypercholesterolaemia and 
preventing CHD has been confirmed in the Lipid Research Clinics Coronary 
Primary Prevention Trial (LRC-CPPT) (Lipid Research Clinics Program 1984a, 
1984b). This was a multi-centre, randomised, double-blind study involving 3806 
middle-aged men with primary hypercholesterolaemia. The participants were 
followed for an average of 7.4 years. Those treated with cholestyramine showed 
an 8.5% reduction in total cholesterol, a 12.6% reduction in LDL-cholesterol, a 3% 
rise in HDL-cholesterol and a 4.5% rise in triglyceride, over the placebo-treated 
control group. These lipid and lipoprotein changes were further enhanced in those 
who had adhered to the prescribed 24 g. d-1 dosage (Lipid Research Clinics 
1984b). The drug induced lipid changes were associated with a 24% fall in definite 
CHD deaths and a 19% fall in non-fatal MI. Incidence rates of new positive 
exercise ECGs, angina and coronary artery bypass grafts were reduced by 25%, 
20%, and 21% respectively in the sequestrant resin treated group. These findings 
provided the stimulus for other groups to investigate the clinical efficacy of lipid
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F igure 8. Structures of the Bile Acid Sequestrant Resins.
lowering therapy, and since 1984 several major intervention trials have been 
published while others are currently underway.
The two sequestrant resins that are available are clinically very similar. Although 
some patients express a preference for one over the other, there is little for the 
physician to choose between them (Glueck etal 1972).
1.6.2 N icotin ic A cid and its D erivatives
Nicotinic acid (vitamin B3) (figure 9) is an important component of a healthy diet 
and is required to play a number of roles in intermediary metabolism. The 
recommended daily allowance of 14 mg (Committee on Medical Aspects of Food 
Policy 1991) provides for this but has no effect on lipoprotein metabolism. If, 
however, nicotinic acid is administered in pharmacological doses (i.e., grams rather 
than milligrams) we may observe profound changes in all lipoprotein fractions.
Nicotinic acid and its analogues have been used to treat both hypercholesterolaemia 
and hypertriglyceridaemia. Their clinical efficacy was first noted by Altschul,
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Hoffer & Stephen (1955) and since then they have been used, with varying success 
in the management of all forms of hyperlipidaemia. Widespread use of nicotinic 
acid has been prevented, however, largely because of its disagreeable side-effects 
of vasodilatation and gastrointestinal irritation. These can be overcome in many 
patients by slowly increasing the dose over a number of weeks, and the 
administration of low-dose aspirin before the lipid-lowering drug is given. 
Nicotinic acid has had a good long term safety record and has been shown to be 
effective in reducing not only coronary but also total mortality in the Coronary Drug 
Project. In this secondary prevention trial conducted between 1966 and 1975 with 
five different lipid lowering drugs, nicotinic acid initially only showed a modest 
benefit in decreasing definite non-fatal myocardial infarctions (Coronary Drug 
Project Research Group 1975). However, after 15 years follow-up (almost 9 years 
after termination of the trial), mortality from all causes in the group given nicotinic 
acid during the study was 11% lower than the placebo group (Canner etal 1986).
Administration of nicotinic acid (2-3 g. d-1) or acipimox (750-1250 mg. d-1) (figure 
9) produces sustained and significant reductions in plasma triglyceride and VLDL- 
cholesterol levels. Although the precise mechanism involved is still unclear, the
o
N COOH
Nicotinic Acid Acipimox
Figure 9. Structures of Nicotinic Acid and Acipimox.
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effect is undoubtedly associated with a profound reduction in plasma free fatty acid 
levels (up to ten-fold) that is thought to reduce hepatic triglyceride synthesis by 
limiting substrate availability (Carlson & Oro 1962; Stirling et al 1985).
Adipocytes contain a hormone sensitive triglyceride lipase that in response to 
catecholamines increases in activity and promotes the release of free fatty acids into 
the bloodstream. Cyclic adenosine monophosphate (cAMP) is thought to act as a 
second messenger in this endocrine response. Nicotinic acid and its analogue 
acipimox are thought to exert their lipid lowering effect by decreasing intracellular 
levels of cAMP, possibly as a result of increased phosphodiesterase activity, 
thereby inhibiting the hormone sensitive lipase in adipose tissue (Fuccella et al
1980). This reduction in peripheral lipolysis leads to a decreased fatty acid flux to 
the liver (Stirling etal 1985), where it has been proposed that VLDL synthesis is 
consequently diminished as a result of reduced substrate supply. Acipimox has 
also been shown to reduce selectively hepatic triglyceride lipase activity while, in 
contrast to the fibrates, postheparin lipoprotein lipase activity is left largely 
unchanged (Stuyt etal 1985, Taskinen & Nikkila 1988).
The means by which nicotinic acid or its derivatives lower plasma cholesterol levels 
have still to be fully defined, but the most likely explanation is that it derives from 
the reduction in VLDL synthesis. A large proportion of the cholesterol leaving the 
liver does so in the form of VLDL-cholesterol. If  this pathway is substantially 
inhibited following down-regulation of VLDL-triglyceride synthesis, then the 
cholesterol that would have accompanied the secreted triglyceride accumulates in the 
hepatocyte, perhaps leading to reduced HMG CoA-reductase activity. However, 
there have been several reports (Grundy etal 1981, Stirling etal 1985, Illingworth 
etal 1991) that nicotinic acid or its analogue acipimox do not affect cholesterol 
synthesis.
LDL is variably affected by nicotinic acid and its analogues and, as with the 
fibrates, its final plasma concentration is dependent on the initial 
hyperlipoproteinaemic phenotype (Carlson, Oro & Ostman 1968; Carlson, Olsson 
& Ballantynel977). Administration of nicotinic acid to subjects with initially high 
LDL levels results in a 10-15% decrease in plasma LDL. Conversely, in subjects 
with raised triglyceride and normal or low LDL levels, an increase in LDL 
concentration follows reduction in triglyceride levels by the drug. Kinetic studies 
(Levy & Langer 1972) suggest that nicotinic acid acts primarily to inhibit LDL
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synthesis, a finding consistent with its suppressant effect on hepatic VLDL 
secretion.
Nicotinic acid often produces marked increases in HDL-cholesterol (Shepherd etal 
1979c), especially in normotriglyceridaemic individuals. Concurrently there is a 
dramatic rise in the HDL2/HDL3 ratio in the plasma. Since HDL2 is considered to 
be cardioprotective, this is interpreted as highly desirable. The metabolic changes 
underlying these changes in HDL subfraction distribution have been studied in 
ApoAI and A ll turnovers. Nicotinic acid alters the turnover rate of these 
apolipoproteins so that the plasma concentration of apoAI rises while that of apo AH 
falls (Shepherd etal 1979c).
More recently, nicotinic acid has been reported as having an effect on elevated Lp(a) 
levels. Carlson, Hamsten & Asplund (1989) using 4g. d-1 showed a mean 
reduction of 34% in the serum levels of Lp(a) in a series o f 31 patients with 
differing forms of dyslipidaemia.
Based on our current understanding of lipoprotein metabolism and its association 
with CHD risk the aggregated actions of nicotinic acid and its analogues on the 
lipoprotein profile should offer the recipient all-round benefit.
1.6.3 Probucol
Probucol (4, 4*-[(l-methylethylidene) bis (thio)] bis-[2, 6 -bis (1, 1-dimethylethyl) 
phenol]) is structurally unique amongst lipid lowering drugs (figure 1 0) and the 
only member of its class in clinical use. It is usually given at a dose of 0.5 g b.d., 
which results in reductions of both LDL and HDL-cholesterol, but with little or no 
effect on triglyceride. The mechanism by which it achieves these effects on the 
lipoprotein profile are far from clear. Suggested actions include increased faecal 
excretion of bile acids (Beyen 1986) and inhibition of hepatic sterol synthesis 
(McNamara et al 1985). There has been renewed interest in probucol since it was 
noted by Parthasarathy and his colleagues (1986) that the drug’s presence in LDL 
prevented oxidative modification of the lipoprotein. The drug has also been shown 
by Carew and his colleagues (1987) to reduce the progression of atherosclerosis in 
vivo. Despite these exciting observations the clinical use of probucol remains 
problematic. Its lipophilicity makes it difficult to study and complicates its 
pharmacokinetics by long term sequestration of the drug in body fat depots. Even 
though probucol has been shown to reduce the size o f tendon xanthomata
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(Yamamoto et al 1983) its hypoalphalipoproteinaemic effect is still regarded by 
many physicians as disturbing.
1.6.4 Fibric Acid Derivatives
The fibric acid derivatives or fibrates form a family of hypolipidaemic dmgs whose 
structure and mode of action are closely related to that of the parent compound 
clofibrate [Ethyl 2-(4-chlorophenoxy)-2-methylpropionate, figure 11]. Clofibrate 
was introduced into the UK in 1962 and found wide application as a lipid lowering 
agent. However, its limited efficacy and its poor benefit to risk ratio in the WHO 
trial (Committee of Principal Investigators 1978) have led to a steady decline in its 
use since 1978 (Wysowski, Kennedy & Gross 1990). Second generation fibrates, 
e.g. bezafibrate, gemfibrozil and more recently fenofibrate and ciprofibrate have 
been developed and marketed as useful agents for the treatment of 
hypertriglyceridaemia where they are first line therapies and, hypercholesterolemia 
where they are used either as first line or second line when bile acid sequestrant 
resin therapy fails. They also have an important place in the management of 
combined hyperlipidaemia (raised cholesterol and triglyceride) and are commonly 
used in combination regimens with the resins cholestyramine and colestipol 
(Goodman, Noble & Dell 1973).
The clinical efficacy of one of the fibrates, gemfibrozil, was confirmed in the large 
Helsinki Heart Study (Frick etal 1987) where reductions in triglyceride of 35% and 
LDL-cholesterol by 11% and an increase in HDL-cholesterol by 11% was 
associated with a 34% reduction in fatal and non fatal myocardial infarctions 
combined.
Fibrate therapy affects all major lipoprotein fractions (chylomicrons, VLDL, LDL, 
and HDL) in the plasma, principally by modulating key enzymes involved in lipid 
metabolism. The primary action of these drugs is to reduce plasma levels of 
triglyceride-rich lipoproteins viz. chylomicrons and VLDL by,
a) stimulating the activity of lipoprotein lipase, the endothelium bound enzyme 
responsible for hydrolysis of triglyceride in chylomicrons and VLDL
b) inhibiting VLDL synthesis and secretion from the liver probably as a result 
of the drug’s effect on free fatty acid flux to the liver.
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The fibrates, therefore, reduce triglyceride levels in a consistent and readily 
explicable fashion. Their actions on LDL levels, however, are variable depending 
on the initial LDL cholesterol value. In hypercholesterolaemia where LDL levels 
are high, the fibrates cause a decrease in LDL, while in hypertriglyceridaemia, 
which is commonly associated with low plasma LDL concentrations, fibrate 
treatment will raise the latter (Shepherd etal 1984b, 1985).
The catabolic rate of LDL has been shown to increase in hypercholesterolaemia 
(Stewart etal 1982) and decrease in hypertriglyceridaemia (Shepherd et al 1984b) 
while LDL synthetic rates in both groups remain unchanged. This apparent 
paradox is resolved when these changes are thought o f as normalization 
phenomena: in hypercholesterolaemia an initially low catabolic rate is increased to 
normal and in hypertriglyceridaemia an initially high catabolic rate is reduced to 
normal.
In hypercholesterolaemia fibrate induced reductions in the atherogenic lipoprotein, 
LDL, are commonly accompanied by increases in the level of the anti-atherogenic 
lipoprotein HDL leading to important changes in the calculated atherogenic risk 
index. Much has been made of this overall reversal of an atherogenic profile 
(lowering LDL and raising HDL) and indeed the clinical use of the modem fibrates 
is built upon it.
1.6.5 HMG Co A-reductase Inhibitors
In contrast to the fibrates, which is one of the oldest classes of lipid lowering 
drugs, the HMG Co A-reductase inhibitors, or ‘statins’ as they have come to be 
known, are the most recent. Interestingly, it was just over a decade from the first 
reports of their discovery in Japan (Endo, Kuroda & Tsujita 1976) before the Food 
and Drug Administration in the US approved the first compound, lovastatin, for 
clinical use as a lipid lowering drug, in 1987. The speed with which this transition 
from experimental compound to clinically approved dmg has taken place is in part 
testament to its efficacy and, at least short-term, safety. In contrast, it has also been 
a cause of some alarm on the part of clinicians who see the widespread use of a 
group of relatively untested drugs as undesirable. The UK, however, had to wait 
two more years before simvastatin was launched and we have had the benefit of 
further clinical trials and wide US experience with the statins upon which to draw 
(Tobert 1988a; Illingworth, Bacon & Larsen 1988).
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These drugs block endogenous cholesterol synthesis by competitively inhibiting the 
rate limiting enzyme HMG Co A-reductase. The structures of the three ‘statins’ in 
clinical use are shown in figure 12, alongside that of HMG CoA for comparison. 
All the body’s cells have the capacity to synthesise cholesterol but the bulk is made 
in the liver. Because the liver cell is prevented from making as much cholesterol as 
it needs it is forced to extract an increased amount from the plasma lipoproteins. It 
does this by increased expression of apoB/E receptors, which bind to passing LDL 
particles and bring them into the cell where they are dismantled and their cholesterol 
load can be channelled into synthetic pathways. The corollary of this is that the 
plasma LDL-cholesterol level falls as the number of receptors rises and will remain 
suppressed as long as the drug exerts its inhibition of intracellular cholesterol 
synthesis. These drugs have found particular use in FH. Such patients were the 
first to receive the drug when the statins were launched in the US but the indications 
for using this class of drug have now been widened in the UK to include 
individuals with primary hypercholesterolaemia intolerant or not responsive to other 
forms of lipid lowering therapy and with total cholesterol levels in excess of 6.5 
mmol. L-l ( Zocor data sheet 1991). Other groups of patients such as those with
HM G  CoA
HO.
HO
Pravastatin Lovastatin
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Figure 12. Structures of the HMG CoA-reductase Inhibitors.
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nephrotic syndrome and those with diabetes mellitus have also received benefit 
from the powerful lipid lowering effects of the statins but their use has generally 
been restricted to those with primary hypercholesterolaemia (Grnndy 1988).
Initial anxieties over the potential of the statins to induce lens opacities in humans 
have been resolved with experience. There now appears to be no increased risk of 
developing cataracts on these drugs (Tobert 1988a). However, the more serious 
possibility of life-threatening rhabdomyolysis in patients receiving statins is still 
regarded as real, although very rare, and seems to occur only in a small number of 
those individuals receiving combination therapy of statin plus fibrate or nicotinic 
acid or cyclosporin (Tobert 1988b). While certain combination therapies offer 
significant advances in the treatment of severe hyperlipidaemia the combinations 
described above should be avoided. Because of this potential problem, patients are 
instructed to report any unexplained muscle pain, tenderness or weakness and the 
statins should be discontinued if there is marked elevation o f the muscle enzyme 
creatine kinase (CK). The statins are also given with caution to those individuals 
with impaired hepatic function and should be discontinued i f  the transaminases 
(AST and ALT) rise excessively. To facilitate this biochemical monitoring of those 
patients receiving statin therapy baseline measurements should be taken prior to 
starting therapy and rechecked in the first few months of treatment.
1.6.6 Marine Oils
The fish-oil ingestion of Greenland Eskimoes has been viewed as a natural 
experiment testing the effects of the long chain polyunsaturates eicosapentaenoic 
acid (EPA, 20:5co3) and docosahexaenoic acid (DHA, 22:6co3) on plasma lipids 
and CHD. These fatty acids are found in significant quantities in cold-water fish 
such as salmon, tuna and mackerel, and have been refined for pharmacological use 
in the preparation, Maxepa®. When used in hypertriglyceridaemic patients the 
marine oils lower triglyceride levels by 64% in type lib patients and an impressive 
79% in type V patients (Phillipson etal 1985). Despite early suggestions that LDL- 
cholesterol levels were also lowered by marine oils, it seems that free-living patients 
may expect either no effect or even increases in their LDL-cholesterol levels (Harris 
1989). Such an apparently adverse effect may not be a problem in the management 
of type V patients who have abnormally low LDL-cholesterol levels initially, but it 
has prevented the widespread use of marine oils in clinical practice. The apparent 
freedom from CHD enjoyed by fish eating populations such as the Eskimoes may
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not be related entirely, or even at all, to the lipid regulating properties of the marine 
oils for they are reported to have other pharmacological effects (Harris 1989). 
Perhaps most importantly they reduce platelet aggregability and may, therefore, 
prevent coronary artery thrombosis (Goodnight, Harris & Connor 1981).
1.6.7 Combination Drug Therapy
The lipid lowering drugs are now also used increasingly in combinations for one or 
both of the following reasons:
a) the therapeutic goals in hyperlipidaemic patients are continually set lower and
have in some patients become unattainable on monotherapy. In the hope that 
two or more drugs offer an additive or even synergistic response, combination 
therapy has been tried.
b) the beneficial effects of lipid lowering drug therapy are often, at least partially,
offset by unwanted metabolic side-effects. These responses are sometimes 
simple homeostatic responses to the mechanism of drug action, e.g. bile acid 
sequestrant resin may de-repress cholesterologenesis or an HMG CoA- 
reductase inhibitor may lead to an increased translation of the enzyme protein 
(Fears 1983). These undesirable perturbations in lipoprotein metabolism may 
be limited by the dual administration of two dmgs with complementary actions.
Almost every combination of hypolipidaemic therapy has been tried, often 
empirically, over the last twenty years. Some regimens have been highly 
successful in achieving their therapeutic goals, while others, such as the 
combination of lovastatin and gemfibrozil, are thought to be potentially detrimental. 
The most potent combinations are discussed below.
a) Bile acid sequestrant resin plus nicotinic acid
This is one of the most effective combinations for cholesterol reduction and one of 
the first tried (Packard et al 1980; Levy, Fredrickson & Schulman 1972). This 
regimen can reduce total and LDL-cholesterol by between 30-40%, even in patients 
with heterozygous FH. Many individuals are, however, unable to tolerate the side 
effects of nicotinic acid, which has prompted its replacement with the derivative, 
acipimox. This combination is reasonably well tolerated and is equally effective in 
reducing LDL-cholesterol levels (Series etal 1990).
b) Bile acid sequestrant resin plus fibrate
The use of fibrates in combined regimens with bile acid sequestrant resins was 
being examined in studies as early as 1973 (Goodman et al 1983), where the
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original fibrate, clofibrate, was used in combination with colestipol. Although the 
combination produced an additional decrement in serum cholesterol the results did 
not achieve statistical significance. New fibric acid derivatives should, in theory, 
produce a better response and indeed when one of these, bezafibrate, was examined 
significant reductions in serum cholesterol and triglyceride were observed (Series et 
al 1989). Combination therapy with resins and fibrates is now in wide use in part 
because such a regimen is particularly attractive when one considers that it brings 
together the two therapeutic modalities shown to be independently effective in 
reducing coronary risk in large-scale prospective trials (Lipid Research Clinics 
Program 1984b; Frick eta l 1987). Its use, however, also raises the question 
whether the joint administration of an anion exchange resin affects the absorption of 
a fibrate To answer this question the combination of gemfibrozil and colestipol was 
examined by Forland, Feng & Cutler (1990) who concluded that simultaneous 
administration of the two drugs did indeed reduce the bioavailability of the fibrate, 
but added that separating the administration of the two drugs by at least two hours 
would obviate this interaction.
c) Bile acid sequestrant resin plus HMG CoA-reductase inhibitor
A combination of equal, if  not greater, promise has been examined in a number of 
clinical studies in the US and Japan (Mabuchi et al 1983; Bilheimer et al 1983, 
Illingworth 1984). When bile acid sequestrant resins are administered, the hepatic 
bile acid pool is depleted and the hepatocytes respond by up-regulating their cell 
surface apoB/E receptors. This promotion of increased receptor-mediated LDL 
clearance is somewhat off-set by a concomitant increase in endogenous cholesterol 
biosynthesis. By co-administration of an HMG CoA-reductase inhibitor this effect 
is minimised and a greater level of apoB/E receptor activity achieved. The clinical 
result is a profound lowering of LDL-cholesterol by as much as 50-70%.
d) Fibrate plus HMG CoA-reductase inhibitor
In designing new combined regimens, a more exciting combination was thought 
initially to be that of fibrate plus HMG CoA reductase inhibitor. Enthusiasm for 
such a regimen was, however, curbed when reports of myopathy associated with 
lovastatin plus gemfibrozil therapy were published (Illingworth & Bacon 1989; 
Pierce, Wysowski & Gross 1990). Despite this, and because the combination had 
shown such early promise Glueck, Speirs &Tracy (1990) examined 25 patients for 
an average duration of 12.5 months while receiving both drugs. While mandating 
careful follow-up with serial creatine kinase (CK) and liver function tests, they 
report the combination to be safe and effective with only a 2.4% incidence of raised
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CK and no symptomatic myositis. This is an important study but should not be 
viewed as a blanket approval of such therapy. Caution with fibrate plus HMG CoA 
reductase inhibitor is again urged by Illingworth & OMalley (1990) who recently 
evaluated the combination of clofibrate and lovastatin in 6  type HI patients and 
monotherapy with one or other drug in 12 patients. They showed that addition of 
lovastatin to clofibrate therapy or vice versa in patients resistant to monotherapy 
was of benefit in further reducing concentrations of total, VLDL and LDL 
cholesterol. These findings offer clinicians an alternative strategy for the 
management of type III hyperlipidaemia, but the authors re-emphasise the 
importance of close monitoring of any patients receiving such therapy.
1.7. General Aims o f this Work
It will be clear from the above discussions that an extensive body of work has 
already been performed to elucidate the pathways of lipoprotein metabolism and the 
mechanisms of action of the various lipid lowering drugs. The present work has 
two aims. Firstly, to supplement this existing corpus by testing a series of 
mechanistic hypotheses of the pharmacological modulation of apolipoprotein B 
metabolism. This will be achieved by satisfying a series of related objectives. 
Representatives of the main lipid lowering drug classes, simvastatin, acipimox, 
colestipol and ciprofibrate will be examined individually and in combination. The 
effects of these drugs on the lipoprotein profiles of hypercholesterolaemic 
individuals will be reported as will their effects on the metabolism of apo B 
containing lipoproteins and, in the case of ciprofibrate, its effect on receptor 
mediated catabolism of apo-LDL. Further analysis of the effects of these drugs in 
vivo will be provided by studying their effects on the subfraction distribution of 
HDL and LDL, and their influence on cholesterol biosynthetic rates as evidenced by 
measurements of urinary mevalonate and plasma lathosterol levels: two indirect 
indices of this metabolic parameter. With this variety of biochemical, structural, 
and kinetic data it will be possible to present a general thesis on the detailed 
mechanism of action of the principal lipid lowering drugs.
By using a series of metabolic inhibitors, viz the lipid lowering drugs listed above, 
it has also been possible to assess the pathophysiology of certain aspects of 
lipoprotein metabolism. The large series of baseline studies presented provides a 
valuable source of data on the metabolic aberrations that contribute to 
hypercholesterolaemia in the individuals studied. Moreover, examination of the 
VLDL-IDL-LDL delipidation cascade using dual isotope turnover studies generates
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a large volume of data on the various lipoprotein interconversions that occur in the 
plasma. When this is analysed in conjunction with the detailed structural data 
provided by lipoprotein subfraction measurements and we consider the metabolic 
influences of the drugs used, novel metabolic concepts are hypothesised for future 
testing. Thus the second aim of this work is to offer new insight into the 
pathophysiology of lipoprotein metabolism.
1.8. Nomenclature and Layout
The results of 79 turnover experiments performed in 32 patients are presented in the 
following chapters. To provide a unique and simple identifier for each patient and 
each turnover, the following system has been adopted. All patients are coded by a 
number prefixed by a three letter code corresponding to their principal drug therapy, 
e.g. the third patient recruited in the study using simvastatin would be coded SIM 
03. Each of the turnovers is identified by the appropriate patient code followed by 
the letter ‘A1 for a baseline study, ‘B’, for initial drug therapy and ‘C  for combined 
therapy.
Each of the following chapters 3-9 contain details of the results of the various 
studies and include a discussion section appropriate to that chapter. The final 
chapter, 10, provides a general discussion and conclusions. For ease of reading, 
much of the raw data and radioactive decay curves relating to the turnover 
experiments have been placed in appendices 2-5.
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Chapter 2 Materials and Methods
One man is measuring the lengths of the feelers of 2,000 beetles; another the 
amount of cholesterol in 1 0 0  samples of human blood; each in the hope, but not in 
the certainty, that his series of numbers will lead him to some definite law.
John BS Haldane, 1927.
2.1 Study Outline
Representatives of the different hypolipidaemic drug classes were studied both as 
single agents and in combination. All subjects studied were defined as having 
prim ary hypercholesterolaem ia but not associated with fa m ilia l  
hypercholesterolaemia. The influence of these drugs on lipid and lipoprotein levels 
was examined as were the changes in lipoprotein (HDL and LDL) subfraction 
distribution.
Assays for the indirect assessment of in vivo cholesterol biosynthesis (mevalonic 
acid and lathosterol) were established and used to examine the effects of different 
lipid lowering drugs on this parameter.
Lipoprotein metabolism was followed using established protocols for the 
assessment of VLDL and LDL turnover at baseline and after drug therapies. The 
results of these studies were analysed using multi-compartmental mathematical 
modelling procedures.
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2.2 Materials
All reagents used were of analytical grade and the names and addresses of all 
suppliers are shown in appendix 1 together with the manufacturers or suppliers 
o f all hardware and software used in this work.
2.3 VLDL apoB Turnover Protocol
The metabolism of large (Sf 60-400) and small (Sf 20-60) VLDL was 
investigated following protocols previously published by Shepherd et al 
(1984b) and Packard etal. (1984).
2.3.1 Isolation o f VLDLi and VLDL2
After a 14 h fast, 250 mL of plasma were obtained from the subject by 
plasmapheresis. From this plasma, total VLDL (d< 1.006 g. mL-1) was 
prepared by ultracentrifugation in a Beckman Ti60 rotor for 24 h at 39,000 rpm 
(10°C). The supernatant was collected and this VLDL solution was diluted 
with 0.15M NaCl to achieve a concentration corresponding to a plasma 
triglyceride level of approximately 1.5 mmol. L*1 if  the subject’s plasma 
triglyceride was initially greater than 2.0 mmol. L*1. This was necessary to 
avoid VLDLi carryover into the VLDL2 subfraction.
The density of 12mL of VLDL solution was adjusted to 1.118 g. mL-1 by the 
addition of solid NaCl (170 mg. mL-1). A 2 mL aliquot of this preparation was 
layered over a 0.5 mL cushion of d 1.182 g. mL-1 NaBr solution in six 
Beckman SW40 rotor tubes which had been pre-coated with polyvinylalcohol to 
reduce internal surface tension and permit improved layering.
A discontinuous salt gradient was constructed above each aliquot from d 1.099- 
1.058 g. mL-1 according to figure 13.
This set-up was centrifuged in a Beckman SW40 rotor at 39,000 rpm for 1 h 38 
min (23°C) and decelerated without braking. VLDLi (Sf 60-400) was removed 
in the top 1.0 mL of solution and the material harvested from all six tubes was 
pooled to yield 6.0mL of VLDLi solution. The volume removed was replaced 
with 1.0 mL of d 1.059 g. mL*1 solution before continuing with the separation.
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F ig u re  13. Discontinuous NaBr gradient as used for the subfractionation of 
apoB containing lipoproteins by ultracentrifugation
This set-up was centrifuged in a Beckman SW40 rotor at 18,500 rpm for 15 h 
41 min (23°C) and decelerated without braking.
VLDL2 (Sf 20-60) was removed in the top 0.5 mL of solution and the material 
harvested from all six tubes was pooled to yield 3.0 mL of VLDL2 solution.
2 .3 .2  Labelling o f VLDL subfractions
Radiolabelling was performed using the iodine monochloride method 
(MacFarlane 1958) as modified by Bilheimer et al (1972). Radiolabelling of 
VLDL in this way will obviously introduce label into the non-B apolipoproteins 
and lipid components of the lipoprotein in addition to the labelling of apoB. 
The specificity of the procedure is only achieved by isolating apoB in the timed 
samples obtained after injection and thereby ensuring that only apoB 
radioactivity or specific activity is measured.
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The iodination mixture was prepared as follows. To separate 2.0 mL aliquots 
of VLDLi and VLDL2 solutions were added 0.5 mL of 1.0M glycine, pH 10.0 
and 2.0 mCi of reductant-free Na [131I] or Na [125I].
Six pL of iodine monochloride solution (25 mM in 1.0M NaCl) were added and 
mixed gently. Free and bound radioiodide were separated by dialysing 
overnight against 3 x 2.0 L of 0 .15M NaCl, pH 7.4 (4°C).
These ratios o f iodine/protein result in the incorporation of no more than one 
atom of iodine per molecule of apoB in VLDL.
2.3.3 Sterilisation and Measurement o f Specific Activity
The labelled tracers were sterilised by membrane filtration through 0.45 pm 
filters (Acrodisc, Gelman Sciences) which had been primed with the subject’s 
native plasma. This was done immediately prior to re-injection into the subject
The radioactivity concentration (pCi. mL-1) was calculated after sterilisation by 
counting a 10 pL aliquot of labelled VLDL and comparing with [131I] and [125I] 
simulated standards.
2.3 .4  Subject Preparation
In all studies it was essential to ensure that thyroidal uptake of radioiodide had 
been blocked by the oral administration of potassium iodate (170mg twice 
daily). This regimen was commenced three days prior to injection of 
radiolabelled lipoproteins and was continued for the next 28 days. The turnover 
studies were conducted on an out-patient basis and all subjects were instructed 
to adhere strictly to their regular diet and lifestyle. This was done to ensure 
steady state conditions for the investigation of lipoprotein metabolism. 
Informed consent was obtained from all subjects prior to the study.
2.3.5 Injection and Sampling Protocol
On the third day after plasmapheresis the subject was admitted at 08.00 h 
following an overnight fast and the following procedure was observed.
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An indwelling cannula was placed in a peripheral vein to facilitate repeated 
venous blood sampling. This was flushed with sterile 0 .15M NaCl to maintain 
patency.
Autologous I13!I]-VLDLi and [125I]-VLDL2 were injected in rapid sequence 
into a peripheral vein in the opposite arm. These injectates were separated and 
chased with boluses of sterile 0.15M NaCl.
10 mL venous blood samples were collected via cannula at the following time 
points post-injection: 10 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6  h, 8  h, 10 h, 
14 h and thereafter 10 mL fasting venous samples were obtained each morning 
for the next 12 days. All samples were collected into tubes containing K2EDTA 
as anti-coagulant to give a final concentration of 1 mg. mL-1.
To minimise chylomicron production the subject remained fasting for the first 
10  h of the study but was allowed unlimited non-caloric fluids.
2.3 .6  Reisolation of Tracer
Plasma was obtained from each of the blood samples by low speed 
centrifugation, 1000g(4°C).
From 2.0 mL aliquots of plasma VLDLi and VLDL2 were isolated as above 
(2.3.1)
In addition IDL (Sf 12-20) and LDL (Sf 0-12) were isolated by subjecting the 
loaded SW40 rotor to two further centrifugation steps of 39,000 rpm for 2 h 35 
min (23°C) and 30,000 rpm for 21 h 10 min (23°C). IDL was removed in the 
top 0.5 mL of the gradient and LDL in the top 1.0 mL.
ApoB was precipitated by adding an equal volume of freshly redistilled 1,1,3,3- 
tetramethylurea (TMU) at 37°C to each lipoprotein fraction (Kane etal 1975). 
This mixture was vortexed immediately and allowed to stand at 37°C for 1 h.
The resulting insoluble pellicle of lipid and apoB was separated by 
centrifugation at lOOOg for 30 min. The TMU-soluble phase was removed 
carefully with a thinly drawn out glass Pasteur pipette and the tube inverted to 
draw off any remaining liquid.
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The apoB pellet was delipidated by extracting with organic solvents 
(ethanol:diethyl ether 3:1 v/v) overnight at -20°C. The protein pellet was 
reformed by further low speed centrifugation and the solvent removed.
The pellet was dried with a diethyl ether wash for 2 h at -20°C and after 
removal of this ether the samples were placed uncapped in an incubator at 40°C 
for 10 min or until all solvent had evaporated.
The isolated apoB was redissolved by adding 1.0 mL of 0.5M NaOH and the 
samples were left at 37°C overnight or until dissolution was complete.
2.3.7 Calculation o f Pool Sizes
V L D Li ,VLDL2 ,IDL and LDL were prepared by cumulative flotation 
ultracentrifugation of 6  x 2 mL aliquots of pooled plasma obtained on four 
occasions during the course of the 13 day VLDL-tumover study.
Total protein and TMU-soluble protein were measured in each lipoprotein 
fraction by the methods of Lowry et al (1951) and Kane et al (1975) 
respectively.
ApoB concentrations were calculated as the difference between total protein and 
TMU-soluble protein and expressed as mg. 100 mL*1
The apoB concentration in each lipoprotein fraction was additionally determined 
by averaging the total protein measurements in each TMU precipitate from every 
time point throughout the study This latter procedure was initially used as a 
check of the TMU-soluble method but because of its greater reliability it was 
adopted as the principal method in the majority of the VLDL apoB turnovers.
Pool sizes for apoB in the four lipoprotein fractions were derived from the 
product of plasma volume and the plasma concentration of apoB in each 
fraction. The subject’s plama volume was estimated as 4% of the body weight. 
This was considered appropriate as none of the subjects studied were obese or 
oedematous.
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Correction of the apoB pool sizes for centrifugal losses was made by comparing 
the VLDLi + VLDL2 +IDL+ LDL cholesterol recovered from the cumulative 
flotation ultracentrifugation, to the ‘non-HDL’ cholesterol measured in the B- 
quantification of plasma as described in section 2.5.1. In most subjects the 
cholesterol recovered using cumulative flotation was 80-90% of the mean ‘non- 
HD L’ cholesterol throughout the turnover period. The apoB pool sizes were 
therefore adjusted by an appropriate multiplication factor to take into account 
these losses.
2.3.8 Data Collection and Handling
[131I] and [125I] were counted in each of the apoB samples prepared from the 
lipoprotein fractions in an automated gamma counter (Packard) for 1.0 min.
To calculate specific activities, the protein content of each sample was measured 
using a modification of the method described by Lowry etal (1951) in which 
the NaOH is omitted from the Cu/alkali reagent. The NaOH added to the apoB 
protein to facilitate its dissolution gave the appropriate pH for the final Lowry 
reaction mixture. The procedure was further modified to allow for large 
throughput o f samples and duplicate analysis. This is further described in 
section 2.5.3.
2.3.9 Data Analysis
The apoB specific activities were multiplied by the average pool size to generate 
total radioactivities. These were then expressed as a fraction of the total apoB 
radioactivity present 10 min after injection. These data were used to construct 
apoB decay curves for each lipoprotein fraction.
These curves and the apoB masses associated with each lipoprotein fraction 
were used to simulate apoB metabolism using a multi-compartmental model 
computed by the SAAM 30 modelling program (Berman & Weiss 1974) on the 
Glasgow University VAX system. The metabolic model used is shown in 
figure 14 and is essentially that described elsewhere (Packard et al 1984, 
Demant etal 1991a) with the exception that two further sub-compartments have 
been added in VLDLj to take account of the second, slower exponential which 
is seen in some individuals.
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F igure  14. Multicompartmental model for apolipoprotein B metabolism in 
VLDLi (Sf 60-400), VLDL2 (Sf 20-60), IDL (Sf 12-20) and LDL (Sf 0-12). 
U( 13) and U(5) represent de novo input of apoB into VLDLi and VLDL2 
respectively. Direct synthesis into the LDL density interval was calculated as 
the difference between the absolute catabolic rate of apoB in this fraction 
(observed mass x overall FCR) and the input from VLDL2 and IDL.
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The main features of the model were as follows:
a) apoB direct input may occur at the level of VLDLi, VLDL2, and LDL. Input 
of newly synthesised apoB into the Sf 20-60 density range (compartment 5) 
was required because firstly not all the Sf 20-60 apoB mass can be accounted 
for by transport from large VLDL and secondly when large and small VLDL 
are labelled separately the kinetics of appearance of these tracers in DDL and 
LDL apoB are different. Usually the radioactivity derived from labelled 
small VLDL appeared more quickly in these denser fractions and accounted 
for a higher proportion of their mass. Provision for this phenomenon was 
made by incorporating in the model parallel pathways for VLDLi and VLDL2 
and their metabolic products appearing in IDL and LDL. De novo synthesis 
of apoB into the LDL density range was permitted to explain the 
discrepancies between observed and calculated LDL apoB metabolism. 
Some consequences of this allowance are discussed in chapters 3 and 10.
b) VLDL is delipidated in a stepwise manner following the concept of Berman 
etal{ 1978).
c) slowly catabolized, remnant pools are postulated in VLDL2 and IDL density 
ranges ( compartments 6  and 9 respectively)
d) LDL was distributed between two plasma pools, to take account of the 
different metablic properties of LDL derived from VLDLi (compartment 11) 
or VLDL2 (compartment 10).
This model provided an acceptable fit for the observed data. The calculated rate 
constants were defined with a fractional standard deviation (FSD) of less than 
0.06. For VLDLi, VLDL2 and IDL, the calculated masses derived from the 
kinetic analyses were within 10% of the observed values in almost every case. 
With LDL, however, the observed apoB pool was consistently greater than the 
calculated mass. Reasons for this discrepancy are discussed with the results 
below.
2.4 LDL Turnover Protocol
The technique used to assess LDL kinetic parameters was basically the same as 
that originally developed by Langer e ta l(1972) with the modification described 
by Shepherd etal (1979a), which allows the measurement of receptor-mediated 
and receptor-independent LDL catabolism.
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2.4.1 Isolation o f LDL
After a 14 h fast, 50 mL of plasma were obtained from the subject.
LDL (d 1.030-1.050 g. mL-1) was prepared by rate zonal ultracentrifugation 
according to the method of Patsch e ta l(1974).
The collected lipoprotein fraction was de-salted by dialysing against 0.15M 
NaCl/0.01% Na2EDTA (pH 7.0) and concentrated by pressure filtration 
through an XM 100 A cellulose membrane (Amicon) to a protein concentration 
of 3-5 mg. mL-1, as determined by the method of Lowry e ta l (1951).
2.4.2 Labelling o f LDL
Radiolabelling was carried out by the iodine monochloride method of 
MacFarlane (1958) as modified by Shepherd, Bedford & Morgan (1976).
The following iodination mixtures were prepared:
Two 1.0 mL aliquots of LDL solution were mixed separately with 0.5 mL of 
1.0M glycine, pH 10.00 and 2.0 mCi of either reductant-free Na [131I] orN a 
t125I].
An appropriate volume of iodine monochloride solution (25 mM in 1.0M NaCl) 
was added to yield an ICl:protein ratio of approximately 20 mol:500,000 Da of 
protein, and mixed gently. This procedure introduces an iodine atom into 
tyrosine residues at a level of less than 10 mol iodine/molecule of LDL protein.
Bound and free radio-iodide were separated by passing the the two iodination 
mixtures over separate 1.0 x 10 cm columns of Sephadex G-25 (PD10 column, 
Pharmacia). The eluting buffer used was 0.15M NaCl containing 0.01% 
Na2EDTA (pH 8.1).
2.4.3 CHD Modification
1.0 mL [131I]-LDL at a protein concentration of 3-5 mg. mL’ 1 in a solution of 
0.15M NaCl containing 0.01% Na2EDTA was added to 2.0 mL of freshly 
prepared 0.15M 1,2 -cyclohexanedione (CHD) in 0.2M sodium borate buffer, 
pH 8.1.
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This mixture was incubated in a water bath at 35°C for 2 h.
Modified LDL was separated from unbound reagents by passing the mixture 
over a 1.0 x 10 cm column of Sephadex G-25 (PD10 column, Pharmacia) and 
eluting with 0 .15M NaCl containing 0.01% Na2EDTA (pH 8 .1).
2.4 .4  Sterilisation and Measurement o f Radioactivity.
The labelled tracers were sterilised immediately prior to re-injection by 
membrane filtration through separate 0.22 pm filters (Acrodisc, Gelman 
Sciences) which had been primed with the subject’s unlabelled LDL.
The radioactivity concentration (pCi. mL-1) was determined after sterilisation by 
counting 10 pL aliquots of CHD-modified [131I]-LDL and native [125I]-LDL 
and comparing with 131I and 125I simulated standards.
2.4.5 Subject Preparation
Thyroidal uptake of radioiodide was blocked as described in 2.3.4. As with the 
VLDL turnovers, the LDL turnover studies were conducted on an out-patient 
basis and all subjects were instructed to adhere strictly to their regular diet and 
lifestyle. This was done to ensure steady state conditions for the investigation 
of lipoprotein metabolism. Subjects received detailed instruction on the 
collection of 24 h urine specimens. Informed consent was obtained from all 
subjects prior to the study.
2.4.6 Injection and Sampling Procedures
Because the initial collection of fasting blood was done at 08.00 h it was 
possible to have the labelled modified and native LDL aliquots ready for re­
injection within the same working day.
Autologous CHD modified [13!I]-LDL and Native [125I]-LDL were injected in 
rapid sequence into a peripheral vein. These injectates were separated and 
chased with boluses of sterile 0.15M NaCl.
After a time lapse of 10 min the first venous blood sample was collected from a 
peripheral vein in the opposite arm of the subject. Thereafter, a 10 mL fasting
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venous blood specimen was collected each morning for the next 14 days. All 
blood specimens were collected into tubes containing K2EDTA as anti­
coagulant to give a final concentration of 1 mg. mL-1.
Continuous 24 h urine collections were collected timed to 08.00 h over the 14 
day turnover period to estimate urinary excretion rates and urinaryiplasma 
radioactivity ratios.
2.4.7 Calculation o f Pool Sizes
LDL was prepared from serial 4.0 mL fasting plasma samples obtained on days 
3, 7, 10 and 13 of the turnover study by ultracentrifugation at limit densities d 
1.010-1.063 g. mL’1.
Each LDL sample was dialysed against 0.15M NaCl and total protein and TMU 
soluble protein were measured by the methods of Lowry eta l (1951) and Kane 
etal (1975) respectively
The apoB concentration in each sample was calculated as the difference between 
total and TMU-soluble protein and expressed as mg. lOOmL-1. In order to 
correct for centrifugal losses, recovered radioactivity was related to that seen in 
plasma.
A pool size for apo-LDL was derived from the product of plasma volume 
(obtained by isotope dilution) and the mean apo-LDL plasma concentration.
2.4.8 Data Collection and Handling
Plasma was obtained from each fasting venous blood sample by low speed 
centrifugation (4°C).
13 ll  and 125I were counted in 2.0 mL aliquots of each sample in an automated 
gamma counter (Packard) for 10 min.
131I and 125I were counted in 4 mL aliquots of each, well-mixed 24 h urine 
collection. Urine volumes were determined and thus total daily urine 
radioactivities. The completeness of these 24 h urine collections was assessed 
by measurement of 24 h urinary creatinine excretion.
Plasma radioactivity decay curves were constructed and urine:plasma ratios 
were calculated for each time point.
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2.4.9 Data Analysis
Plasma 131I and 125I radioactivity data were analysed by the procedure of 
Matthews (1957) as adopted by Shepherd e ta l(1979a) to determine FCRs for 
total, receptor-mediated and receptor-independent apo-LDL catabolism. The 
rate of elimination of 125I-labelled native apo-LDL represented total catabolism 
of this fraction while that o f 13 ^ -labelled CHD modified tracer was used as a 
measure of receptor-independent removal. The difference between these two 
FCRs (native and CHD) therefore provided an index of the activity of the 
receptor pathway. The urine/plasma radioactivity ratios for both native and 
CHD-modified apo-LDL were calculated from the urinary output of 131I or 125I 
in a 24 h period and the plasma radioactivity at the beginning of that period. 
Since there was approximately a half-day delay between the clearance of 
radioactivity from the plasma and its appearance in urine (Boston, Greif & 
Berman 1982; Foster etal 1986), the latter value represents the relevant mean 
plasma radioactivity for the 24 h urine collection. The synthetic rate for apo- 
LDL was calculated as the product of the apo-LDL circulating mass and the 
fractional catabolic rate. This was expressed per kilogram body weight for each 
subject. Additionally, plasma and urine radioactivities were analysed together 
by multi-compartmental modelling using the SAAM 29 (Berman & Weiss 
1974). With this approach, previously described by Boston et al (1982) and 
Foster et a l(1986), LDL was not treated as a single homogeneous entity, but as 
shown in figure 15, two plasma pools, one of which was in equilibrium with an 
extravascular pool, were required for the simultaneous fitting of plasma and 
urine radioactivity data (Caslake etal 1992).
2.5 Lipids, Proteins and Lipoproteins.
These were assayed using a variety of chemical, enzymatic, centrifugal and 
immunoassay techniques as described in detail below.
2.5.1 B Quantification
Lipoprotein classes were prepared by a combination of ultracenrifugation and 
selective precipitation, using standard methodologies (Lipid Research Clinics 
Program 1974). VLDL were separated as a floating fraction. The infranatant 
was then treated with heparin/Mn2+ (at a final concentration of 1.3 g. mL-1 
heparin and 0.092M Mn2+) to precipitate LDL and leave HDL in solution
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F ig u re  15. Model of Apo-LDL Metabolism. Apo-LDL in the plasma is 
divided into two compartments, A and B. Pool A (compartment 5) is more 
readily cleared from the plasma. Pool B (compartment 1) exchanges with the 
extravascular space (compartment 2). The model is similar to that previously 
used by Boston et al (1982) and Foster et al (1986). U(5) and U (l) represent 
input rates for pools A and B respectively. L(3,5) and L(3,l) are elimination 
rate constants for the ‘fast’ and ‘slow* pools. Compartment 3 is the body 
iodidie pool, which is cleared into the urine (compartment 4) at a fixed rate of
2.5 pools. d'L
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(Wamick & Albers 1978). The cholesterol content of whole plasma, of the top 
(VLDL), and bottom (LDL and HDL) fractions, and of the heparin/Mn2+ 
supernatant (HDL) were measured as described below.
Ultracentrifugation.
Five mL of plasma was placed in a Beckman Ultra-clear tube (13x64 mm) and 
overlayered with 2 mL of d 1.006 g. mL-1 solution. Tubes were capped and 
centrifuged overnight at 35,000 rpm (4°C) in a Beckman 50.4 rotor, then 
sliced 25 mm from the top and the supernatant collected into a 3 mL flask. The 
contents of the bottom fraction were transferred to a 5.0 mL volumetric flask, 
the tube washed with saline, the wash added to the flask, and the volume 
adjusted to 5.0 mL with 0.15M NaCl.
Precipitation o f LDL.
An aliquot (1.0 mL) of the bottom fraction was placed in a Beckman centrifuge 
tube and 50 pL of precipitating reagent [9.56 g Mn C12-4 HjO + 1.05 g 
(approximately 5xl05 units) heparin sodium salt (Sigma London Chemical Co.) 
in 25 mL 0 .15M NaCl] were added and mixed. The mixture was kept at 4°C 
for 15 min then centrifuged at 10,000 rpm for 30 min, and the supernatant 
separated immediately for cholesterol analysis.
2.5 .2  Compositional Analyses
Total cholesterol and triglyceride were determined in whole plasma and in 
lipoprotein preparations by enzymatic colorimetric assays on a Hitachi 704 auto­
analyser.
Total cholesterol was assayed using Boehringer Kit No. 704121 the principal of 
which is shown below:
Cholesterol esters + H2O Cholesterol esterase ^  Cholesterol + RCOOH 
Cholesterol + O2 Cholesterol oxidase A4-cholestenone +H2O2 
2 H2O2 + 4-aminophenazone + phenol— 4-(p-benzoquinone-mono-imino)- 
_____________________________________________phenazone + 4 H2Q._______
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Triglyceride was assayed using Boehringer Kit No. 704113 the principal of 
which is shown below:
Triglyceride+ 3 H2O  Lipase ^  glycerol + 3 RCOOH
glycerol + A T P  —►  glycerol-3-phosphate+ ADP
glycerol-3-phosphate + O2 GPO dihydroxyacetone phosphate + H2O2  
H2O2  + 4-aminophenazone + 4-chlorophenol >^erox^^ ase ►4-(p-benzoquinone- 
______________________________mono-imino)-phenazone + 2H2O + HC1.
The resultant colour changes were measured at 505 nm.
Free (unesterified) cholesterol and phospholipid were determined by enzymatic 
colorimetric assays on a Centrifichem Encore centrifugal analyser (Baker 
Instruments).
Free cholesterol was estimated with Boerhinger Kit No. 310328 in which the 
cholesterol esterase above is omitted from the enzyme reagents. Esterified 
cholesterol was calculated by difference.
Phospholipid was estimated with Boerhinger Kit No. 691844, which employs 
an enzymatic,colorimetric assay dependent on the liberation of choline by 
phospholipase D.
2.5.3 Modification o f Lowry Protein Assay
Protein measurements were performed according to the method of Lowry etal 
(1951). Because of the number of samples to be processed in this study the 
Lowry protein assay as originally described was tedious, expensive in terms of 
time, reagents and consumables and often, because of the required sample size, 
did not permit duplicate analyses. The latter point was particularly of concern in 
view of the importance of obtaining accurate results to calculate specific activity 
data for the turnover timepoints and apoB pools sizes. For these reasons it was 
decided to evaluate the adaptation of the current method to microtitre plate 
technology. Exactly the same reagents were used but the volumes of reagents 
and samples were scaled down accordingly and the resultant colour changes 
were read using a microtitre plate scanner, which in addition, generated a 
standard curve and computed the final protein concentrations.
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Reagents
i) Stock Reagents:
Soln A 2% Na2C 0 3 in 0. IN NaOH 
Soln B 2% Na K Tartrate in H20  (deionised)
Soln C 1 % Cu SO4 in H20  (deionised)
Soln D 2% Na2C03 in H20  (deionised)
Folin-Ciocalteu Reagent (BDH)
ii) Working Reagent:
Biuret. To 10 mL Soln A (or Soln D, if VLDL turnover samples) 0.1
mL of Soln B and 0.1 mL of Soln C were added. To clarify turbid
samples, e.g. VLDL, Sodium Dodecyl Sulphate (lmg. mL-1) was 
added to the working Biuret reagent (Curry etal 1978). Failure to add 
SDS yielded erroneously high results in these samples.
Standards
i) Stock standard. Human Serum Albumin lmg. mL-1. Stored in 
aliquots at -20°C
ii) Working standards. A working standard curve in the range 0-300 
jig. mL*1 was prepared in duplicate by taking 0, 2, 4, 6 , 8 and 10 pL of 
stock standard and adjusting the final volume to 40 pL with deionised 
water as shown below:
Vol of Stock Std (pL) Vol of Deionised H20  (pL)
0 40
2 38
4 36
6 34
8 32
10 30
When analysing VLDL turnover samples, 10 pL of 2N NaOH were used in 
place of lOpL of H20. Appropriate aliquots of sample (VLDLi 40pL, VLDL2 
30pL, IDL 15pL, LDL 5pL) were taken and the final volume adjusted to 40 pL 
with deionised water (or 0.5N NaOH if VLDL turnover samples).
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Quality Control
Bovine Serum Albumin 0.15mg. mL'1 stored at -15°C. lOpL of the control
material was taken and the final volume adjusted to 40jiL with deionised water.
Procedure
1) To 40pL of standard, control or sample dilution in a 96 well microtitre 
plate (Sterilin, UK) were added 200 pL working Biuret and mixed.
2) 20pL of working Folin-Ciocalteu reagent (diluted 1:1 v/v with deionised 
water) were added and mixed immediately.
5) Absorbances read on Dynatech MR5000 Microtitre Plate Reader 
(Dynatech Labs Ltd, West Sussex, UK) at 690nm.
6) Equation of regression line of absorbance vs standard concentrations 
computed and unknowns calculated. An example of the standard curve 
obtained is shown in figure 16.
Std Curve Micro-Lowry APX 06C
0 .6 1
y = 5.6893e-2 + 1.7321e-3x 
R 2 = 0.9910.5-
1  0.4-
0ONNO
1  0.3- 
<
0 . 2 -
0.0
0 100 200 300 400
Protein C oncentration (pg . m L-1)
Figure 16. Example of Standard Curve used in Microtitre Lowry Assay.
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Characterisation o f Micro Lowry Protein Assay 
Accuracy: Comparative determinations with existing Lowry
Protein Assay (n=24), r=0.98 
Precision: a) Within batch (n=25) CV= 7%
b) Between batch (n= 12) CV=9%
Sensitivity: 0.06 mg. mL-1
Costing: The micro assay represented an 80% saving in reagents, a 70%
saving in consumables, and depending on the operator, a saving 
in technical time of 50-75 %.
The micro-Lowry protein assay was acceptable in terms of accuracy and 
precision and because it afforded the possibility of performing duplicate 
analyses it was used for all protein estimations in this study with the exception 
of TMU soluble proteins which because of their organic solvent content had to 
be performed in glassware.
2.5.4 Analytical Ultracentrifugation
HDL subfraction masses were estimated by Mrs Dorothy Bedford (Institute of 
Biochemistry, Glasgow Royal Infirmary). Plasma concentrations of HDL2 and 
HDL3 were estimated by analytical ultracentrifugation in a Beckman Model L8 - 
70 ultracentrifuge equipped with an ultraviolet scanning attachment, (Beckman 
Instruments) using an AnF rotor with double sector centrepiece (Shepherd etal 
1984a).
2.5.5 LDL Sub fraction Analysis
The LDL subfraction distribution in the patients presented here were estimated 
by Dr Bruce Griffin and Mrs Muriel Caslake (Institute of Biochemistry, 
Glasgow Royal Infirmary) using non-equilibrium density g rad ien t 
centrifugation as described by Griffin e ta l(1990). Briefly, fresh plasma was 
fractionated into three distinct LDL subfractions on a six-step, curvilinear salt 
gradient that was subjected to 24 h centrifugation in a Beckman SW40 rotor 
(40,000 rpm, 23°C). After centrifugation, the LDL subfiactions were eluted by 
upward displacement using a heavy density solution and detected by continuous 
monitoring of absorbance at 280nm. This procedure generated LDL subfraction 
profiles from which it was possible to resolve three subfractions that 
corresponded in size and density to those described by Krauss (1987a), namely
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LDL-I, LDL-H and LDL-IIL The individual subtraction areas beneath the LDL 
profile were quantified using Beckman ‘Data Graphics’ software (Beckman, 
U.K.). The integrated areas, after being adjusted by specific extinction 
coefficients calculated previously for LDL-I, II and III, were expressed as 
fractions of total LDL mass by proportionating the lipid and protein mass of 
total LDL (d 1.019-1.063 g. mL-1). This resulted in concentration values for 
each LDL subfraction in milligrams of lipoprotein per 100 mL o f plasma 
(Griffin etal 1990).
2.5 .6  Apolipoprotein E Phenotyping
Apolipoprotein E phenotyping was performed on all patients by Mrs Dorothy 
Bedford and Mrs Linda McCusker (Institute of Biochemistry, Glasgow Royal 
Infirmary) using methods as described by Menzel & Utermann (1986) and 
Havekes et al (1987). To detect apoE isoforms, 10 pL of plasma were 
delipidated, redissolved in 6M urea containing 0.1M TRIS pH 10.0, 5% 2- 
mercaptoethanol and 1% sodium decyl sulphate and applied to a vertical 
polyacrylamide slab gel of 5% (w/v) acrylamide in 8 M urea containing 1% 
ampholyte (pH range 4-6). The cathode buffer was 0.2M NaOH and the anode 
buffer 0 .1M H3PO4 . Isoelectric focussing was carried out at 3W per gel for 
16h. Transfer by electrophoresis from the acrylamide slab gels to nitrocellulose 
membranes was performed as described by Towbin, Staehelin & Gordon 
(1979). The transfer buffer contained 0.2M glycine, 0.025M TRIS and 20% 
methanol and the current applied was 0.4A for 3 h. ApoE isoforms bound to 
the membrane were visualised by immunostaining using a monoclonal or 
polyclonal apoE-specific antibody and an appropriate IgG-binding second 
antibody linked to horseradish peroxidase.
2.5 .7 . Lipoprotein (a)
Plasma lipoprotein (a) [Lp(a)] was determined using the commercial kit, 
Innotest Lp(a) (Innogenetics SA, Belgium), by Mrs Linda McCusker or Mrs 
Elizabeth Murray (Institute of Biochemistry, Glasgow Royal Infirmary). This 
assay consists of a solid phase mouse monoclonal anti-Lp(a), and a sheep anti- 
apoB polyclonal second antibody, which is labelled with the enzyme horse­
radish peroxidase. This labelled antibody binds to any solid phase 
antibody/Lp(a) complex because it can bind to the apoB moiety of the Lp(a) 
complex. Further incubation with enzyme substrate produces a blue colour,
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which turns to yellow when the reaction is stopped with sulphuric acid. The 
intensity of the colour formed is proportional to the amount of Lp(a) in the 
original sample.
2.6. Mevalonic Acid
In order to investigate the effects of lipid lowering drug therapy on the 
cholesterol biosynthetic rate an assay for urinary mevalonic acid was established 
based on that in the laboratory of Dr D. Roger Ilingworth in Portland, Oregon, 
USA.
2.6.1 Background
Mevalonic acid is present in both human urine and plasma (Popjak etal 1979) 
and previous work has already established that both plasma and urinary 
concentrations of mevalonate parallel changes in hepatic and whole body 
cholesterol biosynthesis and therefore may serve as an index of hepatic HMG 
CoA reductase activity (Kopito & Brunengraber 1980; Kopito etal 1982; Parker 
eta l 1982; Parker etal 1984).
2.6 .2  Purification o f Mevalonate Kinase from Porcine 
Liver
The purification of this enzyme was performed by the author in the laboratory 
of Dr D. Roger Illingworth under the supervision of Dr Anu Pappu and with the 
help of Ms Shannon Magennis. The method used was that of Levy & Popjak 
(1960) as modified by Popjak et al{ 1979) and Pappu (unpublished). It 
involved the preparation of a crude extract of porcine liver by protamine and 
ammonium sulphate fractionation which was further purified by affinity and 
hydroxylapatite chromatography.
Initial Extract
Approximately 5kg of parasite free pig liver were obtained from the abattoir 
immediately after slaughter of the animal and were placed on ice. Working at 
4°C the liver was trimmed of fat and finely minced in a rust-free meat grinder. 
Each 600g batch of liver mince was extracted with 1L of sucrose solution 
(0.35M sucrose containing 35 mM KHCO3 and ImM disodium EDTA, pH
7.5). This mixture was stirred gently for 90 seconds and centrifuged at 2000g
Chapter 2 Materials and Methods 7 6
for 30 minutes (4°C) yielding approximately 1L of initial extract in the 
supernatant. This gentle and brief extraction procedure minimises the amount 
o f protein and therefore ATPase extracted.
Protamine Precipitation
To each litre of initial extract, 75mL protamine solution (protamine sulphate 
from salmon sperm, lOmg. mL-1, Sigma) was added to achieve a final 
concentration of 0.7mg. mL*l. After mixing for 2 minutes at 4°C the mixture 
was centrifuged at 2000gfor 30 minutes, 4°C. This step increased the specific 
activity of mevalonate kinase in the preparation 3-4 fold.
Ammonium Sulphate Precipitation
Finely powdered ammonium sulphate was slowly added to the protamine 
supernatant to achieve 30% saturation at 4°C. The mixture was stirred gently 
until the salt dissolved while pH was monitored and maintained at 
approximately 7.5, by the addition of NH4OH if necessary. After 30 minutes 
the small precipitate formed was removed by centrifugation at 12,000 g  for 30 
minutes (4°C). More ammonium sulphate was added to the supernatant to 
achieve a 45% saturation and mixed for a further 30 minutes. The precipitate 
was collected by centrifuging at 12,000gfor 30 minutes (4°C). After removing 
the supernatant, the precipitate was resuspended in an equal volume of an 80% 
saturated ammonium sulphate solution containing 20mM potassium phosphate 
buffer, ImM disodium EDTA and 5mM 2-mercaptoethanol, pH 7.5.
Red Sepharose Affinity Chromatography
Affinity adsorption and elution of mevalonate kinase was carried out at room 
temperature using a glass column 25 x 4.4 cm i.d., with a polypropylene 
support net (Amicon) packed with 200mL of Red Sepharose (Amicon Matrix 
Gel Red A). Those sites on the Red Sepharose capable of irreversibly binding 
mevalonate kinase were first inactivated by circulating the column with 2L of 
0.1% bovine serum albumin (BSA) overnight. Excess BSA was washed out 
with 2L of 1M ammonium sulphate in lOmM potassium phosphate buffer and 
ImM disodium EDTA, pH 7.5. Two litres of wash buffer (lOmM potassium 
phosphate buffer with ImM disodium EDTA, and 5mM 2-mercaptoethanol pH
7.5) were passed through the column by gravity. The ammonium sulphate 
preparation above was centrifuged at 12,000 g  for 30 minutes (4°C) and the 
resulting pellet resuspended up to 1L in wash buffer. This sample preparation 
was loaded onto the column by gravity in 5 cycles. Unbound protein was
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eluted with 2L of wash buffer and mevalonate kinase was eluted with 1L of 
0.5M ammonium sulphate solution in lOmM potassium phosphate buffer with 
2mM ATP, ImM Mg CI2 , and 5mM 2-mercaptoethanol, pH 7.5. This eluate 
was concentrated down overnight to approximately 25 mL under nitrogen at 
172kPa, using a Diaflo® ultrafiltration membrane, PM 10 (Amicon). The 
concentrate was centrifuged at 12,000g for 30 minutes, 4°C to remove solids 
and the supernatant was dialysed overnight at 4°C with two changes against 
ImM potassium phosphate buffer with ImM disodium EDTA, and 5mM 2 - 
mercaptoethanol pH 7.5, to remove ammonium sulphate and to dilute the 
potassium phosphate buffer present.
Hydroxylapadte Purification
This procedure was carried out at 4°C and all buffers used were prepared in 
CO2 free deionised water and adjusted to pH 7.5 at 4°C. The column was set 
up by packing 2.5 x 60cm glass column with Bio-gel HT hydroxylapatite (Bio­
rad) in 0.5 mM potassium phophate buffer. Before purification the column was 
equilibrated with 1L ImM potassium phosphate buffer with ImM disodium 
EDTA and 5mM 2-mercaptoethanol. The dialysed sample was loaded onto the 
column by gravity and the column was washed with a further lOOmL of 
equilibration buffer above. Mevalonate kinase was eluted by a linear gradient 
generated from 1L each of ImM and 200mM potassium phosphate buffers 
containing ImM disodium EDTA, and 5mM 2-mercaptoethanol pH 7.5. The 
gradient flowed at 0.5 mL/minute and 12 mL fractions were collected overnight. 
The protein content of each tube was determined by the protein assay of Lowry 
et al (1951) and the enzyme activity present was estimated using the assay 
described below in 2.6.4. The 3-4 fractions of highest specific activity were 
pooled as were those on either side of this peak which also contained significant 
amounts of mevalonate kinase activity. Each pool was adjusted by adding 
lOmg BSA and made up to 2mM disodium EDTA, 2mM dithiothreitol and 
ammonium sulphate, 80% saturation. The desired final specific activity of the 
stored enzyme was approximately 5 pmol. mg-1. min-1.
At each stage in the purification procedure the specific activity and % yield were 
checked using the mevalonate kinase assay described below (2.6.3).
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2.6 .3  Spectrophotom etric Assay o f  M evalonate K inase 
M evalonate Kinase
(ATP: Mevalonate 5-phosphomevalonate EC 2.7.1.36)
This enzyme was first isolated from yeast extracts (Tchen 1958) and was 
subsequently discovered in animal tissues (Markley & Smallman 1961). It is 
known to be abundant in mammalian liver (Popjak 1969). The enzyme 
catalyses the following reaction:
Mg 2+ (Mn 2+)
Mevalonate + ATP -  5-phosphomevalonate + ADP
and has been found to be stereospecific for the R-enantiomer of mevalonic acid 
(Comforth, Comforth & Popjak 1962). Hepatic mevalonate kinase may be 
assayed by the spectrophotometric method of Levy and Popjak (1960). This 
involved coupling the kinase reaction with a pyruvate/LDH system as shown in 
figure 17 and observing the associated change in absorbance at 340nm.
MVA 5-PMVA
ATP ADP
PEPPyruvate
Lactate
NADNADH+H
Figure 17. Coupled Reactions used in the Assay of Mevalonic Acid
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Assay Procedure
Working close to the spectrophotometer the following reagents and water were 
mixed in a lOmL glass test tube:-
Reagent Volume (mL)
Distilled water 2.24
TRIS- HC1 Buffer 0.3M, pH 7.4. 2 . 0 0
Mg Cl2 0.3M 0 . 1 0
KF 1M * 0.06
ATP 0.20M, pH 7.0 0 . 2 0
PEP 50mM, pH 7.0 0 . 1 0
BNADH (disodium salt, grade I I I )
(reconstituted with 2.13mL of 0.01 M
KHCO3 .) 0.40
*KF is only required for the assay of the ‘initial extract’ and the 
‘protamine supernatant’ in order to inhibit ATPase.
The tube was then stored in the ice bucket until required. A batch o f 
approximately 5 tubes was prepared in this fashion in advance.
Next the following were added:
Reagent Volume (mL)
Cysteine hydrochloride 0.6 M 0.10
KOH1M 0.10
LDH/PK solution
(5000 units of each dissolved
together in 4mL of 1% albumin
solution.) 0 . 1 0
0.60 mL of sample was added and mixed.
The reaction mixture was split into 2 x 2.9mL aliquots in 2 quartz 
spectrophotometer cuvettes with path length 1cm. To the reference cuvette
0. lmL distilled water was added and placed in the spectrophotometer. To the 
other cuvette 0. lmL 0.1M Potassium RS-mevalonate was added and the cuvette 
inverted immediately to mix. Because the reaction may proceed to completion 
very rapidly the cuvette was placed in the spectrophotometer and reading 
commenced as quickly as possible. To avoid obtaining a negative curve the
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normal reference/sample arrangement in the spectrophotometer was reversed. 
The absorbance was read at 340nm for 3 minutes and recorded at 10 second 
intervals. As a reagent check ADP solution (2.5mM, pH 7.0) was added in 
place of the mevalonate.
To obtain Potassium RS-mevalonate for use in this assay, 130mg 
mevalonolactone was dissolved in 2mL of 1M K OH and 4mL of distilled 
water, and the solution heated to 50°C for 30 mins. The pH of the cooled 
solution was carefully adjusted to 7.3 with 0 .1M HC1 and the volume made up 
to lOmL with distilled water.
Definitions used in the calculation of mevalonate kinase activity were as 
follows:
One unit of enzyme activity equals the amount of enzyme which when assayed 
spectrophotometrically, phosphorylates mevalonate at an initial rate of 1 jimol 
per minute at 25°C
Specific activity equals units of enzyme activity/mg protein.
2.6 .4  Preparation o f Samples for Mevalonic Acid Assay
Twenty-four hour urine collections were obtained. The completeness of the 
collection was assessed by patient questioning and measurement of 24 hour 
urinary creatinine excretion. Aliquots ( 3 x 5  mL) were taken from the 
collection, centrifuged at 1000# (4°C) for 30 mins to remove any solids. 
Aliquots of the supernatant (lmL) were frozen at -20°C. These aliquots are 
known to be stable for at least 3 years (DR Illingworth, personal 
communication).
2.6.5 Radioenzymatic Assay o f Mevalonic Acid
The assay of mevalonic acid was performed according to the radioenzymatic 
method of Popjak etal (1979) as modified by Illingworth ef a7(1989).
The assay involves phosphorylation of mevalonate with radiolabelled 32P-ATP 
using the enzyme mevalonate kinase to yield radiolabelled 5- 
phosphomevalonate as shown below. This product is isolated by ion exchange 
chromatography along with [14C] labelled 5-phosphomevalonate which has 
been added in known amount to the reaction mixture. The ratio of 32P/14C in
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the 5-phosphomevalonate collected is a linear function of the initial mevalonic 
acid content of the samples.
Mevalonate + [32P]-ATP MeYftlpflate K inase^.5[32p ].phosphomevalonate 
Mg2+ (Mn2+)
Preparation ofTriethylammonium Carbonate Buffer 2M
In a fume cupboard, 275mL triethylamine (BDH) was added to approximately 
600mL of distilled water in a 1L bottle. The bottle was placed in an ice bucket 
and crushed ice packed around it. CO2 was bubbled through the solution at a 
pressure of 3.45kPa for approximately 2.5h until the pH comes down to 9.7. 
The stock 2M TEAC buffer was then made up to 1L with distilled water and 
stored at 4°C for no more than 7 days.
Dialysis o f Stock Enzyme (Mevalonate Kinase)
The stock enzyme was stored at 4°C. Approximately 0.03 units of enzyme was 
required per sample. Therefore, the required volume for each run was 
calculated, depending on the specific activity of the enzyme batch.
Stock enzyme solution (0.3-0.5mL) was taken as appropriate and placed in a 
small plastic eppendorf tube and centrifuged at 12,000# (4°C) for 30 minutes. 
The supernatant was carefully removed leaving behind a yellow/green pellet. 
This pellet was redissolved in 300pL of Potassium Phosphate Buffer 20mM + 
ImM DTT (Sigma) (dialysing buffer) and the resulting enzyme solution 
dialysed against 500 mL of the above buffer overnight with two changes, using 
pre-soaked Spectrapor tubing, 12-14,000 MWCO, 25mm wide.
Preparation o f Standards
Stock Potassium RS-mevalonate was prepared from mevalonolactone as 
described above in 2.6.2. From stock frozen 0.1M solution a lpM solution 
was prepared by dilution and stored in 1 mL aliquots at -20°C. It should be 
noted that lpL of standard contains lpmol of a racemic mixture of potassium 
mevalonate and therefore only contains 0.5pmol of R-enantiomer. Since 
mevalonate kinase as noted above in 2.6.4 is stereospecific this is an important 
point for the final calculation of results.
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Preparation o f Samples
Prepared samples and standards were thawed in water bath at 37°C. and the 
following volumes added to labelled plastic centrifuge tubes:
Urine 20pL
Standards 0, 20, 50, lOOpL
and made up to lOOpL with freshly prepared potassium phosphate buffer 
20mM, pH 7.4.
Preparation o f Incubation Mixture
The following reaction mixture was prepared:
Potassium phosphate buffer 1M (pH 7.4) Stock. 750jiL
Mg Cl2 0.3M 250pL
ATP solution * 8 jiL
Mevalonate kinase + buffer t  1385pL
* ATP (Boehringer Mannheim MV602), 4.9mg in 315pL Potassium
phosphate buffer 20 mM. 
t  Contents of dialysis tubing were taken and the tubing rinsed with the
unused dialysis buffer to obtain appropriate volume.
Behind plexiglas and lead shielding 32P-ATP (NEN 2.0mCi. mL-1) IOOjjL was 
added to this mixture and vortexed immediately. Four microcuries were 
required for each sample, therefore the exact volume o f labelled ATP added 
depended on its specific activity.
Incubation
Fifty microlitres of the above reaction mixture were added to each tube and 
allowed to stand at room temp, for at least 2.5 h behind shielding. The reaction 
was stopped by adding 25pL concentrated. HC1 (10M) to each tube in rapid 
succession. The following were then added in the correct sequence to each 
tube:
i) 30jiL (approx. 0.06jiCi) [14C]-5-phosphomevalonic acid.(Amersham, 
25pCi in 12.5 mL H20).
ii) 25 pL ATP/ADP (0.1152g ATP+0.0160g ADP in 750pLof 0.5M
k h 2p o 4
iii) Ethanol 0.9mL to precipitate ATP/ADP (labelled and unlabelled).
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The tubes were vortexed and left on ice behind plexiglas shielding for 30 
minutes. Samples were transported to the centrifuge in a plexiglas box and 
centrifuged at 1000#(4°C) for 10 minutes.
After centrifugation, behind plexiglas and lead shielding, the supernatant was 
carefully removed from each tube and added to pre-labelled tubes containing 
5mL of 0.1 M TEAC buffer. This transfer was carried out using a new glass 
pasteur pipette for each sample and standard and great care was taken not to take 
up any of the precipitate from the pellet or from the walls o f the centrifuge tube.
Ion-Exchange Chromatography
Ten samples were run in each assay using the custom built fraction collector 
pictured in figures 18 & 19 The specifications of this device are listed below:
i) 10 x Econo-columns (0.7 x 10cm) and caps (Bio Rad).
ii) 12 channel peristaltic pump. (Technicon) Row rate 0.6 mU  minute.
iii) Gradient maker, capacity 2L. (Isolab)
The anion exchange resin used was AG® 1-X8 200-400 mesh chloride form 
(Bio Rad) This was converted to the carbonate form according to the procedure 
described by Popjak e ta l (1979) Briefly, this involved washing newly 
purchased resin repeatedly with methanol and water and cycling with 1M H Cl 
and 1M Na OH. It was then treated with 2M Na2 CO3 over several days and 
then washed with water. It was then equilibrated in a  large column for several 
days with 20mM triethylammonium carbonate buffer, pH 9.7. A fter 
equilibration the resin was removed from the column and kept at 4°C as an 
approximately 50% (w/v) slurry in 20mM TEAC buffer. The resin had to be 
regenerated in a similar fashion after each assay.
Loading Column
The columns were filled with approximately 5mL o f  regenerated resin and 
allowed to settle making sure that all columns had the same height o f resin 
Once equilibrated the columns were loaded with samples and a linear TEAC 
gradient was pumped through.
To check the uniformity of the columns in this custom built fraction collector 
sample blanks containing [14C]-5-phosphomevalonic acid were run. A 
composite graph showing the simultaneous elution of [1 4 C ]-5 - 
phosphomevalonic acid in all 10 channels is illustrated in figure 2 0 .
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F igure  18. Photograph showing the custom built fraction collector used for 
the assay of mevalonic acid.
Gradient Maker
Manifold
Peristaltic Pump
Columns
Ion Exchange Resin
Collection Tubes
Figure 19. Schematic diagram of the custom built fraction collector used for
the assay of mevalonic acid.
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Figure 20. Uniformity Check of The 10 Channel Fraction Collector. Sample 
blanks spiked with [14C]-5-phosphomevalonic acid were run and the 14C 
counted in each 3 min fraction from each column. This composite graph shows 
that the peak fractions for all ten columns are eluted simultaneously.
Collecting Fractions
As the gradient was pumped through the columns the fractions collected in the 
first 20 minutes were discarded and fractions were then collected at 3 minute 
intervals. The appropriate two peak fractions for each column were then 
transferred to counting vials (Super polyethylene scintillation vials 20 mL, 
Canberra Packard). 2.5 mL of each fraction was added to each vial containing 
10 mL of scintillation fluid (Ultima-Gold, Canberra Packard). 32P and 14C 
were counted in the fractions for 10  minutes each an an automated 6 -counter 
(Packard).
The procedure was found to have an inter-assay coefficient of variation of <5%. 
Calculation
The mean 3 2 P/14C ratio of the two peak fractions was taken and the blank 
subtracted. The mean ratio was read from a standard curve (example shown in 
figure 21) to obtain answers in pmol. 20pL_1. These were adjusted to take 
account of the 24h urine volume and expressed as pmol. 24 h_1.
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Figure 21. Example of Standard Curve used in Mevalonic Acid Assay
2.7 Lathosterol
Levels of plasma 7-lathosterol (5a-cholest-7-en-36-ol) have also been shown to 
correlate well with HMG CoA reductase activity in human liver (Bjorkhem etal 
1987). This cholesterol precursor is not present in urine but may be assayed in 
plasma using a commercial derivatisation procedure followed by capillary gas 
chromatography. As shown in figure 22 lathosterol is an isomer of cholesterol 
differing only in the position of a single double bond. As such, it is difficult to 
separate these compounds by means other than an optimised Gas Liquid 
Chromatography system.
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5-cholest-3B-ol (Cholesterol)
HO
5a-cholest-7-en 3B-ol (Lathosterol)HO
F igure 22. Structures of Cholesterol and Lathosterol with Systematic Names
2 .7 .1 . Extraction and D erivitisation o f N on-Saponifiable Lipids
The assay of lathosterol was performed by a modification of the procedure of 
Kempen et al (1988) A 200pL aliquot of plasma, taken at 08 OOh after an 
overnight fast, was saponified using lmL 0.3M NaOH in 90% ethanol 
incubated at 37°C for 60 min. After addition of lmL distilled water, the non- 
saponifiable lipids were extracted with 4mL hexane and blown to dryness with 
nitrogen. 5a-cholestane (10pg, Sigma) was added as an internal standard to 
each of samples. This compound was used because it is not normally present in 
human plasma. The non-saponifiable lipids were converted to their 
trimethylsilyl ethers using the commercial derivitisation preparation, Deriva-sil® 
(Chrompack Ltd, London UK) in which the active ingredients are 
BSTFA:TMCS:TSIM:Pyridine (3:2:3:10).
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2.7 .2 . Gas Liquid Chromatography
Lathosterol and cholesterol were quantified by capillary gas-liquid 
chromatography using the following conditions:
Examples of the tracings obtained from standards and from samples are shown 
in figure 23. The peaks obtained were integrated using the PCI integration 
software package (Chrompack) and quantified with reference to the internal 
standard 5a-cholestane. Pure lathosterol and cholesterol were found to have 
relative retention times of 1.57 and 1.52 respectively in relation to the internal 
standard 5a-cholestane. The procedure was found to have an inter-assay 
coefficient of variation of 10%.
2.7 .3  Expression o f Results
The final concentrations were expressed as lathosterol/cholesterol ratios. This 
practice was originally advocated by Miettinen (1970, 1982, 1985) as a way to 
correct for differences in the levels of cholesterol precursors that would occur as 
a mere consequence of a different number of acceptor (lipoprotein particles) in 
the circulation. Kempen et al (1988), continued this form of expression 
supported by their observations that in hypercholesterolaemic subjects both 
serum lathosterol and cholesterol levels are higher than normal controls, 
whereas the ratio is the same. This is in accord with the observation that 
cholesterol production rates are not elevated in hypercholesterolaemic subjects
Chromatograph
Column
Stationary Phase 
Carrier Gas 
Detection
Temperature Program
CP9000 (Chrompack)
WCOT 50m x 0.25 ID
CP-Sil 5CB Film Thickness 0.4 pm
Helium
Flame Ionisation 
Oven Initial 265°C 
Oven Final 320°C
Rise 1°C. m hr1 for approximately 56 min
Injector Temperature 
Detector Temperature
350°C
320°C
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F ig u re  23. Gas-liquid Chromatograph Pattern of Plasma Sterols. 
Cholesterol, 5a-cholestane and lathosterol peaks are labelled with their retention 
times in minutes after injection. The rising baseline was a consistent feature in 
all lathosterol assays and is taken into account by the integration software. It is 
clear that the small lathosterol peak, although close to the much larger 
cholesterol peak (which appears blunted because of the scale of the graph), is 
distinct and separate.
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as assessed by sterol balance studies (Grundy etal 1972). The increased serum 
lathosterol in hypercholesterolaemia may be due to the decreased clearance rate 
of its carrier, LDL. The effects of ‘statin’ therapy are correctly represented by a 
decrease in the lathosterol/cholesterol ratio. Kempen eta l( 1988) noted a 30% 
reduction in serum cholesterol but a 64% reduction in serum lathosterol so that 
the lathosterol/cholesterol ratio fell by 47%, reflecting enhanced clearance but 
also reduced synthesis of lathosterol.
2.8 Ethical Considerations
All subjects gave informed written consent to the studies which met with the 
requirements of the Ethical Committee of each host institution viz. Glasgow 
Royal Infirmary, Hairmyres Hospital, East Kilbride and Victoria Infirmary, 
Glasgow. All injections of radioactive material were carried out under the 
ARSAC license of Professor James Shepherd.
2.9 Statistical Methods
Differences between the lipid, lipoprotein and compositional data and metabolic 
parameters at different time points in the same individuals as presented in the 
results sections below were analysed by the paired students t-test. Because of 
the highly skewed distribution of plasma Lp(a), differences between the means 
of this analyte were assessed using the non-parametric Wilcoxan Sign Rank 
Test.
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Chapter 3 Simvastatin
...when you can measure what you are speaking about, and express it in 
numbers, you know something about it...when you cannot express it in 
numbers, your knowledge is of a meagre and unsatisfactory kind; it may be the 
beginning of knowledge, but you have scarcely in your thoughts, advanced to 
the stage of Science...
Lord Kelvin.
3.1 In troduction
The publication of the findings from the Lipid Research Clinics Primary 
Prevention Trial (Lipid Research Clinics Program 1984a, 1984b) and more 
recently from the Helsinki Heart Study (Frick etal 1987) has confirmed the 
importance of lipid lowering as a means of preventing CHD. Since the 
completion of these studies, more powerful lipid regulating agents have become 
available; the most potent of these in terms of LDL cholesterol lowering are the 
3-hydroxy, 3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitors or 
‘statins’. This is an important class of lipid lowering drugs whose remarkable 
efficacy has been documented in studies of several different groups of patients 
(Illingworth & Bacon 1989, Garg & Grundy 1989, Rabelink et al 1988, Vega 
& Grundy 1989b, Illingworth & O’Malley 1990, Vega, East & Grundy 1988, 
Mol et al 1988). The precise mechanism of action o f these compounds, 
however, has not yet been elucidated fully. At first, it was thought that these 
drugs affected only LDL via activation of hepatic apoB/E receptors. However, 
further experience has suggested that they have substantial effects on very low 
(Sf 20-400), intermediate density (Sf 12-20), and high density lipoproteins 
(Grundy & Vega 1985, Vega, Krauss & Grundy 1990, Mol eta l 1988) In 
general, all statins have weak but significant plasma triglyceride lowering
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properties. While in type III hyperlipoproteinaemic subjects it has been shown 
that statins are both effective (Stuyt, Mol & Stalenhoef 1991) and can uniquely 
among lipid lowering drugs correct the compositional abnormality seen in 
VLDL (Vega et al 1988). Investigations of the kinetic changes underlying the 
LDL reduction on statin therapy has revealed an unsuspected heterogeneity of 
response. Many subjects, particularly those with familial hypercholesterolaemia 
(FH) exhibit an increase in apo-LDL clearance on drug (Bilheimer etal 1983). 
While in others decreased production of the lipoprotein is the principal cause of 
reduced LDL concentration in the circulation (Grundy & Vega 1985). This 
variable response to a drug with an apparently simple, known mechanism of 
action suggests that inhibition of cholesterol synthesis in vivo has a wide 
ranging effect on apolipoprotein B metabolism. Whether or not the statin 
induced changes are consequent on increased apoB/E receptor activity remains 
to be determined. Certainly in previous studies it has been demonstrated that 
the receptor has a role to play in the metabolism of apoB containing lipoproteins 
throughout most of the Sf 0-400 density range (James eta l 1989, Demant etal 
199 la). Receptor deficiency in FH leads to accumulation of VLDL2 , IDL, and 
LDL (James et al 1989). On the other hand the up-regulation of receptors in 
subjects with apoE2 homozygosity has a profound impact on all apoB 
containing classes (Demant etal 1991a).
The aim of the present study was to examine in detail the mechanism of action 
of HMG CoA reductase inhibitors in patients representative of the largest 
group who will receive such therapy, viz. those with primary, moderate 
hypercholesterolaemia. The dual VLDLi and VLDL2 tracer turnover technique 
used has been previously applied to the study of the VLDL delipidation cascade 
in familial hypercholesterolaemia (James etal 1989), hepatic lipase deficiency 
(Demant etal 1988), lipoprotein lipase deficiency (Demant et al 1991b) and in 
subjects with different apoE phenotypes (Demant eta l 1991a). While a new 
method to determine LDL substructure has been used successfully to examine 
the LDL subfraction distribution in normals and those with CHD (Krauss 1987b, 
Griffin et al 1990) and to look at the effects of other lipid lowering drugs 
(Griffin etal 1992), it was felt that application of these powerful techniques and 
correlation of kinetic parameters with VLDL and LDL structural information 
would yield new insight into lipoprotein physiology and the mechanism of 
action of the HMG CoA reductase inhibitor, simvastatin. This, indeed, proved 
to be the case. Significant correlations were observed between LDL apoB 
kinetic parameters and LDL substructure. The effects of the drug were isolated
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to specific pathways throughout the delipidation cascade, which are believed to 
be receptor dependent.
3 .2 . P ro tocol
This was a single blind study comprising three phases designed to examine the 
influence of simvastatin on the metabolism of apoB containing particles. These 
phases were:
1. Preliminary Screening Period. During this 5 week run in period each patient 
was screened for cardiological, haematological, hepatic, endocrine, renal, 
ophthalmological and metabolic disease by routine clinical and laboratory 
testing.
2. Placebo Baseline Period. For 4 weeks each patient received placebo and in
the final 2 weeks of this period a VLDL turnover study was performed on 
each patient to serve as a control. Baseline lipid, lipoprotein and 
lipoprotein subfractions were measured as described above.
3. Active Treatment Period. Immediately after the baseline assessment of
apolipoprotein B metabolism the patients were commenced on simvastatin 
therapy at an initial dose of lOmg nocte rising to 20mg nocte after 4 weeks. 
Patients remained on this dose for 10 weeks. During the final 2 weeks each 
patient underwent a second turnover investigation while on simvastatin 
therapy. In addition lipid, lipoprotein and lipoprotein subfraction analyses 
were repeated.
3.3 Subjects
Eight study patients were selected from the Risk Factor Clinic at Glasgow 
Royal Infirmary and the Lipid Clinic at Hairmyres Hospital, East Kilbride. All 
patients had an initial elevated total cholesterol level (>7.0 mmol. L_1) despite 
adherence to a standard lipid lowering diet (Study Group, European 
Atherosclerosis Society dietary recommendations, 1988) and a triglyceride level 
less than 4.0 mmol. L’1, but did not have clinical evidence of FH. One 
subject’s (SIM 02) cholesterol level fell below 7.0 mmol. L 1 but because he 
had previously satisfied the inclusion criteria on three occasions he was 
continued in the study. Another subject (SIM 04) completed the protocol but 
was subsequently found to have an E2/E 2 phenotype. In view of recent 
findings by Demant etal( 1991a) outlined above (3.1), regarding the effects of 
apo E2 homozygosity on apoB metabolism this subject was excluded from the
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present analysis, which is based on the remaining 7 subjects. Patients were 
screened for cardiological, haematological, hepatic, endocrine, renal, 
ophthalmological and metabolic disease by routine clinical and laboratory 
testing. Pre-menopausal women were excluded from the study. The 
characteristics of each patient are summarised in Table 3. Five o f the seven 
subjects studied were receiving prescribed medications for other clinical 
conditions, and these were continued unchanged throughout the course of the 
study.
3.4 A dverse Events
Simvastatin was well tolerated by all subjects participating in the study. 
Biochemical and haematological monitoring revealed no clinically significant 
changes from baseline attributable to therapy. Similarly, ophthalmological 
examination with a slit lamp failed to detect alteration in the lens of any subject.
3.5 L ipids and Lipoproteins
Plasma lipid and lipoprotein levels of those patients studied are shown in Table
4. Treatment reduced plasma cholesterol by 29% (p<0.001). Triglyceride was 
not significantly affected although there was a tendency (p=0.091) for it to be 
decreased on therapy. The decrement in the former was due in this group to a 
39% fall in LDL-cholesterol, while VLDL and HDL cholesterol were 
unchanged. Simvastatin therapy had no significant effect on plasma levels of 
Lp(a). Centrifugal analysis of the subfraction distribution in the LDL and HDL 
density intervals revealed that these had also been perturbed by simvastatin 
treatment. HDL2 was increased significantly by 62% (p<0.01) while HDL3 
was unaffected. The change in HDL2 concentration was correlated inversely 
with the fall in triglyceride for the group as a whole, r=0.703. Figure 24 shows 
the LDL subfraction profile obtained upon density gradient fractionation of 
subjects’ plasma. The pattern exhibited considerable variation from subject to 
subject but in most three distinct populations of particles could be distinguished 
both before and during therapy. The decrement in the major LDL-II species 
was the most obvious change in our subjects. Quantitative analysis (table 5) 
revealed that its concentration fell by 39% (p<0.02). LDL-I, the least dense 
fraction was also reduced significantly by 31% (p<0.02). Where LDL-III was 
high (figure 24, table 5) it appeared to fall substantially but a number of the 
subjects in whom it was a minor fraction recorded no change. Thus despite a
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30% reduction in the mean value (table 5), the overall effect was not statistically 
significant. Compositional analysis of the four major apoB containing 
lipoprotein classes (table 6 ) demonstrated that the drug had profoundly altered 
the make-up of these species. A decrease in relative cholesteryl ester content 
was the most noticeable change in all fractions: in IDL, in particular, cholesteryl 
ester fell from 39.3% to 35.3%, while the triglyceride content rose from 11.5% 
to 18.6%. Simvastatin also decreased the percentage free cholesterol in IDL 
and LDL.
T able 5. LDL Subfraction Changes with Simvastatin Therapy.
Subject Tot LDL LDL-I LDL-H LDL-ffl
a a a tM |t  l ifN A n fA ^ A if i  1 f iiY m  1 n l a e f M A  a l _ _ .• u i j j  n p u p r u i c i n .  av/ v i i u  p i n a m a  - - - -
Before Therapy
SIM01A 640 6 6 392 182
SIM 02A 326 63 224 39
SIM 03A 358 39 136 183
SIM 05A 337 53 163 124
SIM 06A 378 70 255 53
SIM 07A 283 88 178 17
SIM 08A 329 30 175 124
Mean 379 58 218 103
(SEM) (44.9) (7.4) (32.7) (25.6)
On Simvastatin
SIM01B 412 74 206 132
SIM 02B 185 48 102 35
SIM 03B 281 2 2 104 155
SIM 05B 224 16 141 67
SIM 06B 216 46 129 41
SIM 07B 224 54 137 33
SIM 08B 170 19 111 40
Mean 245 40 133 72
(SEM) (30.9) (8 .2 ) (13.5) (19.1)
p * <0 .0 0 1 <0 .0 2 <0 .0 2 NS
* Comparison of the means was performed using paired student’s t-test.
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Figure 24. LDL subfraction profiles at baseline (—) and during simvastatin 
therapy (—) in each of the 7 subjects.
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3.6 Apolipoprotein B Metabolism
The influence of simvastatin therapy on apolipoprotein B metabolism was 
examined before and on drag (representative decay curves for one subject, SIM 
05 are shown in figures 25-28). ApoB disappeared rapidly from the VLDLi 
flotation interval and appeared virtually quantitatively in VLDL2 over a period of 
12-24 h after injection (figure 25). The decay of radioactive apoB in VLDL2 
was slower than in VLDLi, taking up to five days to reduce to 1% of the 
injected dose (figure 26). Drug therapy did not appear to affect the clearance 
rate of either VLDLi apoB (figure 27) or VLDL2 apoB (figure 28). Similarly 
the extent of transfer of radioactive apoB into IDL was comparable before and 
during simvastatin therapy for both tracers. However, the decay rate of IDL 
apoB was faster on drug and the peak value attained in the LDL fraction 
consistently less than at baseline. In figure 26, LDL apoB radioactivity reaches 
a maximum of 25% of injected dose about 24 h after VLDL2 injection whereas 
in figure 28, the LDL apoB maximum is only 13%. This finding indicates that 
the metabolic fate of IDL apoB is markedly affected by therapy with more 
material being lost directly from the circulation rather than being converted to 
LDL. In this subject (SIM 05), the clearance rate of LDL apoB radioactivity 
was also increased during simvastatin therapy. Kinetic rate constants and apoB 
fluxes were derived by compartmental modelling. The results for all 7 subjects 
are summarised in table 7; decay curves for the other six subjects and 
individual kinetic constants and masses are given are shown in appendix 2 .
VLDLi apoB synthesis, pool size, and fractional transfer rate to VLDL2 were 
unchanged by therapy and although the mean direct fractional catabolic rate of 
VLDLi apoB increased by some 209% from 1.7 to 5.3 pools. d_1 this just 
failed to reach statistical significance (p=0.06). The VLDL2 apoB pool size 
remained unchanged on drag as did the amount of material derived from VLDLi 
or by direct input. There was, however, a rise in the mean VLDL2 apoB direct 
fractional catabolic rate of 79%, from 1.69 to 3.02 pools.d_1. IDL formation 
from VLDL2 , presumably by delipidation was the same before and during 
simvastatin therapy. The IDL apoB plasma pool size fell significantly from 
1043 to 762mg (27%, p<0.01) due entirely to an increase in direct catabolism 
(147%, p<0.05) of this fraction. In contrast the IDL to LDL fractional transfer 
rate was not affected by the drug. Direct synthesis of LDL apoB decreased in 4 
of the 7 subjects and the LDL apoB synthetic rate from VLDL2 , and IDL 
showed a similar pattiem with 5 of the 7 subjects showing a fall. The LDL
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Figure 25. Baseline. Apolipoprotein B radioactivity decay curves associated 
with VLDLi, VLDL2 , IDL, and LDL in subject SIM 05 after 
injection of autologous [l31I]-VLDLi.
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Figure 26. Baseline Apolipoprotein B radioactivity decay curves associated 
with VLDL2 , IDL, and LDL in subject SIM 05 after injection of 
autologous [125I]-VLDL2 -
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Figure 27. On Simvastatin. Apolipoprotein B radioactivity decay curves 
associated with VLDLi, VLDL2 , IDL, and LDL in subject SIM 
05 after injection of autologous [131I]-VLDLi
SIM 05 B (M etabolism  of VLDL2)100
125-1VLDL2 
125-1 IDL 
125-1 LDL
s
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Figure 28. On Simvastatin. Apolipoprotein B radioactivity decay curves 
associated with VLDL2 , IDL, and LDL in subject SIM 05 after
injection of autologous [125I]-VLDL2.
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Table 7a. VLDLi Apolipoprotein B Metabolism Before and On Simvastatin.
Plasma Direct Flux
Synthesis Pool Catabolism ToVLDL2
(mg.d-1) (mg) (pools, d-1) (pools. <H)
Before Therapy
SIM01A 2280 215 5.26 5.3
SIM 02A 451 62 0.40 6.87
SIM 03A 1333 344 0.51 3.37
SIM 05A 517 126 0.82 3.29
SIM 06A 1491 109 0.03 13.65
SIM 07A 565 89 0 .0 1 6.33
SIM 08A 716 6 8 5.07 4.67
Mean 1050 145 1.73 6 .2 2
(SEM) (257) (39) (0.89) (1.34)
On Simvastatin
SIM 0 IB 3085 160 13.37 5.91
SIM 02B 1332 100 8.96 4.35
SIM 03B 856 154 1.76 3.80
SIM 05B 776 76 0 .1 0 1 0 .1 1
SIM 06B 3473 160 7.31 14.4
SIM 07B 456 77 0 .0 1 5.91
SIM 08B 495 43 5.94 5.57
Mean 1496 11 0 5.35 7.15
(SEM) (475) (18) (1.89) 91.43)
p * NS NS NS NS
♦Differences between the means were assessed by the paired student’s t-test.
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Table 7b. VLDL2 Apolipoprotein B Metabolism Before and On Simvastatin.
Direct Flux from Plasma Direct Flux
Synthesis VLDLi Pool Catabolism to IDL+LDL
(mg.d-1) (mg.d-1) (mg) (pools, d-1) (pools, d*1)
Before Therapy
SIM01A 3065 1149 560 5.46 2.04
SIM 02A 1008 426 304 2.39 2.31
SIM 03A 1547 1158 1353 0.57 1.43
SIM 05A 1030 414 468 1.00 2.08
SIM 06A 155 1488 394 0.01 4.21
SIM 07A 974 564 517 1.49 1.51
SIM 08A 825 371 296 0.89 3.16
Mean 1229 796 556 1.69 2.39
(SEM) (343) (173) (138) (0.69) (0.37)
On Simvastatin
SIM01B 4088 946 429 9.13 2.53
SIM 02B 2867 436 364 3.59 5.42
SIM 03B 1754 585 718 1.12 2.14
SIM 05B 596 768 538 0.19 2.33
SIM 06B 678 2304 612 3.57 1.00
SIM 07B 1132 455 418 1.01 2.81
SIM 08B 1990 239 376 2.54 3.39
Mean 1872 819 494 3.02 2.80
(SEM) (476) (263) (50) (1.13) (0.52)
P NS NS NS NS NS
Chapter 3 Simvastatin 105
T able 7c. IDL Apolipoprotein B Metabolism Before and On Simvastatin.
Flux from Plasma Direct Flux
VLDL2 Pool Catabolism To LDL
(mg.d-1) (mg) (pools. d_l) (pools. d“l)
Before Therapy
SIM01A 1148 714 0.28 1.33
SIM 02A 700 678 0.45 0.58
SIM 03A 1926 1609 0.63 0.56
SIM 05A 971 983 0.60 0.39
SIM 06A 1666 1249 0.83 0.50
SIM 07A 769 1057 0.37 0.35
SIM 08A 933 1011 0 .6 6 0.26
Mean 1159 1043 0.55 0.57
(SEM) (176) (1 2 0) (0.07) (0.13)
On Simvastatin
SEM01B 1087 515 1.26 0.85
SIM 02B 1974 426 2.74 1.90
SIM 03B 1532 994 1 .2 0 0.34
SIM 05B 1258 755 1.25 0.41
SIM 06B 61 1062 0.50 0.08
SIM 07B 1170 8 8 6 1.15 0.17
SIM 08B 1276 695 1.42 0.42
Mean 1273 762 1.36 0.60
(SEM) (158) (90) (0.26) (0.24)
P NS <0 .0 1 <0.05 NS
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Table 7 d. LDL Apolipoprotein B Metabolism Before and On Simvastatin.
Direct Flux from VLDL-derived Fractional TotalApoB
Synthesis { IDL + VLDL2 Plasma Pool Catabolic Rate Synthesis
(mg.d-1) (mg.d-1) (mg) (pools, d"1) (mg.d’1)
Before Therapy
SIM01A 385 950 2910 0.33 5730
SIM 02A 208 397 1203 0.33 1667
SIM 03A 77 910 3592 0.25 2957
SIM 05A 106 386 2160 0.18 1653
SIM 06A 103 641 2866 0 .2 2 1749
SIM 07A 160 378 1918 0 .2 0 1699
SIM08A 8 6 266 1418 0.19 1627
Mean 161 561 2295 0.24 2440
(SEM) (41) (104) (328) (0 .0 2 ) (778)
On Simvastatin
SIM01B 300 474 1837 0.26 7473
SIM 02B 81 825 1296 0.64 4280
SIM 03B 52 342 1406 0.24 2662
SIM 05B 123 315 1114 0.28 1495
SIM 06B 94 260 978 0.27 4245
SIM 07B 168 150 733 0 .2 1 1756
SIM 08B 157 291 869 0.33 2642
Mean 139 380 1176 0.32 3508
(SEM) (31) (83) (141) (0.06) (577)
P NS NS <0 .0 1 NS NS
$ Direct synthesis in LDL was calculated as the difference between the total
absolute catabolic rate (observed mass x overall FCR) and the input from
VLDL and IDL.
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therapy, of 49% from 2295 to 1176mg (p<0.01) due to a combination of 
reduced synthetic and increased catabolic rates. The mean fractional catabolic 
rate of LDL apoB, which we expected to increase in response to therapy did 
indeed rise by 33% but because of the scatter of responses this did not achieve 
overall significance. In this limited group of subjects it was the reduction in 
LDL apoB synthesis rather than any change in catabolism that appeared to be 
the predominant factor in reducing LDL. Before therapy 30% of apoB entering 
the delipidation cascade in these hyperlipidaemic subjects was converted to 
LDL. Following therapy the input remained the same but direct catabolism 
from VLDL2  and IDL density ranges was increased significantly (p<0.05) so 
that only 16% was processed to LDL (figure 29). It was also of note that the 
mean calculated total apoB synthetic rate increased from 2440 to 3508 mg/day 
(p=0.06) in response to therapy (table 7).
From these data, simvastatin is clearly responsible for greater effects on 
lipoprotein metabolism than a simple increase in LDL catabolism. In an attempt 
to correlate the changes in LDL kinetics with changes in LDL substructure, the 
relationship between the LDL apoB synthetic parameters and the plasma 
concentrations of LDL-I, II, and HI was examined. LDL-I and II were grouped 
together for this analysis since they appeared to behave in a similar fashion, 
distinct from that of LDL-III. The relationship between LDL-I+II and LDL 
direct input and LDL-III and LDL direct input are shown in figures 30 and 31. 
The strong correlation between LDL-I+II and LDL direct input before (r=0.890, 
p<0.01) and after therapy (r=0.872, p<0.02) and the lack of correlation 
between LDL-III and LDL direct input was unexpected. The relationship 
between LDL-III and LDL synthesis from VLDL2 , and IDL was also examined. 
Before therapy the correlation coefficient was r=0.633, p=0.127: on therapy it 
was r=0.028, p=0.952.
3.7 Discussion
The mechanism by which the HMG CoA reductase inhibitors (statins) achieve 
their principal effect of lowering LDL cholesterol has been a particular focus of 
research over the last ten years. In an early study Bilheimer et al (1983) 
examined LDL turnover in familial hypercholesterolaemic subjects treated with 
mevinolin (lovastatin). They attributed the drug’s LDL lowering to an increase 
in the apo-LDL fractional catabolic rate (FCR), which was thought to be 
secondary to the effect of the drug in suppressing cholesterol synthesis, 
reducing intracellular cholesterol concentrations and consequently promoting the
Chapter3 Simvastatin 108
CONTROL
VLDL 1
1
788
1229 Z Z = > (v L D L ^ .
1466
ON SIMVASTATIN
VLDL I
819 I
1872 V L D L  2
1273
© ■I346
139 ----- >  (LDL1
380 *
Figure 29. Summary of the effects of simvastatin therapy on apoB 
metabolism. Numbers on arrows represent mass transfer of 
apoB in mg.d'1- * significantly different from control
2312*
LD
L 
D
ire
ct
 I
np
ut
 (
m
g/
d)
 
LD
L 
D
ire
ct
 I
np
ut
 (
m
g/
d)
Chapter 3 Sim vastatin 109
r = 0.890, p<0.01 ■  
r= 0.872, p<0.02 □
400
300
200
100
200100 500300 400
LDL I+1I (mg lipoprotein/100 mL)
30. Correlation between LDL sub fractions I+n and LDL direct input
at baseline (■) and during simvastatin therapy (□)
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Figure 31. Correlation between LDL-III and LDL direct input at baseline (■) 
and during simvastatin therapy (□)
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activity of the apoB/E receptor. A close parallel was drawn between the 
mechanism of action of the statins and that reported previously for bile acid 
sequestrant resins, which also showed an increase in receptor mediated LDL 
catabolism. No overall change in the apo-LDL synthesis rate was seen in these 
statin treated FH subjects although it was noted that 5 out of 6  examined 
showed reductions of up to 22% in this parameter. Further studies in patients 
with ‘polygenic hypercholesterolaemia’ (not attributable to FH) emphasised this 
dual action. In these studies (Grundy & Vega 1985, Vega & Grundy 1987) it 
was reported that both decreased output and increased clearance had to be 
invoked to explain the reduction in LDL in such patients. These workers 
proceeded to investigate apoB metabolism in VLDL, IDL and LDL and found 
that pravastatin therapy altered VLDL production but not the catabolism of any 
of these lipoprotein classes (Vega, Krauss & Grundy 1990). A summary of the 
findings of committed studies so far with this group of drugs is:
i) that functional LDL receptors are essential for their action: FH homozygotes 
show no response to the drug in terms of altered plasma LDL levels or 
turnover (Uauy etal 1988),
ii) subjects with a pronounced catabolic defect ie FH heterozygotes show an 
increase in LDL FCR on statins, and
iii) other hypercholesterolaemic patients are as likely to demonstrate reduced 
apoB input into LDL as increased clearance of the lipoprotein, although, all 
subjects show a consistent 35-40% reduction in LDL pools however this is 
achieved.
The heterogeneous changes in the moderately hypercholesterolaemic group of 
subjects indicate perhaps an as yet unappreciated, underlying variability in 
apoB metabolism in the population. This group of subjects will, of course, be 
the largest group to receive these drugs.
Previously, the usefulness of dual tracer (VLDLi and VLDL2) studies has been 
demonstrated in delineating the role of receptors and lipases in the regulation of 
the VLDL to LDL delipidation cascade. Investigations in receptor defective FH 
homozygotes (James et al 1989) and normolipidaemic subjects who have 
defective apoE ligands (Demant etal 1991a) have revealed multiple steps where 
apoB/E receptors are involved in this metabolic pathway. If  activation of 
receptors is the single most important action of the statins then this should be 
evident throughout the cascade; the results reported here indicate that this is the 
case. Simvastatin clearly stimulated lipoprotein catabolism at various stages in
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the VLDL to LDL conversion and a number of these kinetic changes were 
linked to perturbations in the structure and composition of apoB containing 
lipoproteins. The drug’s influence was not restricted to VLDL and LDL in our 
study. HDL2 , the minor HDL sub fraction, which is believed to have 
cardioprotective properties was increased by 62%. This change was apparently 
linked to the fall in total plasma triglyceride levels but could not be related to a 
perturbation in the kinetic behaviour of any particular VLDL subfraction.
The major finding of the present study was that simvastatin stimulated direct 
catabolism of lipoproteins throughout the VLDL delipidation cascade 
presumably as a result of its ability to increase apoB/E receptor activity. 
Certainly the pathways activated by the drug are those identified from previous 
turnover studies thought to involve receptor-mediated catabolism (James etal
1989). Lipolysis as measured by the fractional transfer rate o f VLDLi to 
VLDL2 and then on to IDL and LDL was not affected by therapy.
Since it is believed that apoB/E receptors play a major role in lipoprotein 
metabolism towards the denser end of the Sf 0-400 spectrum it is not surprising 
that IDL and LDL were the fractions most affected by therapy. There was not 
only a reduction in the plasma concentration, but a change in their composition. 
On therapy, there was a tendency for the cholesteryl ester content of all the 
apoB containing fractions to fall. This was most clearly seen in IDL where the 
absolute cholesteryl ester content of the particle decreased approximately 40%. 
These changes could have been due to either the synthesis of lipoproteins of 
altered composition, or perturbations of cholesteryl ester transfer (CETP) 
activity, or the selective removal of cholesteryl ester rich subpopulations from 
all of these lipoproteins. Bagdade etal (1990) have reported that statins do not 
appear to affect CETP and on the basis of the kinetic changes noted in the 
present study the last hypothesis, that increased receptor activity causes the 
selective removal of cholesteryl ester rich remnant lipoproteins, is favoured. 
There is in vitro evidence from cell culture studies that cholesteryl ester-rich 
remnant lipoproteins have a higher affinity for receptors than their triglyceride- 
rich counterparts (Koo etal 1988). Multicompartmental modelling showed that 
within the IDL subsystem it was the remnant pool (compartment 9, appendix 2) 
that appeared to be most influenced by simvastatin therapy. This interpretation 
is also in accord with the findings that statins uniquely among lipid lowering 
drugs decrease the VLDL remnant population in type HI hyperlipoproteinaemia 
(Vega et al 1988). They alone are able to decrease the cholesteryl ester/
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triglyceride ratio within this lipoprotein fraction towards normality. It is 
noteworthy that IDL appeared to be the most affected of all the apoB containing 
lipoproteins both in terms of its altered composition and its metabolic fate. 
This is significant in terms of the drug’s mechanism of action since IDL 
possibly has the highest affinity of all the lipoprotein fractions to bind to the 
LDL receptor because it contains both apoB and the ancillary ligand apo E. 
This statin induced effect on IDL may also be clinically important because this 
species is quoted as a particularly atherogenic lipoprotein (Krauss 1987b).
These findings are at variance with the study of Vega et al (1990) who found 
that the catabolism of VLDL, IDL and LDL were not affected by pravastatin 
therapy. Rather, VLDL apoB synthesis was diminished in their patients during 
drug treatment. The reasons for this discrepancy between the two reports are 
not clear. It is doubtful that simvastatin and pravastatin have separate actions 
and likely that the inter-individual variation in response to the drugs seen in both 
studies led us to different conclusions as to the overall effect of the drugs. The 
patients in the study of Vega etal (1990) showed, like those presented here, no 
significant reduction in plasma triglyceride levels. However, they did show a 
diminution in VLDL cholesterol levels, whereas in the patients studied here 
VLDL cholesterol levels were not significantly affected by drug therapy. In 
view of the known metabolic effects of the statins the favoured idea is that in the 
majority of subjects their main action is to promote the removal o f apoB/E 
containing lipoproteins from the delipidation cascade by direct catabolism.
As noted above increased catabolism alone did not explain the dramatic statin 
induced fall in LDL levels in moderate hypercholesterolaemic subjects. 
Decreased apoB transport down the delipidation cascade leading to diminished 
LDL production was equally important (figure 29). In this study, the 
opportunity was taken to examine the relationship between apoB kinetics and 
LDL subfraction distribution as defined by a recently developed density gradient 
technique (Griffin etal 1990). As in most subjects these patients demonstrated 
the presence of three LDL subfractions differing in size and density both before 
and during simvastatin therapy. In some subjects LDL-H was the predominant 
species while in others, small, dense LDL-III was the major form found. 
Overall the drug lowered LDL-I and LDL-II concentrations while the small, 
dense LDL-III were not significantly affected. These changes are to some 
extent pre-emptible and concordant with the idea that larger lipid-rich LDL are 
more easily removed by apoB/E receptors (Witztum eta l 1985) and hence most
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affected by increases in receptor activity. Surprisingly, however, a strong 
positive correlation was observed between the concentration of LDL-I and LDL- 
II combined and that computed as direct LDL synthesis both before and during 
simvastatin therapy. This kinetic parameter, which is calculated as the mass of 
LDL unaccounted for by VLDL to LDL catabolism, is the topic of considerable 
controversy (Shames & Havel 1991). The argument centres on whether the 
liver can elaborate LDL perse or as has been argued by Marzetta et al (1989) 
actually produces a rapidly metabolised LDL precursor. Whatever the route of 
apoB input into the LDL density range the pathway appears to be substantial in 
many patients, and accounts for the variation in LDL-I and LDL-II levels in our 
hypercholesterolaemic patients. It is not apparently affected by statin therapy as 
noted by the author (table 7) and Vega et al (1990), although this conclusion 
must be considered tentative since the kinetic parameters for LDL derived by 
direct synthesis are extrapolated from the behaviour of LDL, derived from 
VLDL.
An interpretation of the correlations between LDL kinetics and subfraction 
distribution, and the effects of statins is that in these moderately 
hypercholesterolaemic subjects LDL comes from two sources. One source is 
the classical VLDL to LDL delipidation cascade and it is this that is specifically 
affected by statin therapy. Statins indeed seem to have a very uniform effect on 
this pathway with most individuals showing approximately 50% reduction in 
the LDL that is associated with this route. The other pathway is highly variable 
in these subjects and is responsible for the variation in their levels of LDL-I and 
LDL-II. Clearly, more work needs to be done to delineate the properties of this 
pathway and to examine why it remains resistant to statin therapy. Effects of 
statins on the LDL subfraction profile must be compared with the effects of 
other lipid lowering agents such as nicotinic acid or its derivatives (Chapter 5) 
and fibrates (Chapter 6 ). Griffin etal (1992) have reported that triglyceride 
lowering drugs alter the distribution of LDL subfractions towards the less dense 
end LDL-I and LDL-II with a reduction in LDL-III. Statin therapy on the other 
hand appeared here to reduce LDL-I and LDL-II primarily as has been found 
for cholestyramine therapy (Griffin etal 1992). This differential effect of these 
drugs on LDL subfractions may have consequences for their potential anti­
atherogenic properties. Further studies will elucidate the way in which LDL 
subfraction patterns are controlled and affected by drug therapy.
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In conclusion, statin therapy in moderate hypercholesterolaemia is associated 
with changes throughout the apoB containing lipoproteins and also in HDL. 
The changes are consistent with known mechanisms of action of the drug and 
result in alterations in both the composition and structure of lipoproteins.
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Chapter 4 Colestipol
...a scientist must indeed be freely imaginative and yet sceptical, creative and 
yet a critic. There is a sense in which he must be free, but another in which his 
thought must be very precisely regimented; there is poetry in science, but also a 
lot o f bookkeeping.
Peter B. Medawar, 1965.
4.1 . Introduction
Interruption of the enterohepatic circulation and consequent hepatic depletion of 
the bile acid pool has been demonstrated by pharmacological and surgical means 
to be both effective as a lipid lowering strategy and as a preventive measure for 
CHD. The results from the LRC Coronary Primary Prevention Trial (Lipid 
Research Clinics Program 1984 a, 1984b) and more recently the St Thomas’ 
Atherosclerosis Regression Study (Watts eta l 1992) emphasise the clinical 
benefits of resin therapy in primary and secondary prevention, while Buchwald 
et al (1990) have convincingly demonstrated the benefits of surgical interruption 
of this pathway by partial ileal by-pass.
As surgical intervention is of limited clinical application drug therapy, using the 
bile acid sequestrant resins (or resins), has been widely used over a long period 
of time. These drugs have been used as lipid lowering agents for over 30 years 
(Bergen eta l 1959). Two resins are currently available and, although they 
differ in structure (figure 8 ), they are considered to be clinically equivalent. 
Early studies by Parkinson, Gundersen & Nelson (1970) showed no difference 
between cholestyramine and colestipol in groups of hyperlipidaemic prisoners. 
Similarly, Glueck et al (1972) concluded after studying 25 patients in a 
crossover study that the two resins were, ‘virtually indistinguishable’.
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The mechanism of action of the resins and their pharmacology are described 
briefly in section 1.6.1 above. Resin therapy has been reported to reduce total 
plasma cholesterol by 18-25% (Grundy 1972, Glueck 1982, Levy eta l 1984, 
Lipid Research Clinics Program 1984a) with average LDL-cholesterol 
reductions of 25-35% (Glueck 1982, Levy etal 1984, Lipid Research Clinics 
Program 1984a). Most studies also report small increases in plasma triglyceride 
(Glueck 1982, Levy etal 1984, Lipid Research Clinics Program 1984a). This 
change is usually not considered clinically relevant except in those patients with 
baseline hypertriglyceridaemia. Witztum et al( 1979) have shown in their 
patients, however, this rise to be transient, persisting for only 2 - 1 0  weeks. 
Small increments in HDL-cholesterol have been reported (Levy et al 1984, 
Lipid Research Clinics Program 1984a) as have small but favourable increases 
in the HDL2/3 ratio (Shepherd etal 1979b, Levy etal 1984).
The resins primarily exert these effects on the lipoprotein profile by preventing 
both the passive and active reabsorption of bile acids (Angelin 1992). The 
metabolic consequences of this are of considerable importance, affecting 
cholesterol and triglyceride synthesis and the activities o f three key hepatic 
enzymes, cholesterol 7 a  hydroxylase, phosphatidic acid phosphatase and HMG 
CoA reductase.
These drugs are worthy of further detailed metabolic study for two reasons. 
Firstly, the precise mode of cholesterol lowering and triglyceride raising 
remains to be fully elucidated, and secondly the important links between the 
cholesterol-lipoprotein and cholesterol-bile acid metabolic axes are not yet 
clearly defined (Einarsson & Angelin 1991).
The present study was not designed to answer all the remaining questions in 
this area but aimed to examine the effects of colestipol on the composition and 
metabolism of apoB containing lipoproteins VLDLi, VLDL2 , IDL and LDL in a 
group of patients with moderate hypercholesterolaemia but with established 
coronary heart disease. The same dual tracer VLDLi and VLDL2 turnover 
technique as used in chapter 3 was employed, as was the same ultracentrifugal 
analysis to examine the effects of colestipol therapy on LDL subfractions. 
Significant changes in lipoprotein composition were observed and are 
attributable to resin therapy. Multiple points in the delipidation cascade of apoB 
containing lipoproteins were also shown to be affected by therapy. The known
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effects of this drug on expression of apoB/E receptors is invoked to explain 
these changes observed in the apoB kinetic parameters.
4 .2 . Protocol
This study of the effects of colestipol on the metabolism of apoB containing 
particles consisted of three phases :
1. Preliminary Screening Period. During this 5 week run in period each patient 
was screened for cardiological, haematological, hepatic, endocrine, renal, 
ophthalmological and metabolic disease by routine clinical and laboratory 
testing.
2. Baseline Study. In this period a VLDL turnover study was performed on 
each patient to serve as a control. Baseline lipid, lipoprotein and lipoprotein 
subfractions were measured as described above.
3. Active Treatment Period. Immediately after the baseline assessment of 
apolipoprotein B metabolism the patients were commenced on colestipol 
therapy rising to a dose of 20g. day-1 over a period of 7-10 days. Patients 
remained on this dose for 10 weeks. During the final 2 weeks each patient 
underwent a second turnover investigation while on colestipol therapy. In 
addition lipid, lipoprotein and lipoprotein subfraction analyses were repeated.
4.3 Subjects
Eight study patients were selected from the Cardiac Surgery database at 
Glasgow Royal Infirmary. All patients were male and had an initial elevated 
total cholesterol level (^6.5 mmol. L_1) despite adherence to a standard lipid 
lowering diet (Study Group, European Atherosclerosis Society dietary 
recommendations, 1988) and a triglyceride level less than 3.0 mmol. L_1, but 
did not have clinical evidence of FH. All subjects had undergone coronary 
artery by-pass grafting between 3 and 12 months previously. Patients were 
screened for cardiological, haematological, hepatic, endocrine, renal and 
metabolic disease by routine clinical and laboratory testing to exclude secondary 
causes of hyperlipidaemia and any illness thought to influence the outcome of 
the study. The characteristics of each patient are summarised in table 8 . All 
eight subjects studied were receiving prescribed medications as part of their post
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operative management, and four were receiving drugs for other clinical 
conditions. All prescribed medications were continued unchanged throughout 
the course of the study.
4.4 Adverse Events
Colestipol was reasonably well tolerated by all subjects participating in the 
study. Two patients reported constipation and one patient dyspepsia, but in 
none of the three cases was this severe enough to necessitate intervention or 
withdrawal of drug. Biochemical and haematological monitoring revealed no 
clinically significant changes from baseline attributable to therapy.
4.5 Lipids and Lipoproteins
Plasma lipid and lipoprotein levels of those patients studied are shown in table 
9. Treatment reduced plasma cholesterol by 14% (p<0.002). This decrement 
was due, in this group, to a 23% fall in LDL-cholesterol (p<0.002), while 
VLDL and HDL cholesterol were unchanged. There was also, as expected, a 
non-significant rise in triglyceride of 21%. Centrifugal analysis of the 
subfraction distribution in the HDL and LDL density intervals was performed. 
Due to analytical difficulty three HDL subfraction samples were lost and 
analysis was performed on the remaining five pairs of data. No significant 
change in HDL2 , HDL3 or the HDL2 /3  ratio was observed, although the 
incomplete nature of this data renders the sample size too small for reasonable 
comment. Figure 32 shows the LDL subfraction profiles obtained upon density 
gradient fractionation of subjects’ plasma. There was some inter-individual 
variation in the pattern observed, but in most three distinct populations of 
particles could be distinguished both before and during therapy. Again, one 
data set for subject COL 08 on colestipol was lost during analysis and 
comparison of means is performed on the remaining 7 pairs of data. The 
decrement in the major LDL-II species was the most significant change in these 
subjects. Quantitative analysis revealed that its concentration fell by 38% 
(p<0.005). LDL-I, the least dense fraction was also reduced significantly by 
38% (p<0.01). The colestipol induced response in LDL-III was variable 
(figure 32, table 10). In 3 individuals it appeared to fall substantially, but 
another 3 subjects recorded no change with one subject (COL 06) showing a 
marked increase. Thus despite a 23% reduction in the mean value (table 10), 
the overall effect was not statistically significant. Compositional analysis of the
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HI
COL 01
COL 02
COL 04
COL 05
COL06
COL07
1.025 1.034 1.044
Density (g. m L 1)
1.060
F igu re  32. LDL subfraction profiles at baseline (-)and during colestipol 
therapy (—) in subjects COL 01-COL 07.
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T able 10. LDL Subfraction Changes with Colestipol Therapy
Subject Tot LDL LDL-I LDL-H LDL-m
■ 11 n A n f A f o in 1 f i O m T  n l o c m o  - 1 _ _ ,' • • l l l g  l l j j u p i u i c i l l *  1 U V I 1 1 J - . p i a d l l l d  •
Before Therapy
COLOIA 367 51 248 6 8
COL02A 505 55 240 2 1 0
COL03A 344 45 166 133
COL04A 584 107 261 216
COL05A 305 8 8 193 24
COL06A 401 62 285 55
COL07A 362 104 228 31
COL08A 437 79 154 205
Mean 413 74 2 2 2 118
(SEM) (32.6) (8.5) (16.4) (29.5)
Mean (n-7) 410 73 232 105
(SEM) (37.4) (9.8) (15.3) (30.9)
On Colestipol
COLO IB 2 2 0 38 136 46
COL02B 258 41 114 103
COL 03B 225 25 98 10 2
COL04B 322 41 169 1 1 2
COL05B 300 72 2 0 2 26
COL 06B 302 24 135 143
COL 07B 258 71 153 34
COL 08Bt t t t t
Mean (n=7) 269 45 144 81
(SEM) (15.0) (7.4) (13.1) (17.0)
p * <0 .0 1 <0 .0 1 <0.005 NS
t  Sample lost during analysis
* Comparison of the means was performed using paired student"s t-test.
four major apoB containing lipoprotein classes (table 11) demonstrated that 
colestipol had altered the make-up of these species. There appeared to be a 
differential effect of drug therapy on the relatively triglyceride-rich lipoproteins 
(viz. VLDLi and VLDL2) and the relatively cholesterol-rich species (viz. IDL 
and LDL). The former became larger with increased content of all components 
although only triglyceride and phospholipid enrichment achieved statistical 
significance in VLDL2 (p<0.05 in both cases). IDL and LDL on the other hand 
appeared to become overall reduced in mass particularly in terms o f free
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cholesterol (IDL by 47%, p<0.05, LDL by 42%, p<0.05) and protein (IDL by 
24%, p<0.05, LDL by 32%, NS). There was also a marked fall in mean LDL- 
cholesterokapoB ratio of 58%.
4 .6  A polipoprotein B M etabolism
The influence of colestipol therapy on apolipoprotein B metabolism was 
examined before and on drug (representative decay curves for one subject, 
COL 01 are shown in figures 33-36). ApoB disappeared rapidly from the 
VLDLi flotation interval and appeared in VLDL2 over a period of 6-18 h after 
injection (figure 33). The decay of radioactive apoB in VLDL2 was slower than 
in VLDLi, taking almost 2 days to reduce to 1% of the injected dose (figure 
34). Colestipol therapy appeared to increase the clearance rate of both VLDLi 
apoB (figures 35) and VLDL2 apoB (figures 36). The flux of apoB into IDL 
was comparable before and during therapy for both tracers. However, the 
decay rate of IDL apoB appeared faster on drug with the peak value attained in 
the LDL interval being consistently less than at baseline. Before therapy, LDL 
apoB radioactivity reached a maximum of 25% of injected dose about 24 h after 
VLDL2 injection (figure 34), whereas during therapy (figure 36) the LDL apoB 
maximum was only 15%. These findings suggest that the metabolic fate of IDL 
apoB is markedly affected by therapy with more material being lost directly 
from the circulation rather than being converted to LDL. In this subject (COL 
01) the clearance rate of LDL apoB radioactivity appeared unchanged by 
colestipol therapy.
Kinetic rate constants and apoB fluxes were derived by compartmental 
modelling as described in chapter 2. The results for all 8  subjects are 
summarised in table 12; decay curves for the other 7 subjects and individual 
kinetic constants and masses are shown in appendix 3.
VLDLi apoB synthesis, pool size, and fractional transfer rate to VLDL2 were 
unchanged by therapy but the mean direct fractional catabolic rate of VLDLi 
apoB was reduced by 49% (p<0.05) from 2.5 to 1.3 pools. <H. The VLDL2 
apoB pool size was expanded on drug therapy by 36% (p<0.05). Although no 
other change in VLDL2 kinetic parameters achieved statistical significance this 
alteration in pool size was associated with increases in VLDL2 apoB direct input 
in 6 out of 8 subjects and increased input from VLDLi in 7 out of 8 . IDL 
formation from VLDL2 was unaffected by resin therapy but there was a
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COL 01 A (Metabolism of VLDLI)100
1-131 VLDLI 
1-131 VLDL2 
1-131 IDL 
1-131 LDL
S 1 0 -■o
■o
S'
W.o
168 19212048 72 14496240
Time (Hrs)
F igure  33. Baseline. Apolipoprotein B radioactivity decay curves associated 
with VLDLi, VLDL2 , IDL, and LDL in subject COL 01 after 
injection of autologous [131I]-VLDLi.
COL 01 A (M etabolism  of VLDL2)100
125-1VLDL2 
125-1 IDL 
125-1 LDL
-a4>
c
o
*
72 120 168 19248 96 1440 24
T im e(H rs)
Figure 34. Baseline Apolipoprotein B radioactivity decay curves associated 
with VLDL2 , IDL, and LDL in subject COL 01 after injection of 
autologous [125I]-VLDL2 .
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COL 01 B (Metabolism of VLDLI)
1-131 VLDLI 
1-131 VLDL2 
1-131 IDL 
1-131 LDL
•n
u
vB*
<—o
168 19272 12048 96 144240
Time (Hrs)
F igure  35. On Colestipol. Apolipoprotein B radioactivity decay curves 
associated with VLDLi, VLDL2 , IDL, and LDL in subject COL 
01 after injection of autologous [131I]-VLDLi
COL 01 B (M etabolism of VLDL2)100
125-1VLDL2 
125-1 IDL 
125-1 LDL
ok
V 1
§ 10 -*o
■oV
V
c
19216812072 96 1440 484
T im e(H rs)
F igure  36. On Colestipol. Apolipoprotein B radioactivity decay curves 
associated with VLDL2 , IDL, and LDL in subject COL 01 after 
injection of autologous [125I]-VLDL2.
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Tabic 12a VLDLi Apolipoprotein B Metabolism before and on Colestipol
Subject
Synthesis
(mg.d-1)
Plasma
Pool
(mg)
Direct 
Catabolism 
(pools. <H)
Flux
ToVLDL2 
(pools, d-1)
Before Therapy
COLOIA 758 90 3.99 4.43
COL 02A 1863 242 3.23 4.46
COL 03A 541 42 0 .0 1 12.87
COL04A 354 41 0 .0 1 8.62
COL05A 510 71 3.38 3.79
COL 06A 1597 166 2.48 7.14
COL07A 505 63 2.99 5.01
COL 08A 1187 182 4.17 2.35
Mean 914 1 1 2 2.53 6.08
(SEM) (2 0 0 ) (26) (0.58) (1.19)
On Colestipol
COLO IB 1061 123 3.48 5.14
COL02B 1240 2 2 0 0 .1 1 5.53
COL 03B 400 89 0 .0 1 4.48
COL 04B 464 94 0.57 4.37
COL 05B 423 69 0 .0 1 6 .1 2
COL 06B 1310 240 0.37 5.09
COL 07B 253 55 1.97 2.64
COL 08B 2109 324 3.68 2.83
Mean 907 151 1.28 4.53
(SEM) (225) (34) (0.55) (0.44)
P* NS NS <0.05 NS
* Differences between the means were assessed by the paired student*s t-test.
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Table 12b. VLDL2 Apolipoprotein B Metabolism before and on Colestipol
Direct Flux from Plasma Direct Flux
Synthesis VLDLi Pool Catabolism to IDL+ LDL
(mg.d'l) (mg.d'l) (mg) (pools, d 'l) (pools.d'l)
Before Therapy
COLOIA 484 399 287 1.47 1.61
COL 02A 311 1079 259 1.64 3.75
COL 03A 517 541 234 0.48 4.01
COL04A 661 354 254 1.04 3.99
COL05A 1111 269 263 1 .6 8 3.57
COL 06A 289 1185 352 0.93 3.28
COL 07A 267 316 319 0.04 1.79
COL 08A 964 428 498 0 .2 2 2.58
Mean 576 534 308 0.94 3.07
(SEM) ( 1 1 2) (137) (30) (0.23) (0.34)
On Colestipol
COLO IB 631 632 262 1.38 3.43
COL 02B 339 1217 386 2.15 1 .8 8
COL 03B 568 399 409 0.33 2.04
COL 04B 1534 410 622 1.75 1.38
COL 05B 705 423 257 1.79 2.60
COL06B 716 1 222 532 1.26 2.39
COL07B 736 145 389 0.03 2.23
COL 08B 479 918 503 1 .0 0 1.77
Mean 714 671 420 1 .2 1 2 .2 2
(SEM) (127) (143) (45) (0.26) (0 .2 2 )
P NS NS <0.05 NS NS
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Table 12c. IDL Apolipoprotein B Metabolism before and on Colestipol.
Flux from
v l d l 2
(mg.d-1)
Plasma
Pool
(mg)
Direct 
Catabolism 
(pools, d*1)
Flux 
To LDL 
(pools, d"1)
Before Therapy
COLOIA 434 573 0 .1 2 0.64
COL 02A 958 650 0.45 1 .0 2
COL03A 881 656 0.40 0.95
COL04A 988 1058 0.34 0.59
COL 05A 929 877 0.39 0.67
COL 06A 1076 900 0 .8 8 0 .8 8
COL07A 566 700 0 .2 0 0.61
COL08A 1286 833 0.57 0.97
Mean 890 781 0.42 0.79
(SEM) (96) (58) (0.08) (0.06)
On Colestipol
COLO IB 893 546 1.13 0.51
COL 02B 703 505 0.32 1.08
COL 03B 760 526 0.71 0.73
COL 04B 849 922 0.24 0 .6 8
COL 05B 661 599 0.35 0.76
COL 06B 1270 761 0.74 0.92
COL07B 862 675 0.56 0.72
COL 08B 894 889 0 .2 2 0.78
Mean 862 678 0.53 0.77
(SEM) (6 6 ) (58) (0 . 1 1 ) (0.06)
P NS <0.03 NS NS
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Table 12d. LDL Apolipoprotein B Metabolism before and on Colestipol.
Direct Flux from VLDL-derived Fractional Total ApoB
Synthesis % IDL + VLDL2 Plasma Pool Catabolic Rate Synthesis
(mg.d'1) (mg.d'1) (mg) (pools, d-1) (mg.d-1)
Before Therapy 
COLOIA 351 488 1532 0.32 1593
COL02A 130 681 3191 0 .2 1 2304
COL03A 82 677 2331 0.29 1140
COL04A 203 652 2431 0.27 1218
COL05A 405 601 1921 0.31 2026
COL06A 493 869 3271 0.27 2379
COL07A 342 431 1305 0.33 1114
COL08A 394 810 3284 0.25 2545
Mean 300 651 2408 0.28 1790
(SEM) (51) (52) (279) (0 .0 1 ) (2 1 1 )
On Colestipol
COL01B 197 282 1003 0.28 1889
COL 02B 291 563 1950 0.29 1870
COL03B 43 460 1637 0.28 1 0 1 1
COL04B 0 636 2993 0 .2 1 1998
COL 05B 56 464 2290 0 .2 0 1184
COL 06B 103 703 3041 0.23 2129
COL 07B 0 492 2308 0 .2 1 989
COL 08B 250 696 2793 0.25 2838
Mean 118 537 2252 0.24 1739
(SEM) (40) (50) (250) (0 .0 1 ) (226)
P <0.03 <0 .0 2 NS NS NS
J Direct synthesis in LDL was calculated as the difference between the total absolute 
catabolic rate (observed mass x overall FCR) and the input from VLDL and IDL._________
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Table 12e. LDL Apolipoprotein B Metabolism before and on Colestipol.(continued)
Observed Total LDL
Plasma LDL pool Synthesis
(mg) (mg.d-1)
Before Therapy
COLOIA 2629 839
COL02A 3812 811
COL03A 2615 759
COL04A 3183 855
COL 05A 3226 1006
COL 06A 5096 1362
COL07A 2342 773
COL 08A 4860 1204
Mean 3470 951
(SEM) (367) (79)
On Colestipol
COLO IB 1705 479
COL 02B 2952 854
COL 03B 1789 503
COL 04B 2837 636
COL05B 2569 520
COL 06B 3488 806
COL07B 2125 492
COL 08B 3792 946
Mean 2657 655
(SEM) (269) (6 6 )
P p<0 .0 0 2 p<0.003
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significant fall in the IDL apoB plasma pool size from 781 to 678mg (13%, 
p<0.03). The IDL to LDL fractional transfer rate was unaffected by drug, but 
the amount of LDL apoB derived from VLDL2 and IDL combined fell 
significantly (p<0.02). There was also a fall in the direct synthesis of LDL 
apoB in every subject resulting in a mean fall of 61% (p<0.03). The calculated 
VLDL-derived LDL apoB plasma pool was unaffected by therapy but the 
observed total LDL apoB mass, which includes apoB unaccounted for by that 
labelled in the delipidation cascade, fell from 3427 to 2657 mg (p<0.002). The 
mean fractional catabolic rate of LDL apoB, which may have been expected to 
rise on therapy, was unchanged as was the mean calculated total apoB synthetic 
rate. The observed fall in LDL, in this group of 8 subjects, may be accounted 
for by the reduction in total LDL apoB synthesis (flux from VLDL2 and IDL 
plus direct synthesis) of 32% (p<0.003), rather than any change in catabolism. 
Figure 37 summarises the flux of apo B through the delipidation cascade. 
Following therapy the direct catabolism from VLDL2 and IDL density ranges 
was increased significantly (p<0.05), while there was reduced clearance of 
VLDLi apoB and direct input of LDL apoB.
From these data it is clear that colestipol affects the kinetics of all apoB 
containing lipoproteins to some extent. In an attempt to correlate the changes in 
LDL kinetics with changes in LDL substructure, the relationship between the 
LDL apoB synthetic parameters and the plasma concentrations of LDL-I, II, and 
III was examined. In contrast to the findings reported in chapter 3 with 
simvastatin, no significant correlations were found between the LDL 
subfraction concentrations and the LDL apoB kinetic parameters, although there 
was a tendency for the LDL direct input to increase in accord with the levels of 
LDL-I and II. No such relationship could be found between LDL-III and this 
kinetic parameter.
4 .7  D iscussion
The bile acid sequestrant resins are of proven efficacy in the primary and 
secondary prevention of CHD (Lipid Research Clinics Program 1984a, Watts et 
al 1992). In the present study, using a moderate dose of colestipol (20g.day_1), 
significant reductions in total cholesterol and LDL-cholesterol of 14 and 23% 
respectively were achieved. A non-significant increase in triglyceride was also 
observed consistent with other studies.
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CONTROL ON COLESTIPOL
VLDL 1 VLDL 1
VLDL 2 714 Z = S > V L D L 2
F igure 37. Summary of the effects of colestipol therapy on apoB 
metabolism. Numbers on arrows represent mass transfer of 
apoB in mg.d-1* * p<0.05, ** p<0.02 paired student’s t-test.
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In order to discuss the full implications of the findings in the present study it is 
necessary to review more fully the known mechanisms of action o f the resins. 
These drugs are not absorbed from the gut and act as relatively inert anion 
exchange resins. They exert all their effects on lipoprotein metabolism by 
preventing the reabsorption of bile acids, thus interrupting the enterohepatic 
circulation. Returning bile acids regulate the conversion of cholesterol to bile 
acids by negative feedback inhibition of the rate limiting enzyme, cholesterol 7 a  
hydroxylase (Reihner etal 1989). Interruption of the enterohepatic circulation 
of bile acids results in de-repression of this enzyme and a compensatory rise in 
both hepatic cholesterol synthesis and expression of apoB/E receptors. 
Kovanen etal{ 1981) first demonstrated this increased expression o f receptors 
on hepatocytes in response to resin therapy and Reihner etal( 1990a) confirmed 
these findings in humans demonstrating a more than doubling o f apoB/E 
receptor expression in cholestyramine treated patients. At the same time 
Reihner and her colleagues reported concomitant 6 -fold and 5-fold increases in 
cholesterol 7 a  hydroxylase and HMG Co A reductase respectively in the same 
patients. One of the bile acids, chenodeoxycholic acid, has also been shown to 
be a particularly potent inhibitor of phosphatidic acid phosphatase, the 
pacemaker enzyme of triglyceride synthesis (Angelin, Bjorkhem & Einarsson 
1986). Resin therapy, by depleting the hepatocyte of this regulatory bile acid, 
may therefore affect hepatic triglyceride production by releasing this enzyme 
from bile acid induced inhibition.
By binding irreversibly to the inert matrix of the resins, bile acids are effectively 
trapped in the intestinal lumen, and excreted in the faeces. Resin induced 
increases in faecal sterol excretion were noted by a number of early workers 
including, Hashim & Van Itallie (1965) and Nazir etal{ 1972). The latter group 
proposed as a result of their studies on plasma cholesterol kinetics that 
cholestyramine therapy induced an increase in endogenous synthesis of 
cholesterol. This was confirmed by Goodman, Noble & Dell (1973) who 
demonstrated an increased cholesterol production rate of 8 6 %, (p<0 .0 1 ) on 
colestipol in 7 hypercholesterolaemic subjects.
The effects of resin therapy on triglyceride turnover were examined by Angelin 
et al (1978) using tritiated glycerol. They demonstrated a significant increase in 
the production rate of total plasma triglyceride, but observed no change in 
plasma triglyceride level because of an associated increase in its fractional 
turnover rate. These workers concluded that those factors influencing
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cholesterol and .bile acid synthesis, in this case cholestyramine therapy, also 
affect the metabolism of triglyceride. In a refinement of this study the same 
workers 12 years later examined VLDL-triglyceride kinetics in a defined group 
of FH heterozygotes before and after cholestyramine therapy (Angelin et al
1990). Again they demonstrated a significant increase in VLDL-triglyceride 
synthesis (85%) and FCR (40%) on therapy.
The compositional changes in lipoproteins resulting from resin therapy are well 
documented and are thought to be partly consequent on this increased hepatic 
triglyceride synthesis. Witztum, Schonfeld & Weidman (1976) reported that 
colestipol resulted in relative triglyceride enrichment of VLDL, LDL and HDL 
but also noted that these changes were reversed by some compensatory 
mechanism as therapy was continued. In further studies (Witztum et al 1979) 
colestipol therapy was associated with reduced cholesterol:apoB ratios in all 
apoB containing lipoproteins. In the present study, LDL-cholesterol:apoB ratio 
fell by 58%. There was also a change in VLDLi and VLDL2 towards larger 
and EDL and LDL towards smaller species. When we consider these changes 
alongside the significant alterations seen in the LDL subfraction profiles as a 
result of colestipol therapy (figure 32, table 10) it is possible that this drug is 
exerting two distinct effects at opposite ends on the delipidation cascade. On 
the one hand it is, probably by increasing triglyceride synthesis, giving rise to 
larger VLDL particles; and on the other it is by enhancing apoB/E receptor 
activity resulting in the depletion from the circulation of IDL and larger more 
buoyant LDL, leaving behind those smaller, denser LDL particles that 
correspond to LDL-III.
Building on these important findings in cholesterol and triglyceride kinetics, 
resin induced perturbations in the turnover of apolipoproteins were next 
studied. Shepherd et al (1979b) examined the kinetics of apoAI and apoAII in 4 
hypercholesterolaemic subjects and demonstrated a significant increase in 
apoAI synthetic rate of 12% on cholestyramine therapy. These workers went 
on to examine the effects of cholestyramine on apo-LDL metabolism and 
showed enhanced receptor mediated clearance both in rabbits (Slater etal 1980) 
and in humans (Shepherd etal 1980a). The same question: what are the effects 
of resins on apo-LDL metabolism, was addressed using different methodology 
by other groups. Witztum etal (1985) compared apo-LDL turnover parameters 
in normal and cholestyramine treated guinea pigs, and reported no significant 
difference in LDL-FCR between the two groups. However, these workers did
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demonstrate a 29% fall in apo-LDL production (p<0.02) on therapy. Huff etal 
(1985) examined the kinetic parameters of apoB containing lipoproteins in a 
group of 4 miniature pigs. Again, this group found no significant change in 
LDL-FCR, but reported a marked fall in LDL direct synthesis by 51% 
(p<0.005), and no change in any VLDL kinetic parameters. These studies, 
including the present one, may seem to offer conflicting answers to the question 
of the effect of resin therapy on LDL-FCR. However, these findings may not 
necessarily be at variance when we consider the following arguments.
After studying the effect of resin therapy on LDL composition and metabolism 
in humans, Young et a/ (1989) argued that drug induced enhancement of 
apoB/E receptor activity is incompatible with a reduction or a static response in 
LDL-FCR. There are a number of possible solutions to this apparent paradox. 
Firstly, the apoB/E receptors are responsible not only for the catabolism of LDL 
particles, but potentially of all apoB containing lipoproteins. In the present 
study and that presented in chapter 3, drugs known to enhance receptor activity 
are shown to increase VLDL2 and IDL apoB clearance. Such receptor mediated 
removal of LDL precursors is certainly one possible explanation of resin 
induced reduction of plasma LDL-cholesterol levels with no apparent rise in 
LDL apoB FCR. In the patient group studied here, no overall increase in LDL- 
FCR was demonstrated. Shepherd et al (1980a) reported that the cholestyramine 
induced reduction in LDL-cholesterol was solely attributable to enhanced 
receptor mediated clearance of apo-LDL. However, other studies described 
above have failed to demonstrate an increase in LDL-FCR attributable to resin 
therapy (Witztum etal 1985, Huff eta l 1985). This variability in response to 
resin therapy may be explained when the subjects studied and the methodology 
used are considered. Shepherd et al (1980a) studied a group of 5 women 
heterozygous for FH; a group therefore, with a specific genetic defect of apoB 
catabolism. Such patients respond to resin therapy in the same way as they 
respond to statin therapy (Bilheimer etal 1983) by predominantly increasing 
their LDL clearance. A more heterogeneous group of hypercholesterolaemic 
patients such as that studied here shows a variety of kinetic responses perhaps 
determined by the nature of their underlying metabolic defect. Witztum et al 
(1985) and Huff e ta l(1985) studied normolipidaemic animals, presumably 
without any underlying catabolic defect. Witztum et al (1985) and Young et al 
(1989) have used an alternative to traditional methodology by altering their 
study protocols to take account of drug induced perturbations of the tracer. By 
isolating LDL in a control phase and in a drug treated phase and reinjecting
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these labelled autologous lipoproteins simultaneously in a second drug treated 
phase they demonstrated, both in animals and in humans, the metabolic 
importance of drug-induced changes in LDL composition. Young et al (1989) 
suggest that the lack of observed change in LDL-FCR on resin therapy is a 
function of the altered tracers used in most kinetic experimental protocols. The 
FCR of smaller, denser LDL, which is the product of resin therapy, is reduced 
if anything when compared to the FCR of larger more buoyant LDL, which 
would have been isolated and used as tracer in the control phase o f most LDL 
turnovers. The compositional changes in LDL and the associated changes in 
LDL subfraction profile observed in the present study would confirm these 
findings. However, by injecting a labelled precursor of LDL, as has been done 
in the VLDL turnover protocol described and used here, such obvious effects 
are largely, though not completely, avoided.
In the present study, in accord with many other workers the observed LDL 
apoB mass could not be accounted for by that entering the LDL density interval 
from the delipidation cascade alone. The source of this additional mass can 
only be guessed at using the present methodology and is usually ascribed to de 
novo or direct LDL synthesis. Whatever its source this LDL is unlabelled and 
therefore its FCR cannot be computed. There is a possibility that this portion of 
LDL may have a greatly enhanced FCR as a result of resin therapy or that its 
synthesis rate is reduced. Although the latter is suggested in the kinetic analysis 
above the former cannot be excluded.
One other explanation of the reduction in LDL-cholesterol with resin therapy 
also centres on its precursors. During resin therapy their is increased hepatic 
synthesis and secretion of triglyceride. The larger triglyceride-enriched VLDL 
particles that the liver secretes into the circulation have been shown by others 
(Packard etal 1984) to be removed prematurely from the circulation before 
reaching the LDL density interval. Such a shift in triglyceride metabolism may 
explain the compositional changes observed in this study and in others, and 
may be at least a contributory factor in the observed fall in plasma LDL level.
In conclusion, colestipol therapy in moderate hypercholesterolaemia is 
associated with changes throughout the apoB containing lipoproteins in terms of 
their composition and their kinetic parameters. In the latter, there is some 
degree of similarity with simvastatin (chapter 3). If  we assume that both drugs, 
albeit by fundamentally different means, enhance apoB/E receptor activity these 
kinetic similarities may be readily explained.
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I do not know what I may appear to the world, but to myself I seem to have been 
only like a boy playing on the sea-shore, and diverting myself in now and then 
finding a smoother pebble or a prettier shell than ordinary, whilst the great ocean of 
truth lay all undiscovered before me.
Isaac Newton
5.1. Introduction
Acipimox is a structural analogue of nicotinic acid (figure 9) first described in 1980 
(Ambrogi etal 1980). It was introduced into clinical practice in an attempt to 
reproduce the effective lipid lowering qualities of its parent compound but without 
the significant adverse side effect profile associated with nicotinic acid.
A comparison of the antilipolytic activity of nicotinic acid and acipimox in humans 
by Fuccella eta l(1980) has shown acipimox to be approximately 20 times as potent 
as its parent compound. This means that acipimox has been an effective lipid 
lowering agent at milligram doses, rather than the gram doses of nicotinic acid 
required for pharmacological action.
Inhibition of the hormone sensitive triglyceride lipase present in adipose tissue is 
thought to be the primary action of acipimox and this is described above in section
1.6.2. Other actions have also been proposed for acipimox and these are pertinent
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to the present study. The effects of acipimox on HDL-cholesterol levels and more 
specifically the alteration in the HDL2/3 ratio prompted a number of workers to 
suggest that this drug might affect the balance between lipoprotein lipase and 
hepatic lipase activities.
Sirtori et a/ (1981) initially suggested that acipimox may act as a promotor of 
lipoprotein lipase activity. However, two groups (Stuyt et al 1985, Taskinen & 
Nikkila 1988), studying different types of hyperlipidaemic patients, did not support 
this. Stuyt etal (1985) showed no change in lipoprotein lipase activity associated 
with acipimox therapy in type III and type IV hyperlipoproteinaemic patients, but 
did report a significant decrease in hepatic lipase activity with this drug. Similarly, 
Taskinen & Nikkila (1988) could demonstrate no significant change in post heparin 
plasma lipoprotein lipase activity on acipimox therapy in type IV and type V 
patients, but did show a reduction of 25% in hepatic lipase activity. Although no 
direct, kinetic data on the actions of acipimox was available to the latter workers 
they went on to hypothesise that a reduction in VLDL production was probably the 
main mechanism of LDL lowering in their patients treated with acipimox.
The aim of the present study was to examine in detail the mechanism o f action of 
the nicotinic acid analogue, acipimox, in patients with primary, m oderate 
hypercholesterolaemia and in particular to investigate the mechanisms behind the 
LDL-cholesterol lowering capacity of this drug. The same dual tracer VLDLi and 
VLDL2 turnover technique as used in chapters 3 and 4 was employed, as were the 
same ultracentrifugal analyses to examine the effects of acipimox therapy on the 
lipoprotein subfraction profiles. Drug induced changes in lipoprotein composition 
and in LDL subfraction distribution were noted and, again, as in chapter 4 multiple 
effects were observed on the delipidation chain from VLDLi to LDL. The known 
effects of this drug on hepatic triglyceride synthesis and its inhibition of the enzyme 
hepatic lipase are invoked to explain those changes observed in the apoB kinetic 
parameters.
5.2. Protocol
This study of the effects of acipimox on the metabolism of apoB containing 
particles consisted of three phases :
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1. Preliminary Screening Period. During this 5 week run in period each patient was 
screened for cardiological, haematological, hepatic, endocrine, renal, and 
metabolic disease by routine clinical and laboratory testing.
2. Baseline Study. In this period a VLDL turnover study was performed on each 
patient to serve as a control. Baseline lipid, lipoprotein and lipoprotein 
subfractions were measured as described above.
3. Active Treatment Period. Immediately after the baseline assessment of 
apolipoprotein B metabolism the patients were commenced on acipimox therapy 
rising to a dose of 1250mg. d_1 over a period of 7-10 days. Patients remained 
on this dose for 10 weeks. During the final 2 weeks each patient underwent a 
second turnover investigation while on acipimox therapy. In addition lipid, 
lipoprotein and lipoprotein subfraction analyses were repeated.
5.3 Subjects
Seven study patients were selected from the Risk Factor Clinic at Glasgow Royal 
Infirmary. All patients had an initial elevated total cholesterol level (^.Ommol.L’1) 
despite adherence to a standard lipid lowering diet (Study Group, European 
Atherosclerosis Society dietary recommendations, 1988) and a triglyceride level 
less than 3.0mmol. L_1, but did not have clinical evidence of FH. Patients were 
screened for cardiological, haematological, hepatic, endocrine, renal and metabolic 
disease by routine clinical and laboratory testing to exclude secondary causes of 
hyperlipidaemia and any illness thought to influence the outcome of the study. 
Pre-menopausal women were excluded from the study. The characteristics of each 
patient are summarised in table 13. Three of the subjects studied were receiving 
prescribed medications for concurrent medical problems. All prescribed 
medications were continued unchanged throughout the course of the study.
5.4 Adverse Events
Acipimox was reasonably well tolerated by all subjects participating in the study. 
All patients reported initial facial and neck flushing after the first few doses. This 
resolved after the first 3 days of therapy in all but one patient. In patient APX 01, 
this drug induced vasodilatation continued throughout the course of the study but 
did not force the patient to discontinue or interrupt his therapy. Biochemical and 
haematological monitoring revealed no clinically significant changes from baseline 
attributable to therapy.
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5.5 L ip ids and L ipoproteins
Plasma lipid and lipoprotein levels of those patients studied are shown in table 14. 
Treatment reduced plasma cholesterol by 18% (p<0.001). This decrement was 
due, in this group, to a 20% fall in LDL-cholesterol (p<0.002), while VLDL and 
HDL-cholesterol were unchanged. There was also a non-significant fall in 
triglyceride of 26%. Acipimox therapy had no significant effect on plasma Lp(a). 
Centrifugal analysis of the subfraction distribution in the HDL and LDL density 
intervals was performed. The HDL2/3 ratio increased by 35% due to a 27% rise in 
H D L 2> but the scatter of responses did not allow this to achieve statistical 
significance. Figure 38 shows the LDL subfraction profiles obtained upon density 
gradient fractionation of subjects’ plasma. As before (chapters 3 and 4), there was 
some inter-individual variation in the pattern observed, but in most three distinct 
populations of particles could be distinguished both before and during therapy. The 
increment in the least dense LDL-I species was the most significant change in these 
subjects (57%, p<0.05). LDL-II was unaffected by therapy but LDL-III fell by 
50%. These acipimox induced responses resulted in a general shift from LDL-m to 
LDL-I, i.e. from small, dense LDL to larger, more buoyant species in LDL-III 
(figure 38, table 15). Compositional analysis of the four major apoB containing 
lipoprotein classes (table 16) demonstrated that acipimox had significantly altered 
the make-up of these species. There appeared to be a general fall in the lipid 
components of all apoB containing particles with the most significant changes 
occuring in VLDL2 , where there were significant falls in the absolute content of free 
and esterified cholesterol (p<0.01, p<0.005), triglyceride (p<0.005), phospholipid 
(p<0.05) and protein (p<0.05). The core content of IDL and LDL became 
relatively cholesteryl ester enriched, with the cholesteryl estei/triglyceride ratio 
increasing from 3.4 to 3.9 in IDL and 7.2 to 8.3 in LDL.
5.6 A polipoprotein  B M etabolism
The influence of acipimox therapy on apolipoprotein B metabolism was examined 
before and on drug (representative decay curves for one subject, APX 03 are 
shown in figures 39-42). Before therapy radioactive apoB disappeared rapidly 
from the VLDLi flotation interval and appeared in VLDL2 over a period of 4-6h 
after injection (figure 39). The decay of radioactive apoB in VLDL2 was much 
slower than in VLDLi, taking approximately 60 hours to reduce to 1% of the 
injected dose (figure 40). Acipimox therapy appeared to reduce the clearance rate of 
VLDLi apoB (figures 41) but increase that of VLDL2 apoB (figures 42). The flux
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III
APX01
APX02
APX03
APX04
APX05
APX06
APX07
1 .0 2 5  1 .0 3 4  1 .0 4 4
Density (g. m L 1)
1 .0 6 0
Figure 38. LDL subfraction profiles at baseline (—) and during acipimox therapy 
(---) in subjects APX 01 -APX 07.
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Table 15. LDL Subfraction Changes with Acipimox Therapy
Subject Tot LDL LDL-I LDL-H LDL-III
, _ _ m n l i i v \ n r A t A i f i  1 n H m l  n l o e m o■“ “ I l l g  l i p u p r O l C l i l .  1U UII1.L p ia M ilc L  • •
Before Therapy
APX01A 468 14 73 381
APX02A 337 84 2 2 1 32
APX03A 597 99 385 113
APX 04 A 430 0 79 351
APX05A 280 32 216 32
APX06A 460 64 299 97
APX07A 340 63 225 52
Mean 416 51 214 151
(SEM) (40.3) (13.8) (42.2) (56.8)
On Acipimox
APX 0 IB 466 18 248 2 0 0
APX02B 360 149 171 40
APX 03B 378 154 180 44
APX 04B 474 107 311 56
APX 05B 376 54 233 89
APX 06B 327 42 194 91
APX 07B 309 133 164 12
Mean 384 94 214 76
(SEM) (24.1) (20.9) (2 0 .0 ) (23.2)
p * NS <0.05 NS NS
* Comparison of the means was performed using paired students t-test.
of radioactive apoB through the IDL density interval was very different when the 
effects o f acipimox on IDL derived from VLDLi and that derived from VLDL2 
were compared. Therapy did not significantly alter the peak height or shape of the 
IDL apoB decay curve derived from VLDL2 , but caused a drop in the maximum 
reached by VLDL 1 -derived IDL apoB from 40 to 25% of injected dose and 
markedly delayed the flux of this portion of radioactive IDL apoB into LDL. Before 
therapy, LDL apoB radioactivity reached a maximum of 40% of injected dose about 
24 h after VLDL2 injection (figure 40), whereas during therapy (figure 42)
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APX 03 A (Metabolism of VLDLI)100
□ %131 VLDLI 
A % 131 VLDL 2
o %131IDL 
■ %131 LDL
3J■rO■o
c
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0 48 7224 96 168120 192144
Time (Hrs)
F igu re  39. Baseline. Apolipoprotein B radioactivity decay curves associated 
with VLDLi, VLDL2 , IDL, and LDL in subject APX 03 after 
injection of autologous [131I]-VLDLi.
APX 03 A (Metabolism of VLDL2)100
A % 125 VLDL 2 
o %125 IDL 
■ %125 LDL
c
o
168 19272 96 120 144480 24
Time (Hrs)
Figure 40. Baseline Apolipoprotein B radioactivity decay curves associated with 
V LD L 2 , IDL, and LDL in subject APX 03 after injection of 
autologous [125I]-VLDL2-
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APX 03 B (Metabolism of VLDLI)100
□ %131 VLDLI 
A %131VLDL2 
O %131 IDL 
■ % 131 LDL
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F ig u re  41. On Acipimox. Apolipoprotein B radioactivity decay curves 
associated with VLDLi, VLDL2 , IDL, and LDL in subject APX 03 
after injection of autologous [l3 ll]-VLDLi
APX 03 B (Metabolism of VLDL2)100
A %125VLDL2 
o  % 125 IDL
■ % 125 LDL
VS,O
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F igure 42. On Acipimox. Apolipoprotein B radioactivity decay curves 
associated with VLDL2 , IDL, and LDL in subject APX 03 after 
injection of autologous [125I]-VLDL2.
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Table 17a VLDLi Apolipoprotein B Metabolism before and on Acipimox
Subject Plasma Direct Flux
Synthesis Pool Catabolism ToVLDL2
(mg.d-1) (mg) (pools. d~l) (pools, d-1)
Before Therapy
APX01A 857 239 0.62 2.97
APX02A 1504 1 2 2 7.83 4.49
APX03A 870 49 9.29 8.46
APX04A 452 126 1.76 1.82
APX05A 905 264 1.59 1.84
APX06A 392 93 1.33 2.89
APX07A 352 77 1.47 3.11
Mean 762 139 3.41 3.65
(SEM) (154) (31) (1.35) (0.87)
On Acipimox
APX 0 IB 860 148 1 .8 6 3.95
APX 02B 2 2 0 62 1.42 2.13
APX03B 136 2 0 2.23 4.59
APX 04B 951 122 4.00 3.80
APX05B 263 58 0 .0 1 4.53
APX06B 364 87 2 .1 0 2.08
APX07B 1 1 0 0 58 13.59 5.38
Mean 556 79 3.60 3.78
(SEM) (151) (16) (1.72) (0.47)
p  * NS NS NS NS
Differences between the time points were assessed by the paired t-test.
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Table 17b. VLDL2 Apolipoprotein B Metabolism before and on Acipimox
Direct Flux from Plasma Direct Flux
Synthesis VLDLi Pool Catabolism to IDL+ LDL
(mg.d'l) (mg.d"1) (mg) (pools. d-l) (pools, d '1)
Before Therapy
APX01A 626 710 684 0.56 1.30
APX02A 928 548 486 1.51 1.52
APX03A 492 415 244 0.44 3.24
APX04A 640 230 322 0.13 2.57
APX05A 1178 484 559 0.59 2.39
APX06A 279 269 251 0.32 1 .8 6
APX07A 728 239 355 0.81 1.93
Mean 696 414 414 0.62 2 .1 2
(SEM) ( 1 1 0 ) (6 8 ) (63) (0.17) (0.25)
On Acipimox
APX 0 IB 784 585 369 0.76 2.95
APX 02B 1231 132 257 1.94 3.37
APX 03B 756 92 112 0.51 7.13
APX04B 830 463 296 0 .0 2 4.35
APX05B 932 263 340 0.08 3.45
APX06B 481 181 257 0.58 2 .0 0
APX 07B 901 312 184 2.93 3.65
Mean 845 290 259 0.97 3.84
(SEM) (85) 68 (34) (0.41) (0.61)
P NS NS <0 .0 2 NS <0 .0 1
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Table 17c. IDL Apolipoprotein B Metabolism before and on Acipimox.
Flux from
v l d l 2
(mg.d-1)
Plasma
Pool
(mg)
Direct 
Catabolism 
(pools. d_1)
Flux 
To LDL 
(pools, d-1)
Before Therapy
APX01A 887 978 0.32 0.59
APX02A 734 1023 0 .2 2 0.50
APX03A 769 679 0.29 0.84
APX 04 A 825 716 0.40 0.76
APX05A 1332 970 0.25 1 .1 2
APX06A 462 519 0.30 0.59
APX07A 682 677 0.18 0.83
Mean 813 795 0.28 0.75
(SEM) ( 10 0) (73) (0.03) (0.08)
On Acipimox
APX 0 IB 1084 861 0.39 0.87
APX 02B 856 1053 0.30 0.51
APX 03B 795 454 0.74 1 .0 2
APX04B 1288 1273 0.67 0.34
APX 05B 1171 711 0.73 0.91
APX 06B 513 526 0 .1 1 0 .8 6
APX 07B 648 898 0.30 0.42
Mean 908 825 0.46 0.70
(SEM) (107) (109) (0.09) (0 .1 0 )
P NS NS NS NS
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Table 17d. LDL Apolipoprotein B Metabolism before and on Acipimox.
Direct Flux from VLDL derived Fractional Total ApoB
Synthesis $ IDL + VLDL2 Plasma Pool Catabolic Rate Synthesis
(mg.d-1) (mg.d-1) (mg) (pools, d"1) (mg.d-1)
Before Therapy
APX01A 297 577 2469 0.23 1780
APX02A 794 514 1378 0.37 3226
APX03A 326 592 2921 0 .2 0 1688
APX04A 53 542 2062 0.26 1145
APX05A 476 1090 2935 0.37 2559
APX06A 145 311 1422 0 .2 2 816
APX07A 153 563 3139 0.18 1233
Mean 321 598 2332 0.26 1778
(SEM) (95) (89) (276) (0.03) (321)
On Acipimox
APX 0 IB 9 752 2892 0.26 1653
APX 02B 162 548 1703 0.32 1613
APX 03B 132 464 1362 0.34 1024
APX04B 92 437 2064 0 .2 1 1873
APX 05B 327 651 2138 0.30 1522
APX 06B 251 456 1327 0.34 1096
APX 07B 93 402 2616 0.15 2094
Mean 152 530 2015 0.27 1554
(SEM) (40) (49) (226) (0.03) (146)
P NS NS NS NS NS
J Direct synthesis in LDL was calculated as the difference between the total absolute
catabolic rate (observed mass x overall FCR) and the input from VLDL and IDL.
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Table 17e. LDL Apolipoprotein B Metabolism before and on Acipimox (continued)
Total Total LDL
Plasma LDL pool Synthesis
(mg) (mg.d-1)
Before Therapy
APX01A 3759 874
APX02A 3524 1308
APX03A 4527 918
APX04A 2263 595
APX05A 4216 1566
APX06A 2082 456
APX07A 3991 716
Mean 3480 919
(SEM) (359) 049)
On Acipimox
APX 0 IB 2926 761
APX 02B 2207 710
APX 03B 1750 596
APX 04B 2500 529
APX05B 3227 978
APX06B 2065 707
APX 07B 3238 495
Mean 2559 682
(SEM) (2 2 2 ) (62)
P <0.05 NS
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the LDL apoB maximum was only 25%. In this subject (APX 03) the decay rates 
of LDL apoB before and during therapy were virtually super-imposible suggesting 
that the clearance rate of LDL apoB was unchanged by acipimox therapy.
Kinetic rate constants and apoB fluxes were derived by compartmental modelling as 
described in chapter 2. The results for all 7 subjects are summarised in table 17; 
decay curves for the other 6 subjects and individual kinetic constants and masses 
for all patients are shown in appendix 4.
VLDLi apoB pool size fell by 43%, from 762 to 556mg, and this was associated 
with a 27% fall in apoB synthesis, while the mean direct fractional catabolic rate of 
VLDLi apoB and fractional transfer rate to VLDL2 were unchanged by therapy. 
The VLDL2 apoB pool size was diminished on drug therapy by 37% (p<0 .0 2 ). 
Increases in VLDL2 apoB direct input in 6  out of 7 subjects led to a mean increment 
in this parameter by 21%. VLDL2 apoB fractional transfer to IDL and LDL was 
significantly increased (81%, p<0 .0 1 ) by acipimox therapy but there was no 
significant increase in IDL apoB pool size due to an associated increase in the direct 
catabolic rate of this species (65%) The IDL to LDL fractional transfer rate was 
unaffected by drug, as was the amount of LDL apoB derived from VLDL2 and IDL 
combined. There was also a non-significant fall in the direct synthesis of LDL 
apoB (52%). The calculated VLDL-derived LDL apoB plasma pool was unaffected 
by therapy but the total LDL apoB mass, which includes apoB unaccounted for by 
that labelled in the delipidation cascade, fell from 3480 to 2559mg (p<0.05). The 
mean fractional catabolic rate of LDL apoB was unchanged as was the mean 
calculated total apoB synthetic rate. The observed fall in LDL, in this group of 7 
subjects, may be accounted for by the reduction in total LDL apoB synthesis (flux 
from VLDL2 and IDL plus direct synthesis) of 26% (p=0.08), rather than any 
change in catabolism. Figures 43 and 44 summarise the flux of apo B through the 
delipidation cascade. In contrast to the findings with simvastatin and colestipol 
reported in chapters 3 and 4 respectively, there was no significant increase in the 
combined, direct catabolism from VLDL2 and IDL density ranges following 
acipimox therapy.
From these data it is clear that acipimox significantly affects the kinetics of both 
VLDL apoB fractions studied and, in turn, the synthesis of LDL apoB. In an 
attempt to correlate the changes in LDL kinetics with changes in LDL substructure, 
the relationship between the LDL apoB synthetic parameters and the plasma 
concentrations of LDL-I, II, and III was examined. Again, in contrast to the
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findings reported in chapter 3 with simvastatin, no significant correlations were 
found between the LDL subfraction concentrations and the LDL apoB kinetic 
parameters in these patients.
5 .7  D iscussion
Acipimox, at a dose of 1250mg. d_1 in this group of moderately hyper- 
cholesterolaemic subjects, produced significant reductions of total cholesterol and 
LDL-cholesterol of 18 and 20%, respectively. These lipid and lipoprotein changes 
are consistent with the findings of Crepaldi et al (1988) who noted falls of 16 and 
18% in the same lipid parameters using the slightly reduced dose of 1 2 0 0 mg. d_1 in 
type II hyperlipoproteinaemic patients. These workers also demonstrated 
significant falls in plasma triglyceride level with acipimox in type IV, but not type II 
patients. Similarly, HDL-cholesterol was only noted to rise as a result of therapy in 
hypertriglyceridaemic subjects, but, interestingly, Taskinen & Nikkila (1988) failed 
to demonstrate any significant short-term effect on HDL-cholesterol or the 
subfractions HDL2 and HDL3, even in severely hypertriglyceridaemic patients. 
Ball et al (1986) reported similar findings with a dose of 750mg. d' 1 and concluded 
that the fall in plasma triglyceride was most marked in those patients with an initial 
triglyceride level in excess of 3mmol. L_1. All patients in the present study fell 
below this cut-off and although a fall in triglyceride was observed in the group as a 
whole this was not statistically significant.
Acipimox has been shown to be a potent inhibitor of the hormone-sensitive lipase in 
adipose tissue (Stirling etal 1985). Because the breakdown of stored triglyceride 
is reduced there is also a reduction in the release of non-esterified fatty acids into the 
circulation (Fuccella e ta l 1980, Vaag et al 1991) and consequently reduced 
availability of substrates for hepatic triglyceride synthesis (Carlson & Oro 1962; 
Stirling etal 1985).
Because of this reduction in triglyceride synthesis there appears, as observed here, 
to be a shift in the pattern of hepatic VLDL production from large, triglyceride-rich 
particles (VLDLi) to smaller, relatively triglyceride-poor species (VLDL2). This 
results in a reduction in the contribution that VLDLi apoB makes to VLDL2 apoB 
with acipimox therapy. From the present study, VLDL2 apoB is transferred at an 
increased rate into the IDL density interval. This may be explained by either, or 
both, of the following reasons. Firstly, VLDLi being relatively triglyceride poor 
will be more efficiently delipidated to form IDL, even in the face of unaltered
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lipoprotein lipase activity (Taskinen & Nikkila 1988, Stuyt et al 1985). 
Alternatively, if the VLDL2 fractional transfer rate to IDL is regarded as a composite 
of a slow component (VLDLi-derived VLDL2 going to IDL) and a fast component 
(directly synthesised VLDL2 going to IDL), any alteration in VLDLi apoB 
synthesis will shift the composite FTR towards the faster pathway by reducing 
VLDLi to VLDL2 transfer (figures 43 and 44).
When the VLDL2 to IDL to LDL pathway (i.e. the delipidation chain derived from 
directly synthesised VLDL2) is examined (figure 43 and 44) it is clear that this is 
relatively unaffected by acipimox therapy while those masses of VLDL2 , derived 
from VLDLi, and their products in the IDL and LDL density intervals, are 
markedly diminished.
Such a drug-induced shift in VLDL synthesis, resulting in a larger proportion of 
circulating VLDL2 would perhaps be expected to result in an expanded LDL apoB 
pool, for Packard et al (1984) have demonstrated that small VLDL2 rather than 
VLDLi is the main precursor of plasma LDL derived from delipidation. This 
indeed would probably be the case with acipimox therapy if it were not for this 
drug’s other effects. Acipimox has been shown to inhibit hepatic triglyceride lipase 
(Taskinen & Nikkila 1988, Stuyt et al 1985). Studies of apoB metabolism in 
subjects with hepatic lipase deficiency (Demant etal 1988) have demonstrated that 
this enzyme is responsible for the delipidation of IDL, and therefore the conversion 
of IDL to LDL. The action of acipimox, in inhibiting hepatic lipase, is to cause a 
hold-up in the transfer of apoB down the delipidation cascade from IDL to LDL. 
This results in reduced synthesis of LDL and is one of the identified causes for 
reduced LDL levels in the subjects studied here. In addition, the reduced VLDLi 
apoB synthesis, described above results in decreased input of material into the chain 
reducing the masses of all compartments derived from VLDLi (figure 44). Finally, 
there appears to be a reduction in the circulating LDL mass because of drug-induced 
suppression of direct LDL synthesis.
To explain the mechanism by which acipimox lowers the plasma LDL-cholesterol 
level in hypercholesterolaemic subjects was one of the main objectives of the 
present study. There is a very limited literature in this area and many of the 
suggested mechanisms of action proposed for acipimox are based on indirect 
evidence or extension of work done in the past on nicotinic acid.
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Arguing from the analysis of lipoprotein compositional data Capurso et a/(1987) 
concluded that acipimox did not increase VLDL catabolism but that the reduced 
LDL mass observed with therapy could be explained by either an increase in 
catabolism or a reduction in synthesis. Such inconclusive findings on the nature of 
acipimox’s effect on LDL metabolism perhaps prompted the only report of the 
direct kinetic consequences of acipimox therapy on lipoprotein metabolism, other 
than that presented here. This was an abstract presenting the results of a series of 
ten LDL turnovers in patients with familial combined hyperlipidaemia (Angelin, 
Ericsson, Eriksson, Berglund 1988). This reports the lack of any effect of 
acipimox on apo-LDL-FCR and is consistent with the findings of the present study 
and with those of Levy & Langer (1972) who studied the effects of nicotinic acid 
on apo-LDL metabolism. The latter workers attributed the LDL lowering of 
nicotinic acid to a marked decrease in the synthetic rate of apo-LDL rather than any 
increase in catabolism, and went on to suggest that this may be due to a reduction in 
VLDL synthesis. Although published twenty years ago it appears, by extension of 
the present study with acipimox back to that of nicotinic acid, that Levy & Langer 
were indeed correct.
Another way to explain a reduced circulating LDL-cholesterol level would be to 
propose an inhibitory effect on cholesterol synthesis such as is seen with the 
statins. However, for acipimox, this does not appear to be the case. Stirling et al 
(1985) studied the effects of acipimox on cholesterol synthesis in human jejunal 
mucosa. They concluded that this drug had no consistent effect on cholesterol 
synthesis, which is in accord with findings of Grundy, Mok, Zech & Berman 
(1981) who studied the metabolism of cholesterol in humans receiving nicotinic 
acid therapy. They concluded that the drug produced no detectable changes in 
faecal excretion of cholesterol. More recently, Illingworth et a/ (1991) reported 
some preliminary findings on urinary mevalonate measurements in niacin treated 
patients. Using doses of niacin of 1.5-4.5g. d' 1 in patients heterozygous for FH 
these workers were unable to demonstrate any drug induced effect on urinary 
mevalonate levels and concluded that niacin had no effect on cholesterol synthesis.
In addition to reducing the total LDL-cholesterol level in the plasma, acipimox 
therapy also appeared to redistribute the subfractions of LDL, increasing LDL-I and 
reducing LDL-III. These structural changes have also been observed with acipimox 
in hypertriglyceridaemia (Franceschini eta l 1990), where it was shown that on 
therapy LDL became larger and more buoyant. These workers also were able to 
demonstrate that LDL isolated from acipimox treated patients had a higher affinity
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for the apoB/E receptor in vitro than its pre-therapy counterpart. The mechanism 
for this LDL redistribution is unknown but three mechanisms may be proposed.
Firstly, the inhibitory effect of acipimox on hepatic triglyceride lipase is thought to 
be important. In hepatic lipase deficiency, IDL and large, buoyant LDL have been 
shown to predominate in plasma (Demant eta l 1988, Auwerx eta l 1989). This 
suggests that hepatic lipase has an important role in the conversion of IDL to LDL 
and possibly, by extension, even between LDL subspecies.
Secondly, the redistribution of LDL subfractions may be the result of reduced inter- 
particle exchange of core lipid. A decrease in the level o f triglyceride rich 
lipoproteins in the circulation would limit the opportunity for the transfer of 
triglyceride into LDL. The latter would remain relatively cholesteryl ester enriched, 
as seen here (table 16), and would therefore be less susceptible to lipolysis by 
hepatic lipase with a consequent increase in particle size and buoyancy.
Thirdly, there is kinetic evidence that various LDL subfractions arise from different 
ends of the VLDL spectrum. Large VLDLi are thought to give rise to small, dense 
LDL while smaller VLDL2 are thought to be the potential precursors of larger LDL 
species (Packard etal 1984, Shepherd &Packard 1987). Thus, by causing a shift 
from VLDLi to VLDL2 synthesis, acipimox may alter the pattern of LDL 
subfractions. These three mechanisms are, of course, not mutually exclusive but 
the weight that is given to each will only be resolved by further, specific studies of 
LDL subfraction kinetics.
In conclusion, the present study provides data in support of the proposed 
mechanism of acipimox action. There is reduced synthesis o f triglyceride rich 
particles consistent with a reduction in hepatic triglyceride production. There is a 
marked fall in LDL-cholesterol associated, not with any increase in LDL apoB 
clearance but with a reduction in synthesis. This reduction in LDL apoB synthesis 
is shown to be a result of reduced direct synthesis, reduced IDL to LDL transfer 
consistent with inhibition of hepatic triglyceride lipase, and with a reduction in the 
overall throughput of VLDLi apoB.
161
Chapter 6 Ciprofibrate
The science of life is a superb and dazzlingly lighted hall which may only be 
reached by passing through a long and ghastly kitchen
Claude Bernard 1865
6.1. Introduction
The fibrates are a powerful group of drugs that have found an important place in the 
lipid regulating formulary. While their clinical efficacy is generally accepted their 
mechanism of action has yet to be fully defined In particular, their ability to lower 
plasma LDL-cholesterol levels significantly in patients with hypercholesterolaemia 
has been a point of great interest and controversy (Gaw & Shepherd 1991)
Studies of the mechanism of action of fibrate therapy, have in the past assumed 
LDL to be a homogeneous entity (Langer, Strober & Levy 1972, Stewart et al 
1982). However, more recently it has been demonstrated that LDL exists in the 
plasma of normal and hyperlipidaemic subjects as an heterogeneous population of 
particles that may be divided into three subfractions on the basis of size and density 
(Krauss & Burke 1982, Fisher 1983, Griffin eta l 1990). In addition to these 
studies on LDL structure there has been a re-evaluation of the in vivo kinetic 
behaviour of apo-LDL. Classically, analysis of LDL turnover is performed using 
the model of Matthews (1957), which is based on the assumption that trace-labelled 
apo-LDL is homogeneous and is cleared from the circulation by a single catabolic 
mechanism. More recent detailed investigations (Boston eta l 1982, Foster etal 
1986) have tested the validity of this assumption and found it to be unwarranted in 
most subjects. Radioactive products released from the breakdown of trace-labelled
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apo-LDL appears quantitatively in the urine. Examination of the daily rate of 
urinary radioactivity excretion relative to plasma radioactivity levels (U/P ratio) has 
shown that instead of being constant as predicted by Matthews (1957) this 
parameter decreases over the period of the turnover study. Therefore, a new model 
has been postulated to describe apo-LDL metabolism (Boston eta l 1982, Foster et 
al 1986) in which there are two plasma compartments: Pool A, with a rapid 
clearance rate and proposed high affinity for apoB/E receptors, and Pool B, with a 
slower catabolic rate and a proposed reduced level of receptor-mediated catabolism.
In a previous investigation of the mechanism of action of the fibrate, bezafibrate, in 
type II hyperlipoproteinaemia, Stewart et al (1982) ascribed the LDL lowering 
effect solely to increased clearance of LDL via the apoB/E receptor pathway, as a 
result o f increased receptor expression. In the light of present knowledge of the 
heterogeneity of LDL it would be pertinent to ask whether this enhanced receptor 
UiVUlUiW U V/UlULfUiiJlil cf LDL was due to changes in the receptor or the ligand. It is 
arguable that fibrate therapy may change the LDL subfraction distribution in a way 
that increases the affinity of LDL particles for the apoB/E receptor. In the present 
study, this possibility was examined together with detailed studies of the kinetics of 
apo-LDL using the recently introduced flbric acid derivative, ciprofibrate. This 
lipid-lowering drug (figure 11) has the longest half-life (Davison et al 1975) of the 
fibrates (approximately 42 h), and its efficacy has been demonstrated in type Ha, 
Hb, HI, and IV hyperiipoproteinaemias (Olsson & Oro 1982, Davignon etal 1982). 
In these studies laboratory safety monitoring has in general not revealed any 
clinically significant changes, and the drug has been well-tolerated both during 
short term (Illingworth etal 1982) and long term usage (Schifferdecker etal 1984).
In the present study, ciprofibrate was used to treat a group of subjects with primary 
moderate hypercholesterolaemia and normotriglyceridaemia. The results are 
consistent with the view that the fibrates lower LDL-cholesterol by enhancing 
receptor mediated clearance of LDL, and that changes in the ligand do indeed 
contribute to this process.
6 .2 . P ro toco l
This study of the effects of ciprofibrate on the metabolism of apo-LDL consisted of 
three phases:
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1. Preliminary Screening Period. During this 5 week run in period each patient was 
screened for cardiological, haematological, hepatic, endocrine, renal, and 
metabolic disease by routine clinical and laboratory testing.
2. Baseline Study. In this period an LDL turnover study was performed on each 
patient to serve as a control. Baseline lipid, lipoprotein and lipoprotein 
subfractions were measured as described above.
3. Active Treatment Period. Immediately after the baseline assessment o f apo-LDL 
metabolism the patients were commenced on ciprofibrate therapy at a dose of 
lOOmg. d_1. Patients remained on this dose for 8 weeks. During the final 2 
weeks each patient underwent a second turnover investigation while on 
ciprofibrate therapy. In addition lipid, lipoprotein and lipoprotein subfraction 
analyses were repeated.
6.3 S ub jects
Eleven study patients were selected from the Lipid Clinics at Hairmyres Hospital, 
East Kilbride and the Victoria Infirmary, Glasgow. All patients had an initial 
elevated total cholesterol level (^7.0mmol. L*1) despite adherence to a standard lipid 
lowering diet (Study Group, European Atherosclerosis Society dietary 
recommendations, 1988) and a triglyceride level less than 2.3mmol. L"l, but did 
not have clinical evidence of FH. Patients were screened for cardiological, 
haematological, hepatic, endocrine, renal and metabolic disease by routine clinical 
and laboratory testing to exclude secondary causes of hyperlipidaemia and any 
illness thought to influence the outcome of the study. Pre-menopausal women were 
excluded from the study. One patient completed the baseline turnover study and 
only one week of therapy before asking to be withdrawn from the study. The 
characteristics of the remaining ten patients are summarised in table 18. Six of the 
10  subjects studied were receiving prescribed medications for other clinical 
conditions. All prescribed medications were continued unchanged throughout the 
course of the study.
6 .4 . A dverse Events
One patient, described above, asked to discontinue ciprofibrate treatment after 7 
days because she reported an exacerbation of her long-standing dyspepsia. Drug 
was withdrawn and the dyspepsia resolved. The patient did not allow the 
investigator to rechallenge with ciprofibrate and this event must be recorded as a 
possible drug-related adverse event. The patient recovered completely and was
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discontinued from the study. In the remaining ten patients ciprofibrate was well 
tolerated. Biochemical and haematological monitoring revealed no clinically 
significant changes from baseline attributable to therapy.
6.5. Lipids and Lipoproteins
Plasma lipid and lipoprotein levels of those patients studied are shown in table 19. 
Treatment with ciprofibrate significantly affected all the parameters of the lipid 
profile. Plasma cholesterol was reduced by 17% (p<0.001). This decrement was 
due, in this group, to a 38% fall in VLDL-cholesterol (p<0.001) and a 22% fall in 
LDL- cholesterol (p<0.001). There was also a marked fall in plasma triglyceride of 
41% (p<0.001) and a rise in HDL-cholesterol of 1 1% (p<0.02). No significant 
change in plasma Lp(a) was noted with ciprofibrate therapy. Centrifugal analysis 
of the subfraction distribution in the HDL and LDL density intervals was 
performed. No significant change in HDL2 , HDL3 or the HDLy3 ratio was 
observed. Figure 45 shows the LDL subfraction profiles obtained upon density 
gradient fractionation of subjects’ plasma. There was some inter-individuai 
variation in the pattern observed, but in most three distinct populations of particles 
could be distinguished both before and during therapy. The decrement in the 
major LDL-II species was the most significant change in these subjects. 
Quantitative analysis revealed that its concentration fell by 28% (p<0.01). LDL-I, 
the least dense fraction was unaffected by therapy, while the mean level of small, 
dense LDL-IU fell by 31% (table 20). Analysis of the overall composition of LDL 
(table 21) showed no effect of ciprofibrate therapy, suggesting that the fall in LDL- 
cholesterol observed was due to a reduction in the number of circulating LDL 
particles.
6 .6 . Receptor Mediated and Receptor Independent A po-LD L  
Metabolism
The influence of ciprofibrate therapy on apo-LDL metabolism was examined before 
and on drug using dual-tracer, native and cyclohexanedione-modified apo-LDL 
turnover studies as described above (section 2.4). In two turnovers, CIP 04B and 
CIP 07A the decay curves for native and cyclohexanedione-modified LDL could be 
superimposed suggesting that there may have been some degree of native tracer 
damage before re-injection into the subject. This may be seen in the plasma, urine 
and U/P ratio graphs shown in appendix 5. Because of the unsatisfactory technical 
nature of these turnovers they have been excluded from the analysis of paired data.
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III
CIP01
CIP0 2
CIP03
CIP04
CIP05
CIP06
CIP07
C1P08
C1P09
CI.P10
1.025 1.034 1.044
Density (g. m L 1)
1.060
F igure  45. LDL subfraction profiles at baseline (—) and during ciprofibrate 
therapy (—) in each of the 10 subjects.
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Table 20. LDL Subfraction Changes with Ciprofibrate Therapy
Subject Tot LDL LDL-I LDL-H LDL-HI
........................ mg lipoprotein. lOOmL plasma ........... ........
Before Therapy
CIP01A 410 147 227 36
CIP02A 429 141 2 0 2 8 6
CIP 03A 434 230 181 2 2
CIP04A 536 241 269 27
CIP 05A 471 252 195 24
CIP 06A 484 107 328 49
CIP07A 598 116 341 141
CEP08A 442 97 253 92
CIP 09A 447 181 223 43
CIP 10A 618 139 451 28
Mean 487 165 267 55
(SEM) (23) (18) (27) ( 12)
On CiproGbmte
CIP 0 IB 448 161 224 63
CIP02B 253 114 1 0 2 38
CEP 03B 302 143 130 29
CIP 04B 428 192 214 2 2
CIP 05B 351 224 11 2 15
CIP 06B 367 176 164 27
CIP07B 493 116 298 79
CIP 08B 318 108 163 47
CIP09B 552 129 257 28
CIP 10B 473 180 263 29
Mean 399 154 193 38
(SEM) (30) ( 12) (2 2 ) (6 )
p * <0 .0 2 NSf <0 .0 1 NS
* Comparison of the means was performed using paired students t-test.
The kinetic parameters of apo-LDL metabolism are presented in table 22. 
Ciprofibrate was associated with a 17% increase in the overall FCR of apo-LDL 
(p<0.002). This change was apparently responsible for a 17% fall in the plasma 
concentration of apo-LDL (p<0.05) as there was no significant effect of drug 
therapy on total apo-LDL synthetic rate. When LDL catabolism was divided into 
receptor-mediated versus receptor independent pathways, it was observed that the 
FCR of the former was increased by 34% (p<0.03) while the latter was unchanged. 
Although the rate at which LDL was cleared by the high affinity receptor pathway
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Table 21. Effects of Ciprofibrate on LDL Compostion.
Subject Free Cholesteryl Triglyceride Phospholipid Protein
Cholesterol Ester
............................................g/100g-
Before Therapy
CIP01A 13.1 34.1 5.2 21.9 25.6
CIP 02A 14.5 36.9 3.5 2 0 .0 25.2
CIP 03A 1 2 .6 32.1 6.3 19.8 29.3
CIP04A 1 2 .8 34.1 7.5 2 0 .8 24.8
CIP 05A 1 2 .2 33.9 5.5 2 0 .2 28.2
CIP 06A 1 1 .8 35.1 5.1 19.0 29.0
CIP07A 10.3 40.0 4.6 16.7 28.6
CIP08A 1 0 .6 36.1 8.4 17.8 27.3
CIP09A 12.9 36.7 4.8 2 1 .1 24.6
CIP 10A 13.4 13.4 6 .1 2 0 .2 25.9
Mean 12.4 33.2 5.7 19.8 26.9
(SEM) (0.4) (2.3) (0.5) (0.5) (0 .6 )
On Ciprofibrate
CEP 0 IB 9.9 33.7 4.6 18.4 28.6
CIP02B 1 1 .0 39.2 6 .1 21.9 21.9
CIP03B 10.5 37.0 6 .0 19.8 26.7
CDP04B 14.6 31.4 6 .8 21.3 25.9
CIP05B 1 1 .2 37.0 5.6 2 0 .6 25.6
CIP 06B 13.1 38.4 5.8 16.6 26.0
CIP07B 10.7 39.4 5.0 19.9 25.1
CIP08B 15.0 33.5 5.5 18.4 27.7
CIP09B 6.7 40.6 8.4 18.0 26.0
CIP 10B 12.9 32.3 9.3 23.0 24.5
Mean 1 1 .6 36.3 6.3 19.8 25.8
(SEM) (0 .8 ) ( 1 .0 ) (0.5) (0 .6 ) (0 .6 )
increased with ciprofibrate therapy, there were no significant change in the absolute 
amount of apo-LDL cleared by either pathway.
Examination of the plasma decay curves in conjunction with the daily urinary 
radioactivity excretion rates (shown for subject CIP 08 in figures 46-51) revealed 
that the drug was perturbing LDL metabolism in a complex fashion. During the 
control turnover, the amount of radioactivity excreted into the urine was virtually a 
fixed proportion of the radioactivity present in the plasma. The calculated U/P ratio 
(figure 48), a daily index of catabolic potential, fell only slightly from a peak value 
of 0.37 at 2-3 days post-injection to 0.30, by days 10-12. On ciprofibrate, 
however, the relationship between the urine and plasma decay curves was
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substantially altered (figure 51). In the first 5-6 days of the turnover, the plasma 
curve showed a more rapid decay than in the control phase. This change was due 
to enhanced catabolism rather than increased extravascular exchange, because there 
was a concomitant rise in urinary radioactivity excretion. The U/P ratio in this 
subject (figure 51) was initially high (0.60) and showed a substantial fall over the 
first 5-6 days to the same final value as in the control phase (0.30).
6.7. Mathematical Modelling of Apo-LDL Metabolism
The effects of ciprofibrate on apo-LDL metabolism were further studied by 
subjecting the plasma and urine radioactivity obtained from each patient to more 
detailed analysis using multicompartmental modelling techniques described above. 
Analysis of this data using the two plasma pool model depicted in figure 15 
generated the results shown in table 23 and summarised in figures 52 &53. Again, 
those turnovers that were technically unsatisfactory viz CIP 04B and CIP 07A have 
been excluded from the analysis. In the control phase, pool A (the more rapid 
cleared species) accounted for approximately one third of the total circulating mass 
o f apo-LDL. Its mean synthetic rate was 749 mg. d” 1 and it had a fractional 
catabolic rate of 0.69 pools. d_1. The mean mass of apo-LDL in pool B was 
approximately 2000mg and in most subjects this was the major apo-LDL 
component. Its FCR was a third and its synthetic rate a half of that in pool A. 
There was a trend for ciprofibrate therapy, to increase the synthesis of pool A and at 
the same time decrease that of pool B. The overall result of these balanced changes 
was no difference in the the synthesis of total apo-LDL as shown in table 22. The 
fractional clearance rate of pool B was unaltered by therapy, but that of pool A rose 
in 7 of the 8 subjects studied. The net effect of these changes was that while the 
computed mass of apo-LDL in pool A remained constant that in pool B was reduced 
by 25%.
6.8. Discussion
The results of this study give valuable information not only on the effects o f the 
lipid lowering drug, ciprofibrate, but also on the underlying metabolic heterogeneity 
evident in LDL. As such the following discussion has been divided in two parts to 
allow both facets to be fully explored.
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F i g u r e  4 6 .  Nat ive LDL
1 0 °
P l a s m a  ♦
U r in e  ■
1 o-1
0.0 2.5 5 .0 7.5 15.010.0 12.5
T i m e  ( d a y s )
F igure 47. Cyclohexanedione Modified LDL
U r in e  B
V*>
1o’
'o*
0.0 2.5 5.0 12.5 15.01 0 .07.5
T i m e  ( d a y s )
F ig u re  48. U/P Ratios
N a t iv e
C H D
0 . 0  5
0 . 0 0
10 .0 12.57.55.02.50.0
T i m e  ( d a y s )
F ig u re  46-48. Baseline. Plasma and urine radioactivity decay curves following 
injection of [125I]-native apo-LDL and [131I]-cyclohexanedione-modified apo-LDL. 
Subjects received a bolus dose of apo-LDL tracers and daily plasma samples were 
taken over 14 days. Urine was collected in each 24 h period and the urinary 
radioactivity excretion examined. The urine/plasma ratio was calculated as the 
urinary loss divided by the plasma radioactivity at the beginning of the 24 h 
collection period. Results are shown for subject CIP 08 in the control phase.
F i g u r e  4 9 .  Native  LDL
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F ig u re  50. Cyclohexanedione Modified LDL
1 0 °
P l a s m a  ^
U r i n e  ■
I O’1
15.012.50.0 2.5 5.0 1 0 .07.5
T i m e  ( d a y s )
F ig u re  51. U/P Ratios
0 . 6 0
N a t i v e
C H D
0 . 5 0
0 . 4 0
0 . 3 0
0 . 2 0
0 . 1 0
0 . 00
12.510.07.55.02.50.0
T i m e  ( d a y s )
F ig u re  49-51 . On ciprofibrate. Plasma and urine radioactivity decay curves 
following injection of [125I]-native apo-LDL and [131I]-cyclohexanedione-modified 
apo-LDL. Subjects received a bolus dose of apo-LDL tracers and daily plasma 
samples were taken over 14 days. Urine was collected in each 24 h period and the 
urinary radioactivity excretion examined. The urine/plasma ratio was calculated as 
the urinary loss divided by the plasma radioactivity at the beginning of the 24 h 
collection period. Results are shown for subject CIP 08 on ciprofibrate.
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749 394
0.20
0.40
0.180.69
470
1198 2093
2.50
Urine
F ig u re  52. Summary of apo-LDL metabolism at baseline in eight subjects. 
Numbers in italics on arrows represent fractional transfer rates in pools.d'1. 
Numbers in circles represent mean apo-LDL mass in mg.
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931 306
0.07
0.81
2.50
Urine
F ig u re  53. Summary of the effects of ciprofibrate therapy on apo-LDL 
metabolism in eight subjects. Numbers in italics on arrows represent fractional 
transfer rates in pools. d_1. Numbers in circles represent mean apo-LDL mass in 
mg.
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6.8 .1 . Effects o f Ciprofibrate.
In the present study, using ciprofibrate (lOOmg. d_1), highly significant changes in 
all the parameters of the B-quantification were achieved. The comparative efficacies 
of the fibrates in type Ha hyperlipoproteinaemia are summarized in table 24, where 
it can seen that the percentage changes obtained with ciprofibrate in this study are 
consistent, and in many instances better than, the changes obtained with similar 
drugs in similar patients.
In order to discuss the full implications of the findings in the present study it is 
necessary to review more fully the known mechanisms of action of the fibrates.
The primary action of the fibrates is to reduce plasma levels of triglyceride rich 
lipoproteins. This action is thought to have two main m echan ism s:
1) decreased hepatic triglyceride synthesis, which is secondary to reduced 
peripheral lipolysis and diminished free fatty acid flux back to the liver.
2) enhanced very low density lipoprotein (VLDL) catabolism, due to stimulated 
lipoprotein lipase activity and consequently increased intravascular VLDL 
triglyceride lipolysis.
This latter mechanism is most recently documented by Chan (1989) and Vessby & 
Lithell (1990), who reported increased post heparin lipoprotein lipase activity with 
gemfibrozil and bezafibiate treatment respectively.
The fibrate induced increase in lipoprotein lipase activity noted above offers an 
explanation for the fall in post prandial lipaemia seen in both normo- and 
hypercholesterolaemic patients treated with fenofibrate (Simpson et al 1990) This 
improvement in chylomicron metabolism was associated with a highly significant 
increase in post heparin lipoprotein lipase activity (37%, p<0.001), and only a 
marginal rise in that of hepatic lipase. Such an effect of the fibrates may be very 
important contribution to their anti-atherogenic potential, as post-prandial lipaemia 
is considered by many to be an additional coronary heart disease risk factor 
(Zilversmit 1979). The presence of CHD has also been associated with prolonged 
and exaggerated hypertriglyceridaemia following a fat load. Such abnormal 
clearance of chylomicrons and their remnants seen in patients with CHD is 
corrected by fibrate therapy (Simpson et al 1990). The fibrates, therefore, reduce 
levels of triglyceride-rich lipoproteins in a consistent and readily explicable fashion.
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The action of the fibrates on LDL levels are variable depending on the initial LDL- 
cholesterol value. In hypercholesterolaemia where LDL levels are high, the fibrates 
cause a decrease in LDL apoB, while in hypertriglyceridaemia, which is commonly 
associated with low plasma LDL concentrations, fibrate treatment will raise the 
latter (Shepherd etal 1984b, 1985). This differential in LDL response dependent on 
initial LDL and triglyceride levels has most recently been reported by Manttari etal 
(1990). The FCR of LDL apoB, in response to fibrate therapy, has previously 
been shown to increase in hypercholesterolaemia (Stewart etal 1982) and decrease 
in hypertriglyceridaemia (Shepherd et al 1984b) while apo-LDL synthetic rates in 
both groups remain unchanged. This apparent paradox is resolved when these 
changes are regarded as normalization phenomena: in hypercholesterolaemia an 
initially low FCR is increased to normal and in hypertriglyceridaemia an initially 
high FCR is reduced to normal.
The kinetic results of the present study are very similar both to those reported for 
bezafibrate (Stewart etal 1982) and unpublished findings for fenofibrate (Caslake, 
Packard, Gaw e ta l, submitted manuscript 1992). In both these studies the FCR of 
apo-LDL increased during fibrate therapy to account for the reduction seen in 
plasma LDL-cholesterol.In this study, a more detailed kinetic analysis of plasma 
and urine data was employed, and it may be concluded that the changes in LDL 
metabolism were due to a combination of two main effects: a shift in synthesis, 
favouring the formation of the rapidly metabolised species (pool A) and an increase 
in its rate of elimination. In a previous study of normal individuals, Caslake et al 
(1992) observed that L(3,5) (the elimination rate constant of pool A) was much 
more variable than L(3,l) (the elimination rate constant of pool B) and that when 
the turnover of native and cyclohexanedione-modified apo-LDL were modelled 
together, the former pathway was more closely associated with receptor activity 
than the latter. In light of these findings, the present increase in L(3,5) associated 
with ciprofibrate therapy, may be interpreted as an indication that apoB/E receptor 
activity has been stimulated, perhaps secondary to a fibrate induced suppression of 
hepatic cholesterol synthesis (Bemdt, Gaumert & Still 1978, Stewart eta l 1982). 
However, the principal mechanism for the 22% fall in plasma LDL-cholesterol seen 
in table II was that on therapy the LDL particles formed were better ligands for the 
apoB/E receptor, as reflected in the relative increase in pool A material. This may 
have arisen because ciprofibrate caused a reduction in triglyceride relative to apoB 
synthesis in the liver and therefore promoted the secretion of smaller VLDL 
precursor particles. These, on the basis of previous studies (Demant et al 199 la, 
Griffin etal 1990) are thought to generate receptor-active LDL as the end-product of
Chapter 6 Ciprofibrate 180
intravascular lipolysis. Further evidence to support this hypothesis, comes from 
studies o f type III (Packard eta l 1986) and type IV (Shepherd et al 1984b) 
hyperlipoproteinaemic subjects, which show that fibrate therapy causes a reduction 
in the synthesis of large triglyceride-rich VLDL (VLDLi Sf 60-400).
6.8.2. Use o f a Two Compartment Model for LDL Metabolism
Despite the fact that LDL structure, function and metabolism have been studied 
extensively for twenty years there is still much to be learned about the 
pathophysiology of this lipoprotein and its role in atherogenesis. Recognition that 
LDL is structurally and metabolically heterogeneous has been a significant step 
forward. Foster et al (1986) described a number of two-compartment models of 
apo-LDL metabolism that were all capable of accommodating urine and plasma 
radioactivity data. One of these, shown in figure 15, was adopted for the present as 
well as previous studies (Caslake eta l 1992, Caslake e ta l submitted manuscript 
1992) because it was compatible with the LDL sub-system in the much larger model 
describing the VLDL-EDL-LDL delipidation cascade shown in figure 14 and used in 
the studies reported in chapters 3,4,5,7 & 8 ). In these studies, as well as in other 
published work (Packard etal 1984, Demant etal 1991a) the presence of parallel 
pathways of LDL synthesis and catabolism have been demonstrated. Small VLDL 
(VLDL2 Sf 20-60) gave rise to a species of LDL that was cleared rapidly from the 
circulation with an FCR of 0.3-0.5 pools, d-1 similar to that seen in ‘pool A \ 
Large VLDL (VLDLi Sf 60-400), on the other hand, when lipolysed produced 
LDL that was removed more slowly with an FCR of approximately 0.2 pools. d"l, 
equivalent to that seen for ‘pool B’ material.
The model shown in figure 15 has been used to provide an explanation for the 
relationship between plasma triglyceride and LDL metabolism in normolipaemic 
subjects (Caslake et al 1992). In this work it was observed that as plasma 
triglyceride rose, an increasing proportion of apo-LDL was located in the slowly 
metabolised pool B. This component was present at about 400mg of circulating 
mass in those with low plasma triglyceride levels (<1.0 mmol.L'1), but became 
predominant (1500mg circulating mass) at high-normal plasma triglyceride values 
(1.5-2.0mmol.L_1). Apo-LDL in pool A was relatively invariant accounting for 
approximately lOOOmg in most subjects. Application of the model to the present 
study provided an intuitively acceptable mechanism for the action of ciprofibrate.
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The model has certain features that appear to have physiological significance. First, 
L(3,5) in figure 15 is a key variable in controlling the rate of LDL catabolism. 
Removal by this route is linked to the activity of the high affinity apoB/E receptor 
pathway (Caslake etal 1992). Second, overall LDL clearance is also influenced by 
the distribution of mass between pools A and B. This in turn is dependent on their 
relative synthetic rates and possibly as described above on the nature of the VLDL 
precursors made by the liver. Third, the FCR of pool B is relatively constant in 
most subjects. This is a reflection of the observation that in normals (Caslake etal 
1992) and in the hypercholesterolaemic subjects studied here (figures 46 & 49) 
parallel terminal exponentials appear after 8 - 1 0  days in both plasma and urine 
radioactivity curves. These give a U/P ratio of 0.2-0.3. The mass of pool B 
appears to regulate the overall plasma LDL level and hence its atherogenic potential 
(table 23). Clearly, it is of interest to determine the nature of the LDL that contains 
this slowly catabolised apo-LDL. Since its concentration is directly related to the 
plasma triglyceride level in the same way as small,dense LDL in studies from 
Austin etal( 1988) and Griffin eta l(1990) it was initially speculated that the apo- 
LDL in pool B resided in the LDL-III species. However, on quantitation of the 
latter (table 20) it is clear that the pool B mass exceeds that of the apolipoprotein in 
LDL-III alone. It may by proposed that pool B consists of the apoB in LDL-III and 
a portion of that in LDL-II. This hypothesis is supported by two sets o f  
observations. Firstly, in the present study, the 25% fall in pool B associated with 
ciprofibrate therapy was accompanied by a significant redistribution of LDL 
subfractions with the greatest falls in LDL-II (28%, p<0.01) and LDL-III (31%). 
Secondly, Shepherd et al (1991) reported that in patients who are 
normotriglyceridaemic, yet hypercholesterolaemic, fibrate therapy lowers the total 
LDL mass and that this is predominantly due to a significant decrease in the LDL 
subfraction of mid-density (LDL-II). These workers went on to report that the 
changes in the LDL subfractions of lower density (LDL-I) and higher density 
(LDL-IH) are inversely related, the most consistent finding, during fibrate therapy, 
being an increase in LDL-I and a decrease in LDL-HI.
6 .9 . C onclusion
In conclusion, ciprofibrate therapy in primary, moderate hypercholesterolaemia is 
associated with highly significant and clinically relevant changes in the lipoprotein 
profile, associated with changes in the kinetic parameters describing the metabolism 
of apo-LDL. In the latter, there are changes predominantly in the high-affinity 
receptor mediated clearance of LDL, which may be explained by a drug induced
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shift in the synthesis of LDL towards a species more readily removed by the 
apoB/E receptor. These data do not exclude the possibility of a fibrate induced 
increase in expression of the apoB/E receptor in addition to these observed 
alterations in the ligand.
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Colestipol & Simvastatin
The whole of science is nothing more than a refinement of everyday thinking.
Albert Einstein
7.1 Introduction
Combined drug therapy for hyperlipidaemia is being used increasingly. There are a 
number o f reasons for using combined therapy and these are described in section
1.6.7. Two groups of patients may particularly benefit from this strategy viz. those 
heterozygous FH patients, who do not respond adequately to monotherapy 
(Miettinen 1990), and patients with established CHD, where inhibition of the 
progression of atherosclerosis, and perhaps the induction of its regression are 
possible with profound lipid lowering (Blankenhom etal 1987, Brown etal 1990).
Therapy with a bile acid sequestrant resin plus an HMG CoA-reductase inhibitor 
has been shown to render between 60-70% o f FH heterozygotes 
normocholesterolaemic (Weisweiler 1988, Leren etal 1988, Illingworth & Bacon 
1989), and to influence beneficially both progression and regression of 
atherosclerotic lesions (Brown etal 1990).
The first investigation into the effects of such a combination of drugs on lipoprotein 
metabolism was reported by Bilheimer ef a/(1983). These workers studied the 
apo-LDL kinetics in a male FH heterozygote, before and during lovastatin and
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colestipol therapy. The marked fall in LDL-cholesterol that they observed was 
solely attributed to an increase in apo-LDL clearance. Grundy, Vega & Bilheimer 
(1985) went on to investigate the same combination of drugs in a larger group of 
FH heterozygotes. They again showed the regimen to be highly effective in 
reducing LDL-cholesterol (52%) but on this occasion they attributed the fall to a 
combination of increased clearance and reduced production of apo-LDL. A more 
recent study (Vega, East & Grundy 1989) of FH heterozygotes, and the same 
combination drug therapy of lovastatin and colestipol, reported that the fall in LDL- 
cholesterol could be attributed only to enhanced LDL apoB clearance.
These equivocal results are further confounded when another series of experiments 
is considered. Studies in miniature pigs (Huff etal 1985, Huff & Telford 1989) 
using lovastatin and cholestyramine have shown that the combined drug regimen, in 
this species, causes a marked reduction in LDL direct synthesis and that VLDL- 
derived LDL synthesis is unaffected. Furthermore, Huff & Telford (1989) reported 
an increase in VLDL clearance, suggesting that although no obvious increase in 
LDL apoB FCR was observed these drugs may still enhance apoB/E receptor 
activity resulting in the removal of LDL precursor lipoproteins from the circulation. 
The only published study designed to examine the effects of this drug combination 
in the same type o f patients studied here (i.e. prim ary moderate 
hypercholesterolaemia) was that reported by Vega & Grundy (1987). These 
workers studied a group of 10 subjects with an initial plasma total cholesterol 
>6.5mmol. L_1 and normal triglyceride levels. While there was some heterogeneity 
of response they concluded that the significant reduction observed in LDL- 
cholesterol (48%) was due to combination of three factors: i) a 27% fall in the 
production rate of apo-LDL; ii) a 20% rise in apo-LDL FCR; and iii) a 15% 
depletion in the cholesterol content of LDL particles.
The aim of the present study was to examine in detail the mechanism of action of 
combined bile acid sequestrant resin and HMG CoA reductase inhibitor therapy in 
patients with primary moderate hypercholesterolaemia. The patients studied all had 
established coronary heart disease and were chosen as such to ensure that the 
potentially large alterations expected in their lipid and lipoprotein profiles would be 
ethically acceptable. The results confirmed the marked reduction in LDL-cholesterol 
with combined therapy seen in other studies and studies of the metabolism of the 
apoB containing lipoproteins also revealed marked changes in IDL and LDL apoB 
kinetics, which may be explained by enhanced apoB/E receptor function.
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7.2.  Protocol
This extension of the study described in chapter 4 was designed to examine the 
influence of colestipol and simvastatin on the metabolism of apoB containing 
particles. The preliminary screening period and baseline study period were as 
described in chapter 4. On completion of the second VLDL turnover study, the 
patients were commenced on simvastatin 2 0 mg nocte in addition to their resin 
therapy, colestipol 20g. d*L Patients remained on these doses for 10 weeks. 
During the final 2 weeks each patient underwent a third and final VLDL turnover 
investigation while on combined colestipol and simvastatin therapy. In addition 
lipid, lipoprotein and lipoprotein subfraction analyses were repeated.
7.3 Subjects
The eight study patients were those described in chapter 4 and their characteristics 
are summarised in table 8 . As before all concomitant medications were continued 
unchanged throughout this second study phase.
7.4 Adverse Events
Combination therapy with colestipol and simvastatin was reasonably well tolerated 
by all subjects participating in the study. Only one subject, COL 08 complained of 
any adverse side effects. This patient experienced severe constipation after the 
addition of simvastatin to his regimen, but this resolved with increased fluid intake 
and did not necessitate any further intervention or interruption of therapy. 
Biochemical and haematological monitoring revealed no clinically significant 
changes from baseline attributable to therapy. Similarly, ophthalmological 
examination with a slit lamp failed to detect any alteration from baseline in the lens 
of each subject.
7.5 Lipids and Lipoproteins
Baseline plasma lipid and lipoprotein levels of those patients studied are shown in 
chapter 4, and their levels after combination therapy are displayed in table 25. 
Combined treatment reduced plasma cholesterol by 38% (p<0.001). This 
decrement was due in this group to a 52% fall in LDL-cholesterol (p<0.001), while 
VLDL-cholesterol remained unchanged. Triglyceride was not significantly affected
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T able 26. LDL Subfraction Changes with Colestipol and Simvastatin Therapy
Subject Tot LDL LDL-I LDL-H LDL-m
_nin linAnmfAin 1 OOttiT nldcnKi ~ 1 __■mg u p u p r u i e m .  i u u i u l  p i d d i u a  • •
Before Therapy
Mean 413 74 2 2 2 118
(SEM) (32.6) (8.5) (16.4) (29.5)
On Colestipol and Simvastatin
COLOIC 156 14 75 67
COL 02C 154 26 77 51
COL03C 168 12 69 8 8
COL04C 232 24 80 128
COL05C 195 44 121 30
COL06C 195 17 93 85
COL 07C 190 27 111 52
COL08C 227 0 73 154
Mean 190 21 87 82
(SEM) (10.5) (4.6) (6 .8 ) (14.7)
p* <0 .0 0 1 <0 .0 0 1 <0 .0 0 1 NS
* Comparison of the means was performed using paired students t-test.
by combined therapy, but HDL-cholesterol showed a significant increase (10%, 
p<0.02). Lp(a) levels were unchanged from baseline by combination therapy. 
Centrifugal analysis of the subfraction distribution in the LDL and HDL density 
intervals was also performed before and during therapy. HDL2 and HDL3 masses 
were unaffected by therapy as was the HDL2/3 ratio. Figure 54 shows the LDL 
subfraction profile obtained upon density gradient fractionation of subjects’ plasma. 
The pattern exhibited considerable variation from subject to subject but in most 
three distinct populations of particles could be distinguished both before and during 
therapy. There was a marked fall in total LDL mass (54%, p<0.001), which could 
be explained by profound decreases in both of the larger, more buoyant species 
LDL-I and LDL-II (72%, p<0.001 and 61%, p<0.001 respectively). Despite a 
31% reduction in the mean value of the smaller, denser LDL-III (table 26), the 
overall effect was not statistically significant. Compositional analysis of the four 
major apoB containing lipoprotein classes are summarised in table 27.
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F igure 54.
Ill
COL 01
COL 02
COL03
COL 04
COL 05
COL06
COL07
COLO 8
1 .0 2 5  1 .0 3 4  1 .0 4 4
D en sity  (g. m L 1)
1 .0 6 0
LDL subfraction profiles at baseline (—), during colestipol therapy 
(—) and on combined colestipol and simvastatin therapy (-•-) in 
subjects COL 01-COL 08.
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Combination therapy did not affect the absolute composition of either VLDLi or 
VLDL2 . However, there were marked changes in the composition of IDL and LDL 
with significant falls in all measured parameters. The cholesterol content of LDL 
fell by 51% but the apoB component fell only 44%. This resulted in a fall in the 
LDL cholesterol/apoB ratio and indicates the relative cholesterol depletion of these 
particles in response to combined drug therapy.
7.6 A polipopro tein  B M etabolism
The influence of colestipol and simvastatin therapy on apolipoprotein B metabolism 
was examined before and on the combined drug regimen (representative decay 
curves for one subject, COL 01 are shown in figures 33,34,55&56). Before 
therapy, apoB disappeared rapidly from the VLDLi flotation interval and appeared 
in VLDL2 over a period of 6-18 h after injection (figure 33). The decay of 
radioactive apoB in VLDL2 was slower than in VLDLi, taking almost 2 days to 
to 1% of the injected dose (figure 34). Combination therapy with colestipol 
and simvastatin did not appear to increase the clearance rate of VLDLi apoB (figure 
55) but in this individual the slope of the VLDL2 apoB curve and therefore its 
clearance rate was increased (figure 56). The flux of apoB into IDL was 
comparable before and during therapy for both tracers. However, the decay rate of 
IDL apoB was much faster on combined drug therapy with the peak value attained 
in the LDL interval being consistently less than at baseline. Before therapy, LDL 
apoB radioactivity reached a maximum of 15% of injected dose about 48 h after 
VLDLi injection (figure 33), whereas during therapy (figure 55) the LDL apoB 
maximum was only 5%. These findings suggest that the metabolic fate of IDL 
apoB is markedly affected by therapy with more material being lost directly from 
the circulation rather than being converted to LDL. In this subject (COL 01) the 
clearance rate of LDL apoB radioactivity was also increased by combination 
therapy. Kinetic rate constants and apoB fluxes were derived by compartmental 
modelling. The results for all 8 subjects are summarised in table 28; decay curves 
for the other seven subjects and individual kinetic constants and masses are given 
are shown in appendix 3.
VLDLi apoB synthesis, pool size, and fractional transfer rate to VLDL2 were 
unchanged from baseline by combination therapy. The VLDL2 apoB pool size 
returned to pre-treatment levels with the addition of simvastatin to the regimen while 
the amount of material derived from VLDL2 or by direct input was unaltered. IDL 
formation from VLDL2 , presumably by delipidation was the same before and
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COL 01 C (metabolism of VLDLI)100
1-131 VLDLI 
1-131 VLDL2 
1-131 IDL 
1-131 LDL
s 10-■3
■3
i t
a
o
48 720 24 96 120 168 192144
Time (Hrs)
F ig u re  55. On Colestipol and Simvastatin. Apolipoprotein B radioactivity decay 
curves associated with VLDLi, VLDL2 , IDL, and LDL in subject 
COL 01 after injection of autologous [131I]-VLDLi
COL 01 C (M etabolism of V LD L2)100
% 125-1VLDL2 
% 125-1 IDL 
% 125-1 LDL
s  1 0 :
■3
•3
a
a
a
9
0 24 48 7 2 96 120 144 168 192
Time(Hrs)
F igure  56. On Colestipol and Simvastatin. Apolipoprotein B radioactivity 
decay curves associated with VLDL2 , IDL, and LDL in subject COL 
01 after injection of autologous [125I]-VLDL2.
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Table 28a VLDLi ApoB Metabolism before and on Colestipol & Simvastatin
Plasma Direct Flux
Synthesis Pool Catabolism T0 VLDL2
(mg.d-1) (mg) (pools, d-1) (pools. d_1)
Before Therapy
Mean 914 1 1 2 2.53 6.08
(SEM) (2 0 0 ) (26) (0.58) (1.19)
On Colestipol and Simvastatin
COLO 1C 1150 131 7.64 1.14
COL 02C 543 6 6 1.54 6.69
COL03C 697 89 1.34 6.50
COL 04C 598 74 1.95 6 .0 1
COL 05C 506 47 2.38 8.40
COL 06C 720 108 1.03 5.64
COL 07C 419 34 1 .1 0 1 1 .2 2
COL 08C 1132 219 0 .0 0 5.17
Mean 720 96 2 .1 2 6.35
(SEM) (98) (2 1 ) (0.83) ( 1 .0 1 )
P* NS NS NS NS
* Differences between the time points were assessed by the paired t-test.
Table 28b. VLDL2 ApoB Metabolism before and on Colestipol & Simvastatin
Direct Flux from Plasma Direct Flux
Synthesis VLDLi Pool Catabolism to IDL+ LDL
(mg.d-1) (mg.d-1) (mg) (pools, d-1) (pools, d-1)
Before Therapy
Mean 576 534 308 0.94 3.07
(SEM) ( 1 1 2 ) (137) (30) (0.23) (0.34)
On Colestipol and Simvastatin
COLO 1C 477 150 8 1 ' 0.05 7.77
COL 02C 442 441 107 2.57 5.48
COL03C 731 579 392 0.08 3.26
COL 04C 565 445 342 0.53 2.43
COL 05C 499 395 169 0.39 4.90
COL 06C 1207 609 326 0.26 5.34
COL07C 1128 381 319 1 .0 1 3.68
COL08C 1309 1131 626 1 .2 0 2.70
Mean 795 516 295 0.76 4.45
(SEM) (128) (1 0 1) (63) (0.30) (0.63)
P NS NS NS NS NS
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Table 28c. IDL ApoB Metabolism before and on Colestipol & Simvastatin.
Flux from Plasma Direct Flux
v l d l 2 Pool Catabolism To LDL
(mg.d-1) (mg) (pools, d '1) (pools. d_1)
Before Therapy
Mean 890 781 0.42 0.79
(SEM) (96) (58) (0.08) (0.06)
On Colestipol and Simvastatin
COLO 1C 624 349 0.98 0.81
COL 02C 596 281 0.51 1.61
COL 03C 1275 617 1.13 0.94
COL 04C 832 717 0.54 0.62
COL 05C 831 485 0.82 0.89
COL 06C 1733 541 1 .8 8 1.32
COL07C 1083 704 0.92 0.62
COL 08C 1691 342 3.80 1.15
Mean 1083 505 1.32 1 .0 0
(SEM) (158) (60) (0.39) (0 . 1 2 )
P NS <0.005 <0.05 <0.05
T able 28d. LDL ApoB Metabolism before and on Colestipol & Simvastatin.
Direct Flux from VLDL-derived Fractional Total ApoB
Synthesis $ IDL + VLDL2 Plasma Pool Catabolic Rate Synthesis
(mg.d-1) (mg.d"1) (mg) (pools.d"1) (mg.d-1)
Before Therapy
Mean 300 651 2408 0.28 1790
(SEM) (51) (52) (279) (0 .0 1 ) (2 1 1 )
On Colestipol and Simvastatin
COLOIC 134 282 854 0.33 1761
COL 02C 70 461 1547 0.30 1055
COL 03C 62 565 1348 0.42 1490
COL04C 182 442 1657 0.27 1336
COL 05C 218 432 1216 0.35 1223
COL 06C 112 717 1958 0.37 2039
COL 07C 75 525 1193 0.44 1622
COL 08C 8 391 2450 0.16 2449
Mean 108 477 1528 0.33 1622
(SEM) (24) (46) (177) (0.03) (161)
P <0 .0 1  <0 .0 2 <0 .0 0 2 NS NS
X Direct synthesis in LDL was calculated as the difference between the total absolute
catabolic rate (observed mass x overall FCR) and the input from VLDL and IDL.
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T able 28e. LDL ApoB Metabolism before and on Colestipol & Simvastatin.(continued)
Total Total LDL
Plasma LDL pool Synthesis
(mg) (mg.d’1)
Before Therapy
Mean 3470 951
(SEM) (367) (79)
On Colestipol and Simvastatin
COLOIC 1260 416
COL 02C 1779 531
COL 03C 1496 627
COL 04C 2330 624
COL 05C 1838 650
COL06C 2260 829
COL07C 1363 600
COL 08C 2498 399
Mean 1853 585
(SEM) (166) (49)
P <0.001 <0.003
during combination therapy. The IDL apoB plasma pool size fell significantly 
from 781 to 505mg (35%, p<0.005) due to an increase in direct catabolism (214%, 
p<0.05) and fractional transfer rate into LDL (27%, p<0.05) of IDL apoB. The 
total LDL apoB plasma pool showed a highly significant fall, in response to 
colestipol and simvastatin therapy, from 3427 to 1853mg (p<0.001). The 
calculated LDL apoB pool, i.e. that derived from VLDL was also reduced by 
therapy from 2408 to 1528mg (p<0.002) due to a combination of reduced synthetic 
and increased catabolic rates. The fractional catabolic rate of LDL apoB, rose in 6 
of the 8 patients but because of the scatter of responses this did not achieve overall 
significance. In this relatively small group of subjects it was the reduction in LDL 
apoB synthesis rather than the change in catabolism that appeared to be the 
predominant factor in reducing the plasma LDL-cholesterol level. Total LDL apoB 
synthesis fell by 39% (p<0.005) and direct synthesis of LDL apoB fell by 64% 
(p<0.01). It is also of note that the mean calculated total apoB synthetic rate was 
unchanged with combination therapy (table 28d). Figures 57 and 58 summarise the
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flux o f apoB through the delipidation cascade at baseline and on combination 
therapy.
7.7 Discussion
The lipid lowering efficacy of the combination of a bile acid sequestrant resin and 
an HMG CoA-reductase inhibitor has been clearly demonstrated here with results 
that are in line with previous studies. This combination has been examined with 
favourable results in a number of clinical studies in the US and Japan (Mabuchi etal 
1983, Illingworth 1984, Leren et al 1988). The improvement in the lipid and 
lipoprotein profile reported here is consistent with the results of these and other 
studies, where LDL-cholesterol levels have fallen in the order of 50%. Similarly, 
significant increases in HDL-cholesterol, as shown here, have also been reported 
by Vega & Grundy (1987) and Leren etal {1988). It is interesting to note that the 
latter group also observed no change in Lp(a) level in response to combined 
lovastatin and cholestyramine therapy. Consistent Lp(a) findings are reported in the 
present study with the closely related combination of simvastatin and colestipol.
This combination is attractive to the clinician in that there is a good theoretical basis 
for its improved efficacy over monotherapy with either drug. When bile acid 
sequestrant resins are administered, the hepatic bile acid pool is depleted and the 
hepatocytes are thought to respond by up-regulating their cell surface apoB/E 
receptors. This promotion of receptor-mediated LDL clearance is somewhat off-set 
by a concomitant increase in endogenous cholesterol biosynthesis. By co­
administration of an HMG CoA-reductase inhibitor this effect is minimised and a 
greater level of apoB/E receptor activity achieved. The clinical result is a profound 
lowering of LDL-cholesterol by as much as 50-70%.
If this combination does cause a increase in apoB/E receptor expression it would be 
expected to result in an increase in LDL apoB clearance. This was clearly observed 
in FH heterozygotes (Bilheimer etal 1983, Grundy eta l 1985, Vega eta l 1989), 
but even in this class of subject a reduction in apo-LDL synthesis has been required 
to explain the kinetic findings (Grundy et al 1985). When patients without the 
specific defect of lipoprotein catabolism seen in FH are examined, the principal 
effect of this combined regimen is a fall in apo-LDL production (Vega & Grundy 
1987) although an increase in apo-LDL FCR, and compositional changes in the 
LDL particle are also instrumental in causing an overall reduction in the plasma 
LDL-cholesterol level. The marked increase in IDL apoB catabolism observed in
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F igure 57. Summary of apoB metabolism at baseline. Numbers in circles 
represent apoB pool size [mean (SEM)] in mg. Numbers on arrows 
represent mean transfer of apoB in mg.d'1.
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Figure 58. Summary of the effects of colestipol and simvastatin therapy on 
apoB metabolism. Numbers in circles represent apoB pool size 
[mean (SEM)j in mg. Numbers on arrows represent mean transfer 
of apoB in mg.d-1. * significantly different from control p<0.05.
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the present study in entirely consistent with enhanced apoB/E receptor activity, for 
the IDL particle, with its greater apoE content, is considered to be a m ore 
appropriate ligand for this receptor than LDL itself. As a result of this increased 
removal of IDL apoB there was a fall in the throughput of material into the LDL 
density interval. This fall in VLDL-derived LDL synthesis was complemented by a 
drug induced fall in LDL direct synthesis. These two changes, together resulted in 
a highly significant fall in total LDL apoB synthesis (p<0.003). In 6  o f the 8 
subjects studied there was also a increase in LDL apoB FCR. This is entirely 
consistent with the findings of Vega & Grundy (1987) who observed an increase in 
the apo-LDL FCR in 8 of the 10 subjects with p rim ary , m oderate 
hypercholesterolaemia they studied. These workers also reported compositional 
changes in LDL, which they attributed to combination drug therapy and used to 
explain in part the fall in plasma LDL-cholesterol they observed. In the present 
study there was a fall in cholesterol/protein ratio in both IDL and LDL indicating 
that while the number of particles fell there was also some degree of cholesterol 
depletion in these species. This is consistent with the changes observed in these 
patients* LDL subfraction profiles, where there were significant falls in the larger, 
more cholesteryl ester rich species, LDL-I and LDL-II. Again, this is good 
evidence for the up-regulation of apoB/E receptors as the main mechanism of action 
of this combination regimen. Those LDL species that are relatively rich in 
cholesteryl ester are thought to bind to the apoB/E receptor with greater affinity 
(Koo et al 1988) and may be selectively removed from the circulation leaving 
smaller, denser LDL-III in relative abundance.
In conclusion, the combination of colestipol and simvastatin in this group of 
patients with primary moderate hypercholesterolaemia has been highly effective in 
correcting their aberrant lipid profile. The marked changes observed in LDL- 
cholesterol may be attributed to reduced LDL synthesis both from delipidation of 
VLDL and from de novo synthesis. The changes observed in the kinetics of IDL 
and LDL apoB, and the changes observed in lipoprotein composition and LDL 
subfraction profile are adequately explained by these drugs’ proposed mechanism 
of action in enhancing apoB/E receptor function.
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Chapter 8 Combination II 
Acipimox & Cholestyramine
Experiment alone crowns the efforts of medicine, experiment limited only by the 
natural range of the powers of the human mind. Observation discloses in the 
animal organism numerous phenomena existing side by side, and interconnected 
now profoundly, now indirectly, or accidentally. Confronted with a multitude of 
different assumptions the mind must guess the real nature o f this connection.
Ivan Pavlov
8.1 Introduction
Combination therapy with nicotinic acid or its derivatives and a bile acid sequestrant 
resin is one of the most effective lipid regulating therapies available and one of the 
first tried (Levy, Fredrickson & Schulman 1972). This regimen can reduce total 
and LDL-cholesterol by between 30-40% and is particularly attractive as both drugs 
have individually been shown to reduce coronary morbidity in large scale clinical 
trials (Coronary Drug Project 1975, Lipid Research Clinics 1984a & 1984b). This 
combined drug regimen has been shown to be effective in heterozygous familial 
hypercholesterolaemia (Packard etal 1980, Kane etal 1981) where normalization of 
LDL-cholesterol and regression of tendinous xanthomata have been reported. 
Regression of coronary atherosclerotic lesions has also been demonstrated using 
this combination of lipid lowering drugs. Blankenhom eta l( 1987) reported in the 
Cholesterol Lowering Atherosclerosis Study (CLAS) a significant increase in 
regression and decrease in progression in subjects receiving niacin and colestipol 
therapy compared to placebo treated controls. These findings were confirmed by 
Brown et al (1990) in the Familial Atherosclerosis Treatment Study (FATS). Here
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a combined regimen of niacin and colestipol was shown to be superior to lovastatin 
and colestipol in inducing coronary atherosclerosis regression.
Despite the clinical efficacy of combined nicotinic acid and sequestrant resin, many 
individuals are, however, unable to tolerate the side effects of nicotinic acid, which 
has prompted its substitution with the analogue, acipimox. This combination is 
reasonably well tolerated and is equally effective in reducing LDL-cholesterol levels 
(Series etal 1990).
The aim of the present study was to examine in detail the mechanism of action of 
combined bile acid sequestrant resin and nicotinic acid derivative therapy in patients 
with primary moderate hypercholesterolaemia. The results confirmed the 
significant lipid lowering that may be achieved using combination therapy and the 
kinetic analysis of apoB containing lipoproteins yielded interesting new findings.
8.2. Protocol
This extension of the study described in chapter 5 was designed to examine the 
influence of acipimox and cholestyramine on the metabolism of apoB containing 
particles. The preliminary screening period and baseline study period were as 
described in chapter 5. On completion of the second VLDL turnover study, the 
patients were commenced on cholestyramine 12g^day in addition to their acipimox 
therapy, 1250mg/day. The relatively low dose of cholestyramine was chosen to 
facilitate patient compliance. Patients remained on these doses for 10 weeks. 
During the final 2 weeks each patient underwent a third and final VLDL turnover 
investigation while on combined therapy. In addition lipid, lipoprotein and 
lipoprotein subfraction analyses were repeated at this time.
8.3 Subjects
The seven study patients were those described in chapter 5 and their characteristics 
are summarised in table 13. As before all concomitant medications were continued 
unchanged throughout this second study phase.
8.4 Adverse Events
Combination therapy with acipimox and cholestyramine was reasonably well 
tolerated by all subjects participating in the study. Three patients, APX 05, 06 and
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07 complained of mild constipation after the addition of cholestyramine to their 
regimen, but this resolved after approximately the first two weeks of therapy and 
did not require any further intervention or interruption of therapy. Biochemical and 
haematological monitoring revealed no clinically significant changes from baseline 
attributable to therapy.
8.5 Lipids and Lipoproteins
Baseline plasma lipid and lipoprotein levels of those patients studied are shown in 
chapter 5, and their levels after combination therapy are displayed in table 29. 
Combined treatment reduced plasma cholesterol by 23% (p<0.001). This 
decrement was due in this group to a 27% fall in LDL-cholesterol (p<0.003), and a 
19% fall in VLDL-cholesterol (p<0.02). Triglyceride and HDL-cholesterol were 
not significantly affected by combined therapy, nor was the plasma level of Lp(a). 
Centrifugal analysis of the subfraction distribution in the LDL and HDL density 
intervals was performed before and during therapy but neither HDL2 and HDL3 
masses nor the HDL2/3 ratio were affected by therapy. Figure 59 shows the LDL 
subfraction profile obtained upon density gradient fractionation of each subject’s 
plasma. The pattern exhibited considerable variation from subject to subject but in 
most three distinct populations of particles could be distinguished both before and 
during therapy. There was some shift in the LDL subfraction pattern towards a 
larger more buoyant species with a rise in LDL-I of 33% and a fall in LDL-HI of 
49% (table 30). However, the scatter of responses in this small group was such 
that these changes did not reach statistical significance. Compositional analysis of 
the four major apoB containing lipoprotein classes are summarised in table 31. 
Combination therapy did not affect the absolute composition of either VLDLi or 
VLDL2. However, there were marked changes in the chemical analysis of IDL and 
LDL with significant falls in the absolute value of the measured lipids and protein in 
LDL. When the relative lipid composition of these lipoproteins were considered it 
appeared that while there was a significant reduction in the number of circulating 
particles, as evidenced by the fall in IDL and LDL apoB, the make up of these 
particles was largely unchanged with the exception of cholesteryl ester content. In 
IDL this rose from 38 to 44% and in LDL the rise was from 36 to 40%.
8.6 Apolipoprotein B Metabolism
The influence of acipimox and cholestyramine therapy on apolipoprotein B 
metabolism was examined before and on the combined drug regim en
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Table 30. LDL Subfraction Changes with Acipimox and Cholestyramine Therapy
Subject Tot LDL LDL-I LDL-H LDL-m
_ _ _ m n I m A f V f n t A i n  l O f l m T  n l f l c m o  “ 1 _ _m g  n p u p r u i c i n • i w i u l  p i d a m a  • •
Before Therapy
Mean 416 51 214 151
(SEM) (40.3) (13.8) (42.2) (56.8)
On Adpimoxand Cholestyramine
APX01C 378 83 136 159
APX 02C 268 59 147 62
APX 03C 261 60 157 44
APX04C 274 115 134 25
APX05C 296 18 124 154
APX 06C 305 40 219 46
APX07C 368 103 239 26
Mean 307 68 165 77
(SEM) (18) (13) (17) (22)
P* NS NS NS NS
* Comparison of the means was performed using paired students t-test.
(representative decay curves for one subject, APX 03 are shown in figures 39,40, 
60 & 61). Before therapy apoB disappeared rapidly from the VLDLi flotation 
interval and appeared in VLDL2 over a period of 4-6 h after injection (figure 39). 
The decay of radioactive apoB in VLDL2 was much slower than in VLDLi, taking 
approximately 60 hours to reduce to 1% of the injected dose (figure 40). 
Combination therapy with acipimox and cholestyramine did not appear to increase 
the clearance rate of VLDLi apoB (figure 60) but in this individual the slope of the 
VLDL2 apoB curve and therefore its clearance rate was increased(figure 61). The 
flux of apoB into IDL was affected by therapy for both tracers but in different 
ways. VLDLi derived apoB appeared to enter the IDL fraction more quickly on 
therapy and achieve a higher peak value (60% versus 40% of injected dose) (figure 
60). The decay rate of this VLDLi derived apoB was also initially slower than at 
baseline. VLDL2 derived apoB achieved a smaller peak value in the IDL fraction on 
combined therapy when compared to the control phase, but its rate of decay was 
indistinguishable (figure 61). In this subject (APX 03) the clearance rate of LDL
Chapter 8 Combination Therapy II  204
Figure 59.
APXOl
APX02
APX03
APX04
APX05
APX06
1.025 1.034 1.044
Density (g. m L1)
1.060
LDL subfraction profiles at baseline (—), during acipimox therapy 
(—) and on combined acipimox and cholestyramine therapy (-•-) in 
subjects APX 01-APX 07.
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Figure 60. On Acipimox and Cholestyramine. Apolipoprotein B radioactivity 
decay curves associated with VLDLi, VLDL2 , IDL, and LDL in 
subject APX 03 after injection of autologous [ 131I]-VLDLi
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Figure 61. On Acipimox and Cholestyramine Apolipoprotein B radioactivity 
decay curves associated with VLDL2 , IDL, and LDL in subject APX 
03 after injection of autologous [125I]-VLDL2.
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apoB radioactivity was also unaffected by combination therapy. Kinetic rate 
constants and apoB fluxes were derived by compartmental modelling. The results 
for all 7 subjects are summarised in table 32; decay curves for the other six subjects 
and individual kinetic constants and masses are given are shown in appendix 4.
VLDLi apoB synthesis, pool size, and fractional transfer rate to VLDL2 were 
unchanged from baseline by combination therapy. Despite the latter, the VLDL2 
apoB pool size fell by 36% (p<0.03), due primarily to a significant fall in the 
absolute apoB mass derived from VLDLi (34%, p<0.03). Direct input of VLDL2 
apoB was unaltered, but the fractional transfer rate from VLDL2 into IDL was 
markedly increased from 2.12 to 3.54 pools. d_1 (67%, p<0.005), although the 
absolute mass of apoB transferred into the IDL density interval was unaffected by 
the combined regimen. The IDL apoB plasma pool and FCR were unchanged by 
therapy but the fractional transfer of IDL apoB into LDL was significantly increased 
(26%, p<0.05). The total LDL apoB plasma pool showed a significant fall, in 
response to acipimox and cholestyramine therapy, from 3480 to 2728mg (p<0.02), 
but the calculated LDL apoB pool, i.e. that derived from VLDL was relatively 
unchanged. The fractional catabolic rate of LDL apoB, rose in 5 of the 7 patients 
but because of the scatter of responses this did not achieve overall significance.. 
Total LDL apoB synthesis was unaffected by therapy as was the direct synthesis of 
LDL apoB. In this relatively small group of subjects, it appeared to be the 
collective result of a number of small and statistically insignificant changes in both 
synthetic and catabolic parameters that contributed to the observed fall in plasma 
LDL-cholesterol. Once again, as in all previous chapters, it is interesting to note 
that the mean calculated total apoB synthetic rate remained constant with 
combination therapy (table 32). Figures 43 and 62 summarise the flux of apoB 
through the delipidation cascade at baseline and on combination therapy.
8.7 D iscussion
The 27% fall in mean LDL-cholesterol observed in this group of patients is highly 
significant both statistically and clinically. It is in accord with the findings of Series 
e ta l(1990) who reported the effects of the same combination of acipimox and 
cholestyramine in a larger group of patients with type II hyperlipoproteinaemia. In 
the present study no significant change was noted in HDL-cholesterol or in the 
masses of the HDL subfractions as have been described for both acipimox and resin 
(Series et al 1990) and nicotinic acid and resin (Packard eta l 1980). There was 
however, a 10.4 % rise in HDL-cholesterol in response to combination therapy and
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Table 32a VLDLi ApoB Metabolism before and on Acipimox & Cholestyramine
Plasma Direct Flux
Synthesis Pool Catabolism T0 VLDL2
(mg.d-1) (mg) (pools, d '1) (pools. d_1)
Before Therapy
Mean 762 139 3.41 3.65
(SEM) (154) (31) (1.35) (0.87)
On Acipimox and Cholestyramine
APX01C 1098 238 2.26 2.35
APX 02C 1404 58 21.52 2.69
APX03C 409 31 3.46 9.74
APX04C 330 69 2.65 2.13
APX05C 439 77 1.39 4.32
APX06C 222 68 1.00 2.26
APX07C 956 65 10.72 3.99
Mean 694 87 6.14 3.93
(SEM) (172) (26) (2.85) (1.02)
P* NS NS NS NS
* Differences between the time points were assessed by the paired student’s t-test.
Table 32b. VLDL2 ApoB Metabolism before and on Acipimox & Cholestyramine.
Direct Flux from Plasma Direct Flux
Synthesis VLDLi Pool Catabolism to EDL+ LDL
(mg.d-1) (mg.d-1) (mg) (pools, d-1) (pools.d-1)
Before Therapy
Mean 696 414 414 0.62 2.12
(SEM) (110) (68) (63) (0.17) (0.25)
On Acipimox and Cholestyramine
APX 01C 624 560 477 0.57 1.92
APX 02C 653 156 246 0.53 2.77
APX 03C 1941 302 329 2.26 4.56
APX 04C 452 147 181 0.24 3.07
APX05C 938 333 219 0.58 5.22
APX06C 584 154 188 0.34 3.57
APX 07C 792 259 217 1.14 3.69
Mean 855 273 265 0.81 3.54
(SEM) (190) (56) (40) (0.27) (0.42)
P NS <0.03 <0.03 NS <0.005
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Table 32c. IDL ApoB Metabolism before and on Acipimox & Cholestyramine.
Flux from Plasma Direct Flux
v l d l2 Pool Catabolism To LDL
(mg.d-1) (mg) (pools. d“l) (pools, d-1)
Before Therapy
Mean 813 795 0.28 0.75
(SEM) (100) (73) (0.03) (0.08)
On Acipimox and Cholestyramine
APX 0 IB 913 880 0.26 0.78
APX 02B 672 751 0.38 0.51
APX 03B 1460 776 0.57 1.31
APX 04B 529 443 0.23 0.97
APX 05B 1141 460 0.97 1.51
APX06B 671 896 0.15 0.59
APX07B 794 743 0.16 0.91
Mean 883 707 0.39 0.94
(SEM) (122) (70) (0.11) (0.14)
P NS NS NS <0.04
Table 32d. LDL ApoB Metabolism before and on Acipimox & Cholestyramine.
Direct Flux from VLDL derived Fractional Total ApoB
Synthesis X IDL + VLDL2 Plasma Pool Catabolic Rate Synthesis
(mg.d-1) (mg.d-1) (mg) (pools.d-1) (mg.d-1)
Before Therapy
Mean 321 598 2332 0.26 1778
(SEM) (95) (89) (276) (0.03) (321)
On Acipimox and Cholestyramine
APX01C 232 685 2526 0.27 1954
APX02C 276 395 1261 0.31 2333
APX 03C 507 1056 2692 0.39 2857
APX04C 161 454 1595 0.28 943
APX 05C 33 696 2496 0.28 1410
APX06C 0 532 1809 0.29 806
APX07C 154 681 2458 0.28 1902
Mean 195 643 2120 0.30 1744
(SEM) (64) (83) (210) (0.02) (280)
P NS NS NS NS NS
J Direct synthesis in LDL was calculated as the difference between the total absolute
catabolic rate (observed mass x overall FCR) and the input from VLDL and IDL.
Chapter 8 Combination Therapy I I  210 
T able 32e. LDL ApoB Metabolism before and on Acipimox & Cholestyramine (cont)
Total Total LDL
Plasma LDL pool Synthesis
(mg) (mg.d-1)
Before Therapy
Mean 3480 919
(SEM) (359) (149)
On Acipimox and Cholestyramine
APX01C 3384 917
APX02C 2152 671
APX 03C 3991 1563
APX 04C 2170 615
APX05C 2614 729
APX06C 1777 532
APX07C 3008 835
Mean 2728 837
(SEM) (295) (130)
P <0.02 NS
this just fell short of statistical significance (p=0.09). This lack of effect on HDL 
metabolism is readily explained when the relatively small sample size studied and 
their inherently diverse underlying lipoprotein metabolism are considered.
The use of this combination of lipid lowering drugs has a sound theoretical basis. 
Bile acid sequestrant resin therapy, as described in chapter 4, exerts its lipid 
lowering effects by interrupting the enterohepatic circulation of bile acids. This 
results in depletion of the regulatory sterol pool in the hepatocyte and increased 
expression of apoB/E receptors. A homeostatic side effect of resin therapy is 
increased hepatic cholesterologenesis, secondary to the activation of the liver 
enzyme HMG CoA reductase. Nicotinic acid and its analogue, acipimox, exert 
their hypolipidaemic effect by inhibiting peripheral lipolysis and thereby reducing 
free fatty acid flux to the liver where VLDL triglyceride synthesis is curtailed. This 
action is thought not only to minimise the resin-induced hypertriglyceridaemia, but
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Figure 62. Summary of the effects of acipimox and cholestyramine therapy on 
apoB metabolism. Numbers in circles represent apoB pool size 
[mean (SEM)] in mg. Numbers on arrows represent mean transfer 
of apoB in mg.cb1. * significantly different from control p<0.05.
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also to enhance the cholesterol lowering effect of the resins by reducing the input 
into the VLDL-IDL-LDL delipidation cascade.
The relative compositional changes noted here are interesting because they would 
not support enhanced apoB/E receptor activity as a means of explaining the lipid 
lowering seen with this regimen. The apoB/E receptor is thought to selectively 
remove cholesteryl ester rich particles from the circulation (chapter 3). While 
colestipol on its own would be expected to enhance apoB/E receptor activity, an 
increase in these cholesteryl ester rich species, as seen here and as opposed to a fall 
in their number, would seem to counter this explanation.
The effects of acipimox and cholestyramine in combination on the LDL subfraction 
profile are not surprising when the individual effects of these drugs are considered. 
Acipimox, in common with other triglyceride-lowering drugs shifts the LDL 
subfraction profile towards the lighter and larger species (chapter 5), while the bile 
acid sequestrant resin, colestipol, has been shown, in chapter 4, to have the 
opposite effect. When cholestyramine was added to the regimen it appeared to 
completely offset the dramatic shift in LDL subfractions seen with acipimox alone 
(chapter 5), although there was a further fall in total LDL mass. Acipimox therapy 
appeared to favour the formation of potentially apoB/E receptor active LDL species 
viz. LDL-I & LDL-II. It may be speculated that as cholestyramine enhances 
apoB/E receptor expression these species will be quickly removed from the 
circulation resulting in an apparent reversal of the subfraction profile. Such an 
hypothesis may explain the apparent clinical efficacy of a similar combined regimen 
(colestipol & niacin) as used in the ‘CLAS’ study (Blankenhom etal 1987).
As described in chapter 5 there is virtually no literature describing the influence of 
acipimox on lipoprotein kinetics, and there is none at all reporting the effects of 
combined acipimox and bile acid sequestrant resin therapy. When a drug that is 
thought to enhance clearance of apoB containing lipoproteins yet stimulate 
cholesterol synthesis is given in conjunction with a drug that has no known effect 
on apoB/E receptor function but has the disparate effects of reducing VLDL 
production and inhibiting lipolysis at the lower end of the delipidation cascade, it 
may be expected that there will be some confusion in trying to unravel their 
composite metabolic effects. This has indeed been the case. There appeared to be 
remnants of the action of acipimox on the delipidation cascade i.e. reduced total 
VLDL pool size and enhanced fractional transfer of apoB from VLDL2 to IDL, and 
there were findings that demonstrated the additive effects of the drugs e.g. the flux
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of apoB from VLDLi to VLDL2 , which fell on acipimox therapy and fell further on 
combination therapy to achieve a statistically significant fall from baseline. There 
were also anomalous findings e.g. the slight increases in total LDL synthesis and 
observed LDL apoB mass seen when cholestyramine was added to the regimen. 
Such apparently discordant findings are difficult to explain in the context of the 
present study and will only be resolved by larger studies, or a similar study in a 
group with less heterogeous hyperlipidaemia.
In conclusion, combination therapy with acipimox and cholestyramine therapy in 
primary moderate hypercholesterolaemia has been shown to be highly effective in 
lowering total and LDL-cholesterol. In contrast to other studies no significant 
change was observed in HDL-cholesterol or in HDL subfraction mass. This lack of 
response may be explained by the small group size studied. The investigation of 
apoB metabolism in these patients provided equivocal yet interesting findings. A 
combination of reduced synthesis and increased catabolism of apoB containing LDL 
precursors and of LDL itself has to be invoked to explain the observed fall in 
plasma LDL-cholesterol.
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Chapter 9 Cholesterol Biosynthesis
I must begin with a good body of facts and not from a principle (in which I always 
suspect some fallacy) and then as much deduction as you please.
Charles Darwin
9.1 Introduction
Because the classical method of assessing whole body cholesterol synthesis in 
humans, involving sterol balance studies, is laborious and insensitive to acute 
changes in cholesterol synthesis, alternative methods have been sought Serum or 
plasma levels of various cholesterol precursors have been proposed as indirect 
indices of cholesterol biosynthesis viz. free methylsterols (Miettinen 1970,1982), 
squalene (Nestel & Kudchodkar 1975), mevalonic acid (Parker et al 1982) and 
most recently total lathosterol (Bjorkhem et al 1987, Kempen et al 1988). Only the 
latter two, mevalonic acid and lathosterol have stood the test of time. However, 
they are very different compounds from opposite ends of the cholesterol 
biosynthetic pathway determined by very different assay systems. To investigate 
the effects of the lipid lowering drugs, simvastatin and fenofibrate, assays for these 
cholesterol precursors were established. Because these assays are infrequently 
used they are described in detail in chapter 2.
Mevalonic acid, an intermediate of cholesterol biosynthesis, is the immediate 
product of the important rate-limiting step catalysed by HMG CoA reductase 
(Popjak & Comforth 1960), as shown in figure 63.
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Acetoacetyl CoA + Acetyl Co A + H20  
3-hydroxy-3-methyl glutaryl CoA
HMG CoA reductase
Mevalonate kinase
MEVALONATE
c ATPADP
5 -Phosphomevalonate
c -  ATP -►ADP
5-Pyrophosphomevalonate
c -ATP-ADP
3-phospho-5-pyrophosphomevalonate
CC>2 + Pi 
Isopentenyl pyrophosphate : Dimethylallyl pyrophosphate
Geranyl pyrophosphate
c -  Isopentenyl pyrophosphate ► PPi
Famesyl pyrophosphate
Fam esyl pyrophosphate + NADPH  
NA DP+ +2PPi + H+
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Squalene epoxide 
Lanosterol 
Cholesterol
Figure 63. The Cholesterol Biosynthetic Pathway (Adapted from Stryer 1981)
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Plasma mevalonic acid exhibits a diurnal variation (Parker e t a l 1982, Parker e t  al 
1984), the control of which has yet to be fully elucidated. The measurement of 
serial plasma mevalonic acid levels in human subjects is interesting and may yield 
very useful data on the possible mechanisms controlling the diurnal cycle. 
However, such serial plasma sampling is difficult and impractical on all but an in­
patient basis. Unlike other lipid soluble intermediates in sterol biosynthesis 
mevalonic acid is excreted in the urine (Kopito & Brunengraber 1980, Kopito e t a l 
1982). 24 hour urinary mevalonic acid estimation has been shown to reflect the 
integrated plasma concentration throughout the 24 hour period (Parker et al 1984). 
The use of this assay in place of one-off plasma mevalonic acid levels obviates 
potential problems and allows ready comparison between or within subjects at 
different times (Parker et al 1982, Parker et al 1984).
This approach is considered to be a simpler and more practical way of indirectly 
assessing human cholesterol biosynthetic rates than conventional sterol balance 
studies (Pappu, Illingworth & Bacon 1989, Illingworth, Pappu & Gregg 1989). 
The effects of physiological and pharmacological modulation of cholesterol 
metabolism may therefore be assessed by 24 hour urinary mevalonic acid assays 
(Kopito e t a l 1982, Pappu & Illingworth 1989).
Serum levels of lathosterol, a late precursor of cholesterol (figure 64), have been 
shown to alter in the same direction as the expected rates of cholesterol synthesis 
with various manipulations including small bowel resection (Miettinen 1985) and 
cholestyramine and bile acid administration (Miettinen 1981). Further validation of 
the use of serum lathosterol as an index of cholesterol biosynthesis was obtained by 
correlating lathosterol levels with hepatic HMG CoA reductase activity (Bjorkhem 
e t al 1987) and cholesterol balance studies (Kempen e t  a l 1988). Additional 
corroboration was gained with the demonstration that this cholesterol precursor fell 
markedly in patients receiving HMG CoA reductase inhibitor therapy (Kempen e t al 
1988, Reihner et a l 1990b, Elmberger et al 1991).
While there have been these reports of the effects of an HMG CoA reductase 
inhibitor on serum lathosterol, and others documenting changes in urinary 
mevalonate excretion with these drugs (Pappu & Illingworth 1989), these 
cholesterol precursors have never been determined simultaneously in the same 
subjects nor have there been any reports of the effects of the fibric acid derivatives 
on these indices of cholesterol biosynthesis. The latter is of particular interest as 
there is considerable controversy over the precise mechanism of cholesterol 
lowering with the fibrates.
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Dihydrolanqsterol
Squalene 
_ — Lanosterol
A8, A24 Dimethylsterol^
* A8 Dimethylsterol 
Methostenol-1 ^
Lathostenol-*- " '  
Cholesterol-- - "
A8, A2f Methostenol
A8 Lathosterol
Desmosterol
Figure 64. Proposed Conversion of Squalene to Cholesterol in Humans. Major 
pathways are shown with solid arrows and minor or hypothetical pathways are 
shown with broken arrows (Redrawn from Bjorkhem et al 1987).
9.2 Study Protocols
I. Simvastatin. In 6 of the subjects recruited for the kinetic study described in 
chapter 3, plasma lathosterol and urinary mevalonate excretion were measured both 
at baseline and after 8 weeks therapy with simvastatin (20mg. d*1).
II. Fenofibrate. In 6 subjects who were recruited for a study to examine the effects 
of the fibric acid derivative, fenofibrate, on apo-LDL metabolism (results not 
reported here), plasma lathosterol and urinary mevalonate excretion were measured 
both at baseline and after 8 weeks therapy with fenofibrate (lOOmg Li.d.).
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In each study, the patients were maintained on their standard lipid lowering diet 
throughout. Just before starting drug therapy the patients collected a 24 h urine 
specimen, which was delivered to the laboratory immediately on completion, where 
it was aliquotted and frozen without delay for mevalonate estimation. At the same 
time a plasma sample was collected at 08.00h after a 14 h fast. The timing of this 
sample was strictly adhered to in order to minimise the effects of diurnal variation 
on plasma lathosterol levels. This procedure was repeated after 8 weeks of therapy 
with either drug. The control and drug phase samples for each patient were placed 
in the same assay run to minimise inter-assay variability. The plasma lathosterol 
estimations were also performed in duplicate.
9.3. Results I Simvastatin
The effects of simvastatin on the lipid profile of the 6 subjects studied are shown in 
table 33. There were highly significant falls in total and LDL-cholesterol as 
previously described (chapter 3) with no significant effect on triglyceride, VLDL, 
or HDL-cholesterol. The responses in urinary mevaiunaic w ac uuukcu anu 
uniform (figure 65) with all subjects showing a fall in this parameter of between 30 
and 76% (mean 57%, p<0.03). Similarly, when plasma total lathosterol/cholesterol 
ratio was examined before and during therapy all subjects showed a fall in this 
parameter of between 20 and 61% (mean 49%, p<0.01) (table 33, figure 65).
9.4. Results II Fenofibrate
The effects of fenofibrate on the lipid profile of the 6 subjects studied are shown in 
table 34. There were significant falls in total, LDL and VLDL-cholesterol and in 
triglyceride while the increase in HDL-cholesterol did not reach statistical 
significance. The responses in urinary mevalonate were variable (figure 66) with 
two subjects showing a marked fall, two a marked increase and two staying 
approximately the same. The result of these variable changes was no overall 
change in the mean. Similarly, when plasma total lathosterol/cholesterol ratio was 
examined before and during therapy no significant change was observed (table 34, 
figure 66).
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9.5 Discussion
The use of simvastatin, a known inhibitor of cholesterol synthesis, in these studies 
has served to test the ability of the mevalonate and lathosterol assays to detect 
changes in cholesterol synthesis. Significant changes in both plasma lathosterol 
and urinary mevalonate excretion confirm previous findings of Pappu & Illingworth 
(1989), who noted a 34% fall in urinary mevalonate associated with lovastatin 
therapy. These workers also quoted a reference interval for urinary mevalonate 
excretion of 1.0-2.95 pmcl. 24h'l. The range of baseline values recorded in the 
present studies was 0.48-3.80 pmol. 24h"l, which encompasses their interval and 
is therefore reasonably consistent in view of the relatively small number of 
measurements.
The main objective of this study was to assess the effects of a fibric acid derivative 
on cholesterol synthesis. A more detailed background to this question will be 
germane to the discussion that follows.
Besides their effects on triglyceride and apoB metabolism the fibrates are also 
reputed to have an inhibitory effect on hepatic cholesterol synthesis. This action is 
thought to be mediated through the inhibition of HMG CoA reductase, the rate 
limiting enzyme of cholesterol biosynthesis. Early work by Bemdt and coworkers 
(1978) demonstrated both the inhibition of this enzyme by clofibrate and bezafibrate 
in rat liver microsomes in vitro, and its reduced activity in liver microsomes isolated 
from fibrate fed rats. Schneider et a l (1985) have also demonstrated reduced 
activity of HMG CoA reductase in freshly isolated mononuclear cells from patients 
treated with fenofibrate, but in similar studies, using bezafibrate, Stange and 
colleagues (1991) report no drug induced effect on HMG CoA reductase activity. 
McNamara et a l (1980) also observed no change in the rate of cholesterol synthesis 
in mononuclear cells freshly isolated from patients receiving clofibrate therapy. 
Other recent studies have demonstrated fibrate induced inhibition of the regulatory 
enzymes in cholesterol biosynthesis. Castillo et a l (1990) showed reduced activity 
of the enzyme HMG CoA reductase in vivo and in vitro in chick liver in response to 
clofibrate, while Cosentini et al (1989) demonstrated in a total of 15 patients that 
bezafibrate reduced the incorporation of labelled acetate into non-saponifiable lipids 
in freshly isolated blood mononuclear cells. Again, however, there is some 
equivocation in the literature in that another fibrate, gemfibrozil, has been shown to 
increase hepatic sterol biosynthesis, albeit in rats (Maxwell e t a l 1983).
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Published reports to date have, however, been criticised on a number of counts. 
Just as there are differences between rodents and humans in the hepatic toxicology 
of the fibrates, there also appear to be important species dissimilarities in the effect 
of the fibrates on the enzymes of cholesterol metabolism as documented by 
Stahlberg e t a l (1991). These workers report an approximately two-fold increase 
in HMG CoA reductase activity in human liver microsomes from bezafibrate treated 
individuals, in contrast to the reductions seen in other studies in animals. The 
message here is that work done in animal models may not be readily extrapolated to 
man.
Much of the published data have also been criticised either because of invalid 
methodology (Fears 1983), or the use of unrealistically high concentrations of drug 
in vitro  (Newton & Krause 1986). The latter workers point out that many in vitro  
experiments may be flawed because the concentrations of fibrates used, greatly 
exceed potential in vivo, pharmacological levels. Similar levels of HMG CoA 
reductase inhibition were achieved by these workers when compactin was used as a 
positive control at in vitro levels 10,000 fold lower than that required of the 
fibrates. On this basis, Newton and Krause (1986) suggest that the observed 
inhibitory effect of the fibrates on HMG CoA reductase in vitro  may represent a 
non-specific rather than a physiological effect at a specific, regulatory site on the 
enzyme. It is not appropriate, therefore, to class the fibrates with the specific HMG 
CoA reductase inhibitors or ‘statins' even though there is some good evidence that 
they do indeed inhibit cholesterol synthesis, for they must effect this action by other 
means. Indirect effects of the fibrates on cholesterol biosynthesis have been 
proposed by Kleinman et al (1985). They have shown that the compositional 
changes in LDL induced by bezafibrate therapy enhances LDL receptor-mediated 
uptake of this lipoprotein and its ability to down-regulate LDL receptor activity and 
to suppress cholesterol synthesis in cultured fibroblasts. This enhanced delivery of 
sterol to cells may indirectly inhibit cholesterol synthesis in fibrate treated patients, 
in accord with the concept of Brown e t a l (1974), who found that cholesterol itself 
was the feedback suppressor of HMG CoA reductase activity in fibroblasts. 
Another indirect effect of the fibrates on the enzymes of cholesterol synthesis may 
be mediated by drug induced changes in membrane cholesterol content, and, in 
turn, membrane fluidity. Mitropoulos and Venkatesan (1985) describe possible 
mechanisms by which the enzyme HMG CoA reductase, a membrane bound 
protein, may be regulated by the cholesterol content of its supporting phospholipid 
bilayer. Needham et a l (1985) have studied the effects of fibrate therapy on 
membrane fluidity and conclude that the drug clofibrate decreases the molar
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cholesterol/phospholipid ratio of plasma membranes and that this environmental 
change alters the functioning of integral membrane proteins. Thus, fibrate induced 
changes in the membranes of the endoplasmic reticulum, where HMG CoA 
reductase is mainly located, may indirectly influence this enzyme's activity. While 
there has been some equivocation in the literature from in vivo and in vitro 
experiments, there is now emerging a consensus that the fibrates do indeed inhibit 
cholesterol synthesis in man but that they do so by some means other than the direct 
inhibition of the enzyme HMG CoA reductase. The present study, however, which 
is the only report of the effects of a fibrate on indirect indices of cholesterol 
synthesis does not support this hypothesis. The lack of a consistent lowering effect 
of fenofibrate on plasma lathosterol, or in the same subjects, urinary mevalonate 
excretion, suggests that this drug is not a cholesterol synthesis inhibitor in the same 
way that simvastatin obviously is. Further work in this area is clearly needed 
before we fullv understand the nature of the mechanisms by which the fibrates exert 
their cholesterol lowering effect
9.6. F u rth e r Considerations
Before leaving this topic there are two other areas that deserve some comment. 
These are alternative ways of measuring mevalonate and alternative uses of the 
mevalonate and lathosterol assays.
The mevalonate assay, while useful as a research tool is difficult to perform and is 
very expensive in terms of time reagents and consumables. Alternative ways to 
measure mevalonate have therefore been sought. The estimation of mevalonate in 
urine and plasma using gas chromatography-mass spectrometry (GC-MS) and 
selected ion monitoring has been described by Del Puppo et al (1988). This 
procedure gives results in the same range as those obtained with the radio- 
enzymatic assay reported here, but has been criticised by another team (Hoffman & 
Sweetman 1990) who considered the method unsuitable to quantify normal 
physiological samples reliably. Galli Kienle et al (1991) replied to these 
methodological criticisms, stating that they found the derivitisation technique used 
to be convenient and to yield consistent results. The controversy over the validity 
of the determination of mevalonate by GC-MS continued until Scoppola et al (1991) 
reported their modifications of the assay described by Del Puppo et al (1988). 
Using an electron-capturing bis(trifluoromethyl)benzyl derivative in a GC-ECMS 
system these workers reported improved specificity and sensitivity.
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The mevalonic acid and lathosterol assays has recently gained a new clinical 
significance with the introduction of the HMG CoA reductase inhibitor class of 
hypolipidaemic drugs. The measurement of mevalonic acid in patients receiving 
such therapy has been suggested as a useful biochemical monitor in addition to 
lipoprotein levels (Kempen et al 1988, Pappu, et al 1989, Pappu & Illingworth 
1989, Thompson et al 1989). Further applications of the mevalonate and 
lathosterol have also been identified in recent years. The autosomal recessive 
inborn error of metabolism, Mevalonic Aciduria is due to a deficiency of the 
enzyme mevalonic kinase (figure 63). First described by Berger et al (1985) and 
subsequently by Hoffman et al (1986) it is an extremely rare condition (only three 
cases are described in the literature), but its diagnosis is largely dependent on the 
assay of mevalonate in plasma or urine. Because it can produce severe neurological 
defects and failure to thrive with death in infancy this disease is suitable for prenatal 
diagnosis in affected families. Such a diagnosis is described by Hoffman et al 
(1986) where grossly elevated levels of mevalonate in maternal urine indicated that 
the fetus was affected. This condition is the only known inborn error of the 
cholesterol biosynthetic pathway and as such offers a unique possibility of greater 
understanding of this complex area.
More recently, Wolthers et al (1991) reported a new application of the lathosterol 
assay. Investigating the condition, cerebrotendinous xanthomatosis (CTX) 
(cholesterol 26-hydroxylase deficiency), they identified a significant difference in 
serum lathosterol concentrations between normals and untreated CTX patients. 
Furthermore, these workers noted that the elevated levels of lathosterol in CTX 
returned to normal with oral bile acid therapy. They concluded that serum 
lathosterol may be useful to monitor the treatment of these patients.
Recent investigations have found that several cellular proteins viz. growth- 
regulating p 2 \ras proteins, encoded by ras proto-oncognes and oncogenes, are 
isoprenylated and contain covalently bound famesyl or geranyl-geranyl moieties, 
which anchor them to cell membranes (Goldstein & Brown 1990). Inhibition of 
mevalonate synthesis prevents famesylation of these proteins and blocks cell 
growth. Therefore, the importance of products of the mevalonate pathway in the 
pathology of malignancy as well as that of atherosclerosis places these compounds 
at the centre of modem medicine. Further studies of this pathway, in part facilitated 
by assays such as described here, may yield new and exciting developments in both 
these spheres.
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9.7. Conclusion
In conclusion, this short study has served to confirm the lipid lowering efficacy of 
simvastatin and fenofibrate in two groups of moderately hypercholesterolaemic 
subjects. With the measurement of plasma lathosterol and urinary mevalonate 
excretion, two established indirect indices of cholesterol biosynthesis, the inhibitory 
effect of simvastatin on this pathway has been demonstrated. The effects of 
fenofibrate have, on the other hand, failed to confirm that this drug exerts any 
consistent effect on the cholesterol biosynthetic pathway. Such new information 
may be used to re-evaluate the mechanism of action of the fibric acid derivatives, 
the execution of these studies has also served to establish two new and powerful 
assays side by side, which if early work is confirmed, may have much wider 
applications than originallv thought.
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Chapter 10 Conclusions
As the area of light increases, so does the circumference of darkness.
Albert Einstein.
10.1 Introduction
As Einstein perceived, one of the principal products of scientific discovery is a 
realisation of what has yet to be uncovered. Most theses will have a collection 
of interesting conclusions but many will pose even more interesting questions. 
This thesis is no different. In chapter one, the dual aims of this work were set 
out: to investigate the pathophysiology of apoB metabolism and to test the 
effects of a range of lipid lowering drugs, singly and in combination, on this 
system. It is the purpose of this final chapter to assess the extent to which 
these aims have been satisfied and, in turn, the contributions that have been 
made to this field.
10.2 Pathophysiology of Lipoprotein Metabolism
A schematic representation of apoB metabolism, which includes information 
derived from the present studies is illustrated in figure 67. What follows is a 
short discussion on the main findings, relating to the pathophysiology of the 
apoB containing lipoproteins, which are included either because they offer 
important new information or because they point in a new direction.
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LDL
F igure  67. Schematic Representation of ApoB M etabolism. 
LpL=Lipoprotein Lipase, HL=Hepatic Lipase, &=apoB/E receptor.
Total apoB synthesis (1) is relatively constant both in hyperlipidaemic states and 
after drug therapy. This parameter must be under different control from that of 
apoB/E receptor expression, cholesterol (2) and triglyceride synthesis. Lp(a) 
synthesis (3) and catabolism (4) were unaffected by drug therapy, which altered 
LDL levels, and are therefore placed separately from the other apoB containing 
lipoproteins. There is direct hepatic synthesis of VLDLi (5) and VLDL2 (7), 
and direct clearance of these lipoproteins, mediated by the apoB/E receptor in 
the case of VLDL2 (8) but not VLDLi (6). Clearance of IDL (9) is markedly 
affected by up-regulation of the apoB/E receptor and this appears to be one of 
the principal effects of those drugs which enhance receptor function. The direct 
synthesis of LDL (10) has been shown to be correlated with the plasma levels 
of LDL-I and II but not III. As such, direct synthetic pathways are shown only 
involving the larger and lighter subfractions, although receptor mediated 
clearance is probably involved in the catabolism of all three subfractions albeit 
in differing proportions. The final step in VLDL-derived LDL synthesis, i.e. 
the conversion of IDL to LDL (11) is mediated by hepatic lipase. Inhibition of 
this enzyme by various means including acipimox therapy results in decreased 
LDL synthesis. The question of which LDL subfraction are specifically derived 
from the delipidation cascade and the nature of their interconversions has not 
been the subject of this thesis and is not shown in the diagram.
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10.2.1. The Nature of LDL Production
The rate and nature of LDL generated from VLDL may be perturbed 
pharmacologically, as has been shown in the proceeding chapters. This has 
important implications for the potentail atherogenicity of LDL. A more 
contentious issue, which we are forced to address because of its quantitative 
importance, is that of direct LDL synthesis. A feature of the model of apoB 
metabolism used throughout this work is a direct input pathway at the level of 
LDL (figure 14). This was required to explain the observed LDL apoB mass, 
which is unaccounted for by that entering the LDL interval from the delipidation 
cascade, as detected using VLDLi and VLDL2 tracers. As discussed in chapter 
3, the nature of the physiological manifestation that explains this mathematical 
requirement is controversial. The consistent need for such a pathway in these 
studies may be offered as supportive evidence for its existence, although the 
nature of the present studies do not allow us to say whether this LDL is derived 
d,c novo or from a rapidly metabolised LDL precursor pool. All that can be said 
with surety is that there is an LDL apoB pool of variable size in almost all 
individuals, which is not trace labelled by the injection of the radiolabelled 
precursors, VLDLi and VLDL2 . Of course, it may also be argued that there is 
some consistent error in the methodology used here, and that there would be no 
need to invoke the direct input of LDL if all LDL precursors were trace labelled 
equally.
It is not possible to resolve this question simply by re-analysing the data with 
alternative models of apoB metabolism, because a large number of equally 
plausible answers may be obtained by this manipulative strategy. The model 
used must be as simple and as physiologically pertinent as possible. The model 
must also explain the data obtained in all patients, in all situations. The current 
model has been developed over a number of years and has only been changed 
or expanded to accommodate new data when absolutely necessary. As such, 
although apparently complex, this model does satisfy the above criteria, in 
being the simplest solution possible for all circumstances.
The resolution of this issue will need a fundamentally different approach. Such 
a new technology is already available in the form of stable isotope labelled 
precursor turnovers. In these studies, the infusion of deuterated or l5N-labelled 
amino acids, results in the stable isotopic enrichment of all proteins synthesised 
during the infusion period. If these proteins can be isolated in a pure form then
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a direct measure of their fractional synthetic rate (FSR) can be made. With 
radioisotopic studies, such as described in this thesis, all estimates of synthetic 
parameters are derived indirectly from directly measured catabolic parameters 
using the assumptions of steady state kinetics. With stable isotope technology, 
on the other hand, synthetic parameters are measured directly, and it should be 
possible not only to demonstrate if LDL is produced de novo as well as by the 
delipidation of VLDL, but also which LDL subfractions are involved.
10.2.2. LDL Subfractions
An important observation in the present study was the correlation between LDL 
direct synthesis and the LDL subfractions I+n, but not LDL III. Although this 
correlation was significant only in those subjects recruited for the simvastatin 
study described in chapter 3, there was a similar trend in the other groups. 
Using the stable isotope technology described above the differential synthetic 
rates, if any, in the LDL subfractions may be observed. Such experiments, to 
test the hypothesis generated by the present work, that LDL direct synthesis 
accounts for a portion of the LDL I+II but not LDL m  plasma concentrations, 
are currently underway in the Institute of Biochemistry at Glasgow Royal 
Infirmary.
The model of apoB metabolism used (figure 14) does embrace the concept of 
LDL heterogeneity by having two LDL compartments (10 and 11). With recent 
findings, including those reported here, this LDL subsystem will have to be re­
evaluated and possibly redefined to allow for the three subfractions of LDL 
consistently observed in those patients studied. It is not known as yet, whether 
the three subfractions, although structurally distinct are metabolically dissimilar. 
The suggestion from the present work is that small dense LDL-III may be 
metabolically distinct from the larger more buoyant LDL I and II, while the 
latter two may behave in a similar fashion. Little is known about the potential 
interconversions of the LDL subfractions but this will be readily studied using 
radiolabelled LDL subfraction turnovers. Such studies are again currently 
underway and their results should provide valuable new information on the 
intravascular remodelling of these lipoproteins as well as their metabolic fates. 
With this new data an improved model of apo-LDL metabolism encompassing 
the observed heterogeneity in LDL will be constructed.
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10.2.3. Lp(a)
The lack of any effect on plasma Lp(a) levels by the lipid lowering drugs 
studied here is consistent with many other reports. In view of the report from 
Carlson et al (1989) of the Lp(a) lowering observed with nicotinic acid therapy, 
it is particularly interesting to note the inability of the nicotinic acid analogue, 
acipimox, to lower Lp(a). This observation has recently been corroborated by 
Seed and her colleagues (1992) who reported a 32% fall in Lp(a) with nicotinic 
acid therapy (3g. d_1) but no change with acipimox (lOOOmg. d_1). Despite the 
similarities in the mechanisms of action of these two closely related drugs there 
is clearly a marked difference in their effects on Lp(a). Seed et al (1992) 
suggest that the Lp(a) lowering observed with nicotinic acid is due to a decrease 
in the synthesis of the lipoprotein rather than any change in its rate of clearance. 
Morrisett et al (1992) recently reported the results of kinetic studies of apo(a) 
using deuterated leucine. With this use of stable isotope labelled precursors a 
direct assessment of the synthetic rate of the endogenously labelled protein may 
be made. Morrisett et al (1992) showed that the FSR of apo(a) in Lp(a) was 
similar to that of apoB in Lp(a). The latter, however, was markedly lower than 
the FSR of apoB in LDL and these workers concluded that there must be two 
separate apoB pools for LDL and Lp(a) production. In addition they noted a 
strong negative correlation (r=-0.914) between the apo(a) FSR and the plasma 
triglyceride level. This new information would suggest that the Lp(a) lowering 
facility of nicotinic acid is unrelated to its effects on triglyceride metabolism, as 
it would be expected from these findings that a drug such as nicotinic acid, 
which causes marked falls in plasma triglyceride would lead to enhanced Lp(a) 
production. However, the opposite effect is observed. With the information 
currently available it is not possible to offer a good explanation for this 
differential effect on Lp(a) by two apparently very similar drugs. With further 
studies on Lp(a) metabolism, particularly using stable isotope technology we 
may be able to dissect out the subtle differences in action of these drugs. As a 
corollary, further direct investigation into the mechanisms of action of nicotinic 
acid as compared with acipimox may also offer new insight into the metabolic 
control of plasma Lp(a) levels. As this lipoprotein is being viewed increasingly 
as an important therapeutic target, the design of competent new Lp(a) lowering 
drugs will largely depend on advances in this area.
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10.2.4. The Role of the Apo B/E Receptor
By using drugs as stimulants of the apoB/E receptor, such as the HMG CoA 
reductase inhibitor, simvastatin, it has been possible to observe the changes in 
the apoB containing lipoproteins resulting from enhanced receptor activity. 
Increased clearance of LDL apoB, which was previously thought to be the 
principal result of increased apoB/E receptor expression was not consistently 
observed. Much more evident was the enhanced clearance of the LDL 
precursor, IDL apoB. This is an important finding drawing attention to the true 
nature of the apoB/E receptor, whose original name, the LDL receptor, reveals 
only part of the truth.
10.2.5. Metabolic Heterogeneity and the Applicability of the 
Present Studies
The marked variation in kinetic parameters between subjects presented a 
significant problem in the analyses of these data. The subjects studied here 
were deliberately chosen to represent the most commonly treated group of 
dyslipidaemics viz. those with primary moderate hypercholesterolaemia. Under 
this title there must clearly exist a whole range of metabolic defects contributing 
to the patients' hyperlipidaemia. This underlying heterogeneity presents 
problems when trying to study apolipoprotein kinetics. These studies are 
complex and labour intensive and pragmatic constraints usually confine the 
sample size to between 5 and 10 patients. One solution to this problem would 
be to select from this population of primary moderate hypercholesterolaemic 
subjects a group fully characterised for a specific set of genetic defects or 
phenotyped in a much more detailed manner. While this strategy would obviate 
much of the underlying heterogeneity observed in the present studies it could be 
argued that the results would be applicable only to that specific defect and not to 
the population as a whole, just as the findings both in terms of baseline kinetics 
and responses to drugs in those with FH are clearly inapplicable to the wider 
population.
10.3 Mechanism of Action of Lipid Lowering Drugs
The second main aim of this study was to obtain new information on the 
mechanisms of action of examples of the main classes of lipid lowering drugs. 
The findings have already been discussed in the individual chapters and are now
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summarised in figure 68. In the following sections the most relevant new 
findings are reiterated with suggested future possibilities.
10.3.1. Simvastatin
The most important finding here was the enhanced clearance of LDL 
precursors, VLDL2 and EDL resulting in reduced throughput of apoB into the 
LDL interval. This drug induced effect on LDL synthesis rather than LDL 
clearance was surprising in view of the proposed mechanism of action of the 
statins i.e. enhanced apoB/E receptor function. However, with closer analysis 
of the literature it becomes clear that the LDL lowering facility of the statins can 
only be completely explained by increased LDL clearance in those individuals 
with a recognised defect of this kinetic parameter i.e. FH heterozygotes. The 
importance of this statin induced effect on apoB metabolism is the removal from 
the circulation of the more atherogenic lipoproteins. Such an effect should have 
important consequences in the prevention of CHD.
10.3.2. Colestipol
By studying the kinetics of the apoB containing lipoproteins a mechanism for 
the triglyceride raising effects of the bile acid sequestrant resins has been 
proposed. The marked reduction in the direct catabolism of VLDLi largely 
explains the increase in VLDL-cholesterol and plasma triglyceride observed 
with colestipol and its sister compound cholestyramine. With the renewed 
interest in the atherogenic potential of triglyceride rich lipoproteins this effect of 
a commonly used lipid lowering drug, albeit in conjunction with a lowering of 
LDL-cholesterol, may be considered disadvantageous. In the study of 
combined colestipol and simvastatin therapy (chapter 7) it was particularly of 
interest to note the complete reversal of this colestipol induced effect on VLDL 
metabolism when simvastatin as added to the regimen. Also in this study the 
beneficial effects on HDL-cholesterol were of note re-affirming the importance 
of this combination as an effective anti-atherosclerotic regimen.
10.3.3. Acipimox
The study of the nicotinic acid analogue acipimox provided the opportunity to 
examine a drug with diverse effects on opposite ends of the delipidation 
cascade. Inhibition of the synthesis of triglyceride-rich particles partly
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Figure 68. Effects of Lipid Lowering Drugs on ApoB Metabolism. Baseline 
metabolism is shown in black, with the effects of simvastatin in red, colestipol 
in green, acipimox in blue and the fibrates in purple. Broken lines illustrate 
inhibition of a pathway, while solid lines show stimulation.
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contributed to the fall in LDL by reducing the availability of lipoprotein 
precursors. However, acipimox also reduced the direct input of LDL and 
reduced the IDL to LDL apoB transfer. The latter is attributed to the known 
inhibitory effect of acipimox on hepatic lipase activity. These multiple effects 
on the metabolism of apoB containing lipoproteins serve to normalise not only 
an oversynthesis of LDL particles but also to reduce the circulating mass of 
triglyceride-rich particles, which as described above are considered to make a 
significant contribution to the the risk of atherogenesis.
10.3.4. Ciprofibrate and Fenofibrate
By choosing specifically to study the effects of a fibrate on receptor mediated 
clearance of apo-LDL it was possible to confirm that the LDL-cholesterol 
lowering of ciprofibrate was indeed due to enhanced clearance of LDL by the 
high affinity receptor mediated route. It was also possible by studying the LDL 
subtraction changes associated with drug therapy to suggest that this kinetic 
effect may not simply be due to enhanced apoB/E receptor expression but may 
instead be due to the synthesis of more receptor-active LDL species. These 
proposed ligand changes were not supported by simple LDL compositional 
changes but were supported by significant changes in the LDL subfraction 
profile.
Another important finding in the present work was the lack of effect of the fibric 
acid derivative, fenofibrate on cholesterol biosynthesis, indirectly assessed by 
measurement of plasma lathosterol and urinary mevalonate excretion. This 
finding offers important human in vivo evidence in support of the hypothesis 
that the fibrates have no effect on HMG CoA reductase activity. This 
hypothesis has received an increasing body of supportive evidence from in vitro 
studies, most recently by Qin et al (1992). These workers reported a complete 
lack of effect of ciprofibrate on HMG CoA reductase or LDL receptor activity, 
or the gene expression of these two proteins in a human intestinal cell line, 
CaCo2. The present study is the first report of the effects of a fibrate on these 
indirect indices of cholesterol biosynthesis and highlights the utility of these 
assays in tandem as an important tool for the evaluation and investigation of 
new lipid lowering drugs that purport to have an effect on the cholesterol 
biosynthetic pathway. Such drugs to be investigated in the future might include 
the recently reported squalene synthase inhibitor (McCarthy et al 1992) and the 
new second generation HMG CoA reductase inhibitor BA W 6228 (Bischoff & 
Petzinna 1992).
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10.4. Full Circle
This thesis began with the words of an ancient physician, Hippocrates. While 
he would surely be fascinated, not to say beguiled, by the advances made in 
medicine in the last two millenia, he would be dismayed if we, as clinicians and 
scientists, were to forget his simple yet far reaching guidelines of medical care, 
placing the patient at the centre of all things. If this thesis has some merit it will 
be in advancing our understanding of an area of clinically relevant physiology, 
that of lipoprotein metabolism, and in placing the use of the lipid lowering 
drugs on a firmer theoretical footing. This is done first and foremost to help 
patients and to assist others in this simple yet all too often forgotten goal.
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Appendix 1
Suppliers of Reagents, Equipm ent and Software.
A m ersham  In ternational pic
Amersham Place, Little Chalfont, Amesham, Bucks. HP7 9NA, UK.
Na [131I]
Na [125I].
[14C]-5-phosphomevalonic acid.
Amicon L td .
Upper Mill, Stonehouse, Glos. GL10 2BJ, UK.
Chromatography column Red Sepharose (Amicon Matrix Gel Red A)
Ultrafiltration membrane (Diaflo)
B aker Instrum ents Ltd
Rusham Park, Whitehall Lane, Egham, Surrey, TW20 9NW, UK.
Encore Chemistry System Centrifi Chem®
B axter H ealthcare Ltd
8 Tollpark Place, Wardpark East, Cumbernauld G68 OLN, UK.
0.9% sodium chloride intravenous infusion BP
Beckm an In stru m en ts, Spinco Division
Beckman Instruments (UK) Ltd Analytical Sales and Service Operation 
Progress Road, Sands Industrial Estate, High Wycombe, Bucks. HP 12 4JL, UK.
L8-60M ultracentrifuge L8-70 ultracentrifuge
Prep UV Scanner AnF rotor
SW 40 rotor Ti 60 rotor
Ultra-Clear ™ centrifuge tubes Ti 50.4 rotor
Polycarbonate centrifuge bottles and caps Spinkote 
Silicone vacuum grease Tube Slicer
Becton Dickinson
Dublin Eire.
Microlance®2 21G Needles Syringes
BDH L ab o ra to ry  Supplies
McQuilkin and Co., 21 Polmadie Avenue, Glasgow G5 OBB, UK.
Triethylamine Folin-Ciocalteau Reagent
Bio-Rad L aboratories Ltd
Bio-Rad House, Marylands Avenue, Hemel Hempstead, Herts. HP2 7TD, UK.
Bio-gel HT hydroxylapatite AG® 1-X8 200-400 mesh chloride form
Econo-columns
Boehringer M annheim  GmbH
Boehringer Mannheim UK (Diagnostics and Biochemicals) Ltd 
Bell Lane, Lewes, East Sussex BN71LG, UK.
ATP (MV 602) Hitachi 704 automatic analyser.
Kit No 310328 (free cholesterol) Kit No. 69184 (phospholipid)
Kit No. 704121 (cholesterol) Kit No. 704113 (triglyceride).
Bristol M yers Squibb
Squibb House, 141-149 Staines Rd, Hounslow, Middlx TW3 3JA, UK.
Cholestyramine
Chrom pack Ltd
Unit 4, Indescon Crt, Millharbour, London, E14 9TN, UK.
CP 9000 Gas chromatograph Deriva-Sil®
WCOT 50m x 0.25 capillary column PCI integration software package
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C laris™
440 Clyde Ave, Mountain View, CA, USA.
MacDraw II
C rick e t Software Inc
40 Valley Stream, Malvern, PA, USA.
Cricket Graph Version 1.3.1 Statworks Version 1.2
D ynatech L aboratories Ltd
Daux Road, Billingshurst, West Sussex, RH14 95J, UK.
MR5000 microtitre plate reader
E astm an  Fine Chemicals
Eastman Kodak Co, Rochester, NY, USA.
Decyl-sodium sulphate
F arm ita lia  Carlo E rba Ltd
Italia House, 23 Grosvenor Rd, St Albans, AL1 3AW, UK.
Acipimox
F luka Chemical Ltd
Peakdale Rd, Glossop, Derbyshire, SK13 9XE, UK.
1,2 Cyclohexanedione
F o u rn ie r
Centre de Recherches de Daix, 50 rue de Dijon, Daix, 21121 Fontaine les Dijon, France. 
Fenofibrate
G elm an Sciences Ltd
Brackmill Business Park, Caswell Road, Northampton NN4 OES, UK.
Acrodisc filters 0.22 and 0.45 pm
H aem onetics C orporation
400 Wood Rd, Braintree, MA, USA.
Haemonetics plasma collection system (PCS)
Innogenetics SA
Kronenburgstraat 45, B 2000 Antwerp, Belgium.
Lp(a) Kit
Iso la b
Advanced Laboratory Techniques, 11 Bounds Oak Way, Southborough, Tunbridge Wells, 
Kent, TN4 OUB, UK.
Gradient maker
M erck, Sharp and Dohme Ltd
Hertford Rd, Hoddesdon, Herts. EN11 9BU, UK.
Simvastatin
M icroso ft C orporation
1 Microsoft Way, Redmond, WA, USA.
MS Word Version 4.0
M S E
Fisons Instruments, Sussex Manor Park, Gatwick Rd, Crawley, Sussex, RH10 2QQ, UK. 
Mistral 4L refrigerated centrifuge.
New England Nuclear
NEN Research Products, Wedwood Way, Stevenage Herts. SGI 4QN.UK.
32p -a t p .
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P a a r  Scientific Ltd
594 Kington Road, Raynes Park, London SW20 8DN, UK.
Digital densitometer DMA 35
P ack a rd  Instrum ent Co.
Canberra Packard Ltd, Brook House, 14 Station Road, Pangbourne, Berks. RG8 7DT, UK. 
Ultima Gold scintillation fluid Auto gamma 500 C
Super polyethylene vials (20mL) Auto 6 counter
P h arm ac ia  AB
Pharmacia Ltd, Pharmacia LKB Biotechnology Division, Midsummer Boulevard, Central 
Milton Keynes, Bucks. MK9 3HP, UK.
Sephadex G-25 (PD10 columns)
R esource Facility for Kinetic Analysis
Center fo r  Bioengineering, FL-20, University o f Washington, Seattle, WA 98195, USA. 
SAAM 29 
SAAM 30
S an o fi-W in th ro p
Onslow St, Guildford, Surrey, GUI 4YS, UK.
Ciprofibrate
S c o tla b
Kirkshaws Rd, Coatbridge, MLS 8AD, UK.
Plexiglas shielding
S ig m a
Sigma Chemical Co. Ltd, Fancy Road, Poole, Dorset BH17 7TG, UK.
Iodine monochloride (IC1) Dithiothreitol (DTT)
Trishydroxymethylaminomethane (TRIS) Tetramethylurea (TMU)
Protamine Sulphate 5a-cholestane
Adenosine triphosphate (ATP) Mevalonolactone
Phosphoenol pyruvate (PEP) Pyruvate kinase (PK)
6 NADH Lactate dehydrogenase (LDH)
S p ec tra p o r
Orme Technology, PO Box 3, Stakehill Industrial Park, Middleton, Manchester, M24 2RH, 
UK.
Dialysis tubing 
S te rilin  UK
McQuilkin and Co., 21 Polmadie Avenue, Glasgow G5 OBB, UK.
96 well microtitre plates
Technicon (Ireland) Ltd.
Swords Co. Dublin, Eire.
12 channel Peristaltic pump
U pjohn Ltd
Fleming Way, Crawley, West Sussex, RH10 2NJ, UK.
Colestipol
Viggo AB
Helsingborg, Sweden.
Venflon®2 intravenous cannulae
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SIM 01 A (Metabolism of VLDL1)100
□ % 1-131 VLDLl 
A % 1-131 VLDL2 
o % 1-131IDL 
■ % 1-131 LDL
n 24 48 72 96 120 144
t ime (t trs)
A -l. Apolipoprotein B radioactivity decay curves associated with 
V L D L j, VLDL2, IDL & LDL after injection of autologous 
[131l]-VLDLi.
SIM 01 A (M etabolism of VLDL2)100
125-1VLDL2 
125-1 IDL 
125-1 LDL
10 -
1921680 24 72 12048 96 144
T im e(H rs)
F igure A-2. Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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SIM 01 B (Metabolism of VLDL1)100
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1-131 VLDL2 
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Figure A -3 . Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2, IDL & LDL after injection of autologous
[131i j -V L D L i .
SIM 01 B (M etabolism of VLDL 2)100 -3
125-1VLDL2 
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Figure A-4. Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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SIM 02 A (Metabolism of VLDL 1)100
1-131 VLDL1 
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1-131 IDL 
1-131 LDL
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A-5. Apolipoprotein B radioactivity decay curves associated with 
VLDLj, VLDL2 , IDL & LDL after injection of autologous 
[131r]-VLDLi.
SIM 02 A (M etabolism  of VLDL 2)100
125-1 VLDL2 
125-1 IDL 
% 125-1 LDL
168 192120 14424 72 960 48
T im e(H rs)
Figure A-6. Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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SIM 02 B (Metabolism of VLDLI)100
1-131 VLDLI 
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Figure A -7 . Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2, IDL & LDL after injection o f autologous 
[131l]-VLDLi.
SIM 02 B (M etabolism of VLDL2)100
125-1 VLDL2 
125-1 IDL 
1-125 LDL
o . I
0 24 48 72 96 120 168 192144
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Figure A-8. Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-9. Apolipoprotein B radioactivity decay curves associated with 
VLDLi, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
SIM 03 A (M etabolism of VLDL2)100 -r
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Figure A -10 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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SIM 03 B (Metabolism of VLDLI)100
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F ig u re  A - l i  Apoiipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2, IDL & LDL after injection of autologous 
[131I]-VLDLi.
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Figure A-12 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [ l25I]-VLDL2 .
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SIM 06 A (Metabolism of VLDL 1)100
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F ig u re  A -13 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[ 131r j - V L D L i .
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Figure A -14 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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F ig u re  A -15 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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F ig u re  A-16 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-17 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
SIM 07 A (M etabolism of VLDL 2)100
A % 125-1 VLDL2 
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Figure A-18 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125Ij-VLDL2 .
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Figure A-19 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-20 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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F ig u re  A -15 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-16 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-17 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-18 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125l]-VLDL2.
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F ig u re  A-19 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-20 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-21 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131I]-VLDLi.
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Figure A-22 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-23 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-24 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-25 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-26 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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F igu re  A-27 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous
[131l]-VLDLi.
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Figure A-28 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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COL 02 C (Metabolism of VLDL1)100
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Figure A-29 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-30 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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F ig u re  A-31 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131I]-VLDLi.
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Figure A-32 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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COL 03 B (Metabolism of VLDL1)100
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Figure A-33 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous
[131i]-VLDLi.
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Figure A-34 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-35 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection o f autologous 
[DllJ-VLDLi.
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Figure A-36 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [ l25I]-VLDL2 .
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Figure A-37 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-38 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-39 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131I]-VLDLi.
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Figure A-40 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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COL 04 C (Metabolism of VLDL1)100
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Figure A-41 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous
[131l]-VLDLi.
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Figure A-42 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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COL 05 A (Metabolism of VLDL1)100
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Figure A-43 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection o f autologous 
[131IJ-VLDL!.
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Figure A-44 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-45 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-46 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-47 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-48 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-49 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-50 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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F ig u re  A-51 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous
[ttlq-VLDL!.
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Figure A-52 Apolipoprotein B radioactivity decay curves associated with
VLDL2, IDL & LDL after injection of autologous [I25I]-VLDL2 .
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COL 06 C (Metabolism of VLDL1)100
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Figure  A-53 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2 , IDL & LDL after injection of autologous 
[131^-VLDLi.
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Figure A-54 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [ l25I]-VLDL2 .
Appendix 3 312
COL 07 A (M etabolism of VLDL1)100
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Figure A -55  Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2, IDL & LDL after injection of autologous
[Hlq-VLDLi.
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Figure A-56 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A -57  Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2, IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-58 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-5 9  Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2, IDL & LDL after injection o f autologous 
[131i]-VLDLi.
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Figure A-60 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-61 Apolipoprotein B radioactivity decay curves associated with 
V L D L i, VLDL2, IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-62 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-63 Apolipoprotein B radioactivity decay curves associated with 
V L D L j ,  VLDL2, IDL & LDL after injection of autologous 
[131l]-VLDLi.
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Figure A-64 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-65 Apolipoprotein B radioactivity decay curves associated with 
V LD Lj ,  VLDL2, IDL & LDL after injection of autologous 
[13lI]-VLDLi.
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Figure A-66 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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F igure  A -67  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injection of autologous [131I]-VLDLi-
APX 01 A (M etabolism of VLDL2)100
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Figure A-68 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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APX 01 B (M etabolism of VLDL1)100
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Figure A-69  Apolipoprotein B radioactivity decay curves associated with V LD Li, 
VLDL2, IDL & LDL after injection of autologous [131I]-VLDLi.
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Figure A-70 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
DDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-71  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, EDL & LDL after injection of autologous [131I]-VLDLi.
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Figure A-72 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
EDL & LDL after injection of autologous [125I]-VLDL2 .
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APX 02 A (M etabolism of VLDL1)100
a  %131 VLDLl 
a % 131 VLDL 2 
o %131 IDL 
■ % 131 LDL
|  10 V■3
uu~a
u—o
0 24 48 72 96 120 144 168 192
Time (Hrs)
Figure A -73  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injection of autologous [131I]-VLDLi.
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Figure A-74 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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A -75  Apolipoprotein B radioactivity decay curves associated with VLDLj, 
VLDL2, IDL & LDL after injection of autologous [131I]-VLDLi.
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Figure A-76 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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A -77  Apolipoprotein B radioactivity decay curves associated with VLDLj, 
VLDL2, DDL & LDL after injection of autologous [131Ij-VLDLj.
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Figure A-78 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A -7 9  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injection of autologous [131I]-VLDLi.
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Figure A-80 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-81 Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injection of autologous VLDLi.
APX 04 B (M etabolism of VLDL2)100
A %125 VLDL2 
O %125 IDL
55 1 0  -a
-a
w-
a
1920 72 96 16824 48 120 144
Time (Hrs)
Figure A-82 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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F igu re  A -83  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injection of autologous [131I]-VLDLi.
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Figure A-84 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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F ig u re  A -85  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injection of autologous [DllJ-VLDLi.
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Figure A-86 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A -87  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injection of autologous [D lrj-V LD Lp
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Figure A-88 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A -8 9  Apolipoprotein B radioactivity decay curves associated with VT DLi, 
VLDL2, IDL & LDL after injection of autologous [131I]-VLDLi.
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Figure A-90 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-91 Apolipoprotein B radioactivity decay curves associated with VLDLj, 
VLDL2, IDL & LDL after injection of autologous [131I]-VLDLi.
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Figure A-92 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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F igu re  A-93  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injection of autologous [ 13 ^ -V L D L p
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Figure A-94 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A -95  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injecdon of autologous [131I]-VLDLi.
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Figure A-96 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-9 7  Apolipoprotein B radioactivity decay curves associated with VLDLi, 
VLDL2, IDL & LDL after injection of autologous [l31I]-VLDLi.
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Figure A-98 Apolipoprotein B radioactivity decay curves associated with VLDL2 ,
IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A-9 9  Apolipoprotein B radioactivity decay curves associated with VLDLj, 
VLDL2, IDL & LDL after injection of autologous [131I]-VLDLi.
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Figure A-100 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure A -1 0 1  Apolipoprotein B radioactivity decay curves associated  with 
VLDLi ,  VLDL2, IDL & LDL after injection of autologous [ 131I]- 
VLDLi.
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Figure A-102 Apolipoprotein B radioactivity decay curves associated with
VLDL2 , IDL & LDL after injection of autologous [125I]-VLDL2 .
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Figure 103 Native LDL
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Figures A -103-105. CIP 01 A. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [13 ^ -cyclohexanedione modified
apo-LDL.
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Figures A-106-108. CIP 01B. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [13 ^ -cyclohexanedione modified
apo-LDL.
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Figures A-109-111. CIP 02A. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [13^-cyclohexanedione modified
apo-LDL.
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Figures A -112-114. CIP 02B. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [13 ^ -cyclohexanedione modified
apo-LDL.
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Figures A-115-117. CIP 03A. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [13lI]-cyclohexanedione modified
apo-LDL.
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Figures A-118-120. CIP 03B. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [131I]-cyclohexanedione modified
apo-LDL.
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Figures A -121-123. CIP 04A. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [13ll]-cyclohexanedione modified
apo-LDL.
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Figures A -127-129. CIP 05A. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [^IfJ-cyclohexanedione modified
apo-LDL.
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Figures A-130-132. CIP 05B. Plasma and urinary radioactivity decay curves
following injection of [1251]-native apo-LDL and [13^-cyclohexanedione modified
apo-LDL.
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Figures A -133-135. CIP 06A. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [1311]-cyclohexanedione modified
apo-LDL.
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Figures A-136-138. CIP 06B. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [13 ^ -cyclohexanedione modified
apo-LDL.
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Figures A-139-141. CIP 07A. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [131I]-cyclohexanedione modified
apo-LDL.
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Figures A-142-144. CIP 07B. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [1211]-cyclohexanedione modified
apo-LDL.
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Figures A-145-147. CIP 09A. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [1311]-cyclohexanedione modified
apo-LDL.
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Figures A-148-150. CIP 09B. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [13 ^ -cyclohexanedione modified
apo-LDL.
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Figures A-151-153. CIP 10A. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [13 ^ -cyclohexanedione modified
apo-LDL.
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Figures A-154-156. CIP 10B. Plasma and urinary radioactivity decay curves
following injection of [125I]-native apo-LDL and [^llj-cyclohexanedione modified
apo-LDL.
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Glossary
ACAT................................... Acyl Coenzyme A:cholesterol acyl transferase
A C R....................................  Absolute Catabolic Rate
ALP.....................................  Atherogenic Lipoprotein Phenotype
A p o ...................................... Apolipoprotein
A PX ....................................  Acipimox
BSA.....................................  Bovine Serum Albumin
cAMP................................... Cyclic Adenosine Monophosphate
CETP................................... Cholesteryl Ester Transfer Protein
CH D ....................................  Coronary Heart Disease
Ci.......................................... Curie
CIP....................................... Ciprofibrate
C K ....................................... Creatine Kinase
CM .......................................  Chylomicron
COL.....................................  Colestipol
cpm ...................................... Counts Per Minute
C TX ................................ . Cerebrotendinous Xanthomatosis
d ...........................................  Density
EDTA................................... Ethylenediaminetetra-acetate
FCR.....................................  Fractional Catabolic Rate
FEN.....................................  Fenofibrate
F H .......................................  Familial Hypercholesterolaemia
FSD .....................................  Fractional Standard Deviation
FSR .....................................  Fractional Synthetic Rate
GC-MS................................ Gas Chomatography-Mass Spectrometry
H D L....................................  High Density Lipoprotein
H L ....................................... Hepatic Lipase
HMG C oA ..........................  3-hydroxy, 3-methylglutaryl Coenzyme A
IDL....................................... Intermediate Density Lipoprotein
LCAT................................... Lecithin: cholesterol acyl transferase
LD H ....................................  Lactate Dehydrogenase
LDL.....................................  Low Density Lipoprotein
Lp(a)....................................  Lipoprotein (a)
L pL ...................................... Lipoprotein Lipase
LRC.....................................  Lipid Research Clinics
LRP.....................................  LDL Receptor Related Protein
M I........................................  Myocardial Infarction
MM-LDL............................. Minimally Modified Low Density Lipoprotein
MVA....................................  Mevalonic Acid
P E P .....................................  Phosphoenol pymvate
PK ........................................ Pyruvate Kinase
rpm....................................... Revolutions Per Minute
SAAM.................................  Simulation, Analysis and Modeling
SDS.....................................  Sodium Dodecyl Sulphate
Sf.......................................... Svedberg Flotation Units
SIM .....................................  Simvastatin
TEAC..................................  Triethylammonium carbonate
TMU....................................  1,1,3,3-tetramethylurea
TRIS....................................  Tris hydroxymethylamino methane
U/P....................................... Urine/Plasma Ratio
VLDL................................... Very Low Density Lipoprotein
WH HL................................  Watanabe Heritable Hyperlipidaemic
W HO................................... World Health Organization
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